Last updated: Apr 18, 2020 - 02:00 BST
| CounterCovid19: Countering Lung Damage in COVID-19 infection (CounterCovid) studyCountering Lung Damage in COVID-19 infection study |
Coronavirus disease 19 infection, Lung injury |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Amsterdam UMC |
|
Netherlands |
2020-03-31 |
2020-06-30 |
2020.158, CounterCovid19, NL8491 |
Phase 3 Clinical |
Recruiting |
0 |
3 Months |
386 |
Harm Jan Bogaard |
2020-04-17 |
| PVC-RAM: Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial |
Coronavirus disease 19 infection |
Virtual Care and Remote Automated Monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Population Health Research Institute |
Hamilton Health Sciences Corp, McMaster University |
Canada |
2020-04-30 |
2020-09-30 |
NCT04344665, PVC-RAM, V1.0, 2020.04.06 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
900 |
Michael McGillion, PhD, PJ Devereaux, PhD, Valerie Harvey, BSc |
2020-04-17 |
| LUS-CC: Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients |
Coronavirus disease 19 infection, Viral pneumonia |
Lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Radboudumc |
|
Netherlands |
2020-03-15 |
2020-05-31 |
2020-6371, LUS-CC, NL8498 |
Phase Not Applicable |
Recruiting |
0 |
2 Months |
20 |
Frank Bosch |
2020-04-17 |
| A clinicla trial of repurposed NP-120 for teh treatment of acute lung injury due to COVID-19 |
Acute lung injury, Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak |
Coronavirus disease 19 infection |
Ayurveda Self-Management alone, Yoga breathing alone, paracetamol alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Aarogyam UK |
|
UK |
2020-02-26 |
2020-03-30 |
AU08, NCT04345549 |
Phase Not Applicable |
Completed |
0 |
1 Month |
18 |
Jaydeep Joshi, Neha Sharma |
2020-04-17 |
| ReportAge-COVID: Clinical and Biological Predictors of COVID-19 Disease in Older Patients |
Coronavirus disease 19 infection |
|
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto Nazionale di Ricovero e Cura per Anziani |
|
Italy |
2020-04-30 |
2020-12-31 |
INRCA_01_2020, NCT04348396, ReportAge-COVID |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
300 |
Antonio Cherubini, MD, Silvia Bustacchini, MD |
2020-04-17 |
| UPSAT: Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
postural positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-20 |
2021-05-31 |
IRB00246834, NCT04344561, UPSAT |
Phase Not Applicable |
Not yet recruiting |
0 |
13 Months |
70 |
Luu Pham, MD, Trishul Siddharthan, MD |
2020-04-17 |
| COVIDIMMUNE: Evaluating the Immune Response for COVID-19 |
Coronavirus disease 19 infection |
2019-NCoV IgM/IgG (MAGLUMI) alone, Anti-SARS-CoV-2 (EuroImmun) alone, COVID-19 IgM/IgG (DIA PRO) alone, Coronavirus COVID-19 IgG ELISA (IBL) alone, Immunocomb (BioGal) alone, NADAL COVID-19 IgG/Igm (Nal Von Minden) alone, Rt-PCR kit alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assaf-Harofeh Medical Center |
|
Israel |
2020-04-20 |
2020-12-31 |
105-20-ASF, COVIDIMMUNE, NCT04348422 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
1000 |
Amir Hadanny, MD, Prof. Shay Efrati, Shai Efrati, MD |
2020-04-17 |
| Saved From COVID-19 |
Coronavirus disease 19 infection |
chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
|
US |
2020-04-30 |
2021-04-30 |
AAAS9992, NCT04349371 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
350 |
Anca Askanase, MD, MPH, Anca D. Askanase, MD, MPH, Tommy Chen |
2020-04-17 |
| PRODEX: Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
dexmedetomidine alone |
Alpha 2 adrenoceptor agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Limoges |
|
France |
2020-04-20 |
2020-11-20 |
87RI20_0011 (PRODEX), NCT04350086, PRODEX |
Phase 4 Clinical |
Not yet recruiting |
1 |
7 Months |
10 |
Paul-Antoine QUESNEL, MD |
2020-04-17 |
| Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
Hope Biosciences Stem Cell Research Foundation |
US |
2020-04-23 |
2021-04-30 |
ALLOGENEIC COVID-19 PROTECTION, NCT04348435 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
100 |
Thanh Cheng, MD |
2020-04-17 |
| Telerehabilitation for Patients Diagnosed With Coronavirus |
Coronavirus disease 19 infection |
Telerehabilitation alone, exercise brochure alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Istinye Universitesi |
|
|
2020-04-10 |
2020-07-31 |
009, NCT04346927 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
30 |
Yasemin Çırak |
2020-04-17 |
| Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Shanghai East Hospital |
|
China |
2020-03-01 |
2020-04-30 |
ChiCTR2000031707 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
47 |
Chen Li |
2020-04-17 |
| Study for prevention of novel coronavirus pneumonia (COVID-19) in high risk population by Chinese medicine |
Coronavirus disease 19 infection, Viral pneumonia |
Traditional Chinese medicine sachet alone, general basic epidemic prevention measures alone, oral and nasal spray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing institute of Traditional Chinese Medicine |
|
China |
2020-04-01 |
2020-12-31 |
ChiCTR2000031955 |
Phase 0 Clinical |
Recruiting |
0 |
9 Months |
3808 |
Lingru Li |
2020-04-17 |
| Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Prevent Senior Private Operadora de Saúde LTDA |
Brazil |
2020-04-20 |
2020-07-31 |
HIAPRE0420OR, NCT04348474 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
200 |
Luciana Ferrara, Rafael Souza, MD, PhD, Álvaro Razuk Filho, MD, PhD |
2020-04-17 |
| Clinical observation for the effect of Ke-Gan-Li-Yan oral liquid on the relief of laryngeal symptoms of novel coronavirus pneumonia (COVID-19) convalescence and suspected patients and other susceptible people |
Coronavirus disease 19 infection, Viral pneumonia |
Ke-Gan-Li-Yan oral liquid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fifth Affiliated Hospital, Sun Yat-Sen University |
|
China |
2020-04-01 |
2020-08-31 |
ChiCTR2000031982, ChiMCTR2000003216 |
Phase 4 Clinical |
Not yet recruiting |
1 |
5 Months |
240 |
Hu Guanying, Huang Mingxing |
2020-04-17 |
| Study for the influence of novel coronavirus pneumonia (COVID-19) on mental health of Chinese public hospital stuffs |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Asian Ancestry |
Fujian Provincial Hospital |
|
China |
2020-02-05 |
2020-02-10 |
ChiCTR2000031896 |
Phase Not Applicable |
No longer recruiting |
1 |
|
923 |
Miao Xing |
2020-04-17 |
| Delineate the prevalence, risk factors, temporal distribution and epidemiological characteristics of hidden novel coronavirus (2019-nCoV) infection in the community |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
Health and Medical Research Fund, Hong Kong |
China |
2020-04-15 |
2021-04-14 |
ChiCTR2000031928 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
3000 |
Peter Choi Ching Lam, Prof. KS Chan Paul |
2020-04-17 |
| POINT-C: ICU Trial in Critical Ill COVID-19 Patients |
Cardiovascular disease, Coronavirus disease 19 infection |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Graz |
|
Austria |
2020-04-08 |
2020-07-31 |
250320, NCT04349982, POINT-C |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
50 |
Christoph Klivinyi, Dr., Martin Rief, Dr, Martin Rief, Dr. |
2020-04-17 |
| A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
|
US |
2020-04-16 |
2020-12-31 |
NCT04349631, PROTECTION AGAINST COVID-19 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
56 |
Thanh Cheng, MD |
2020-04-17 |
| Resi-CoV: Resilience During Covid-19 Epidemic |
Coronavirus disease 19 infection |
CD-RISC 25 questionnaire alone |
|
Healthy volunteers accepted |
University Hospital, Angers |
|
|
2020-04-15 |
2020-05-25 |
2020-A00831-39, NCT04349163, Resi-CoV |
Phase Not Applicable |
Not yet recruiting |
0 |
1 Month |
280 |
Delphine Douillet, MD |
2020-04-17 |
| A COVID-19 Symptom, Exposure and Immune Response Registry |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ObvioHealth |
|
|
2020-04-20 |
2021-05-01 |
NCT04348942, OBVIO-OBV-001 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
10000 |
Joshua Lowndes, MA, MS, Kamalia Sazali, MS |
2020-04-17 |
| Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Dental and Craniofacial Research |
National Institutes of Health Clinical Center |
US |
2020-04-21 |
2020-07-01 |
20-D-0094, 200094, NCT04348240 |
Phase Not Applicable |
Recruiting |
0 |
2 Months |
30 |
Blake M Warner, D.D.S. |
2020-04-17 |
| APPROVE-CARE: Awake Prone Positioning to Reduce Invasive Ventilation in COVID-19 Induced Acute Respiratory failure |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
Prone positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University College Galway |
|
Ireland |
2020-04-11 |
2021-05-11 |
APPROVE-CARE, APPROVE-CARE-2020, NCT04347941 |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
200 |
Bairbre A McNicholas, MB BCh PhD, David Cosgrave, MB BCh FARSI |
2020-04-17 |
| Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 |
Coronavirus disease 19 infection |
nitazoxanide alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Centro De Genomas, Emilio Ribas Infectious Diseases Institute, Farmoquimica SA, Hospital Vera Cruz |
Brazil |
2020-04-12 |
2020-06-30 |
NCT04348409, NITFQM0320OR |
Phase 2 Clinical |
Not yet recruiting |
2 |
2 Months |
50 |
Florentino de Araujo Cardoso Filho, MD, PhD, Luciana Ferrara, Ricardo Diaz, MD, PhD, Sérgio Cimerman, MD, PhD |
2020-04-17 |
| CoPE It: An e-Mental Health Intervention to Support burdened People in Times of the COVID-19 pandemic |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection |
CoPE It training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinik für Psychosomatische Medizin und Psychotherapie am LVR-Klinikum Essen, Universität Duisburg-Essen |
|
Germany |
2020-04-23 |
|
20-9243-BO, CoPE It, DRKS00021301 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
90 |
Alexander Bäuerle, Martin Teufel |
2020-04-17 |
| Analysis of clinical characteristics and therapeutic effect of nine cases of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
Affiliated Hospital of Zunyi Medical College |
National Natural Science Foundation of China |
China |
2019-12-31 |
2020-03-01 |
ChiCTR2000031930 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
9 |
Chen Hongjun, Chen Miao |
2020-04-17 |
| An Open, Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19 |
Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome |
Variable regimens including Dalargin , azithromycin , hydroxychloroquine , tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Burnasyan Federal Medical Biophysical Center |
|
Russian Federation |
2020-04-08 |
2020-12-31 |
DAL-05-04-2020, NCT04346693 |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
320 |
Tatyana Astrelina |
2020-04-17 |
| Thy-Support: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection |
Coronavirus disease 19 infection |
triiodothyronine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories Sa |
Attikon Hospital |
Greece |
2020-05-02 |
2021-05-31 |
NCT04348513, T3INJ-02/THYSUPPORT, Thy-Support |
Phase 2 Clinical |
Not yet recruiting |
1 |
12 Months |
60 |
Apostolos Armaganidis, MD, Georgia Kostopanagiotou, MD |
2020-04-17 |
| Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Saint Etienne |
|
France |
2020-03-30 |
|
2020-001281-11, 20CH065 |
Phase 4 Clinical |
Recruiting |
1 |
|
50 |
project manager |
2020-04-17 |
| A potential clinical trial of SARS-CoV-2 3C-like (3CL) protease inhibitors for the potential iv treatment of COVID-19 caused by SARS-CoV-2 (2019-nCoV) |
Coronavirus disease 19 infection |
SARS-CoV-2 3C-like (3CL) protease inhibitors (Coronavirus disease 19 infection), Pfizer alone |
Protease inhibitor |
|
Pfizer Inc |
|
|
2020-09-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| CORIPLASM: Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
Etablissement Francais du Sang |
France |
2020-04-14 |
2020-06-01 |
2020-001246-18, APHP200375-10, CORIPLASM, NCT04345991 |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
120 |
Karine LACOMBE |
2020-04-17 |
| Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19): A Randomized Controlled Trial |
Coronavirus disease 19 infection, Viral pneumonia |
Chinese herbal tea alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
China Academy of Chinese Medical Sciences |
|
China |
2020-04-16 |
2020-12-31 |
ChiCTR2000031944, ChiMCTR2000003212 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
2000 |
Liu Bin, Lu Cheng |
2020-04-17 |
| A clinical study of haNK cells combined with convalescent plasma for the treatment in mild, moderate to the severe or critically ill COVID-19 patients |
Coronavirus disease 19 infection |
convalescent plasma plus haNK cells (cancer), NantKwest/Fox Chase Cancer Center |
|
|
NantKwest Inc |
|
US |
2020-06-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| Efficacy and safety of convalescent plasma in the treatment of COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Artesh University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.AJAUMS.REC.1399.007, IRCT20200404046948N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
60 |
Ebrahim Hazrati, Mohammad Aminianfar, Neginsadat Hosseini Mohammadi, Ramin Hamidi Farahani, Saeed Soleimani Meigouni, Seyed Javad Hosseini Shokouh |
2020-04-17 |
| PSI RECORd-XP: Non-COVID Patient-safety Incidents Reported by Primary Care Professionals in Time of Lockdown: Protocol for a Cross-sectional, Descriptive Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
CHU De Nantes |
|
France |
2020-04-15 |
2020-06-15 |
NCT04348552, PSI RECORd-XP, RC20_0183 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
1000 |
Jean-Pascal FOURNIER, Doctor |
2020-04-17 |
| Medical Records Based Study for Maternal and Perinatal Outcomes of Women with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Female |
International Peace Maternity and Child Health Hospital, Renmin Hospital of Wuhan University, The Central Hospital of Wuhan, Tongji Medical College, Wuhan Children’s Hospital |
|
China |
2020-04-15 |
2020-04-30 |
ChiCTR2000031954 |
Phase Not Applicable |
Recruiting |
3 |
|
30 |
He-Feng Huang, Yan-Ting Wu |
2020-04-17 |
| BLAST COVID-19: Beaumont Health Large-scale Automated Serologic Testing for COVID-19 |
Coronavirus disease 19 infection |
EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits alone, EUROIMMUN assay alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
William Beaumont Hospitals |
|
US |
2020-04-30 |
2021-06-30 |
2020-134, BLAST COVID-19, NCT04349202 |
Phase Not Applicable |
Recruiting |
0 |
14 Months |
50000 |
Matthew Sims, MD, PhD, Maureen Cooney, RN, BSN |
2020-04-17 |
| A clinical study of N-803 in COVID-19 patients with mild, moderate to the severe or critically ill state |
Coronavirus disease 19 infection |
ALT-803 alone |
IL-15 receptor agonist, IL-15 receptor modulator |
|
NantKwest Inc |
|
|
2020-06-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| ARCHAIC: An open-label, randomized, controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
The Netherlands Organisation for Health Research and Development |
Netherlands |
2020-04-12 |
2021-04-12 |
ARCHAIC, NL73529.041.20, NL8490 |
Phase 3 Clinical |
Not yet recruiting |
1 |
12 Months |
950 |
Jesper Weehuizen |
2020-04-17 |
| Using eHealth to support COVID-19 self-assessment and collection of self-reported health data |
Coronavirus disease 19 infection |
|
|
|
Interactive Studios |
|
Netherlands |
2020-03-23 |
2020-06-30 |
20.039, NL8501, TBA |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
2000 |
Thomas Timmers |
2020-04-17 |
| Covid-19 en ACE remmers: The use of ACE2 receptor increasing medication at hospital admission and mortality rates in COVID-19 patiënts |
Coronavirus disease 19 infection |
|
|
|
Noordwest Ziekenhuisgroep |
|
Netherlands |
2020-03-18 |
2020-09-18 |
2020.165, Covid-19 en ACE remmers, NL8512 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
400 |
Diederik van Wijk |
2020-04-17 |
| Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Unita Sanitaria Locale Della Romagna |
|
|
2020-04-30 |
2020-09-30 |
CANASCOV, NCT04348448 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
100 |
|
2020-04-17 |
| PreToVid: Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective, randomized trial |
Coronavirus disease 19 infection, Hypoxia, SARS coronavirus infection |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Roche Holding AG, University Medical Center Groningen |
|
Netherlands |
2020-04-06 |
2020-12-31 |
NL8504, PreToVid |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
354 |
Margriet Dijkstra |
2020-04-17 |
| COVID-19 in rheumatic patients: a prospective, cohort study |
Ankylosing spondylitis, Coronavirus disease 19 infection, Psoriatic arthritis, Rheumatoid arthritis, SARS coronavirus infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jan van Breemen Institute |
|
Netherlands |
2020-04-13 |
2021-04-13 |
2020.169 - NL73521.029.20, NL8513, TBA |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
8000 |
Femke Hooijberg |
2020-04-17 |
| How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU? |
Coronavirus disease 19 infection |
enhanced hygiene measures alone |
|
|
Hôpital Universitaire Fattouma Bourguiba |
|
Tunisia |
2020-03-01 |
2020-07-04 |
MALEK KHEMILI, NCT04348227 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
120 |
Malek Khemili, Resident |
2020-04-17 |
| Evaluation the effect of asafoetida in the treatment of coronavirus infection |
Coronavirus disease 19 infection |
Variable regimens including asafoetida (Mashhad School of Pharmacy) , azithromycin , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.071, IRCT20200413047053N1 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
60 |
Dr. Dehghan Nayeri, Mehrdad Iranshahi, Mohsen Tafaghodi |
2020-04-17 |
| CWC-19: COPING With COVID-19 |
Coronavirus disease 19 infection |
crisis management coaching alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-13 |
2020-06-30 |
CWC-19, NCT04343690, PRO00105319 |
Phase Not Applicable |
Not yet recruiting |
0 |
2 Months |
100 |
Erika Ratcliffe, Patty Lee, MD, Sangeeta Joshi, MD |
2020-04-17 |
| Tocilizumab-Corticosteroids COVID-19 Trial |
Coronavirus disease 19 infection |
tocilizumab alone |
|
|
National Institutes of Health |
|
Malaysia |
2020-04-27 |
2020-10-30 |
54656, NMRR-20-735-54656 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
310 |
Dr Suresh Kumar, Norazida binti Ab. Rahman |
2020-04-17 |
| Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory disease |
routine treatment alone, umifenovir alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Progress and Development of Iran |
|
Iran |
2020-03-30 |
|
IR.BMSU.REC.1399.037, IRCT20080901001165N46 |
Phase 3 Clinical |
Recruiting |
1 |
|
200 |
Morteza Pirali, Parisa Kianpour, Yunes Panahi |
2020-04-17 |
| Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King Fahad Specialist Hospital Dammam |
Johns Hopkins Aramco Healthcare, King Fahad Medical City, King Fahad National Guard Hospital, King Fahd Military Medical Complex, King Faisal Specialized Hospital & Research Center, King Faisal University, King Khalid University Hospital, King Saud University, Taibah University |
Saudi Arabia |
2020-04-12 |
2021-04-11 |
HAEM0321, NCT04347681 |
Phase 2 Clinical |
Not yet recruiting |
10 |
12 Months |
40 |
Ahmed Alsagheir, MD, Arwa Nabhan, MD, Hani Al-Hashmi, MD, Hazza AlZahrani, MD, Jawaher AlOtaibi, MD, Mahammad Awadallah, MSc, Mohammed Albalawi, MD, Mona Alfaraj, MD, Nawal AlShehry, MD, Nour AlMozain, MD, Rehab Al-Ansari, MD, Yem Abulhamayel, MD |
2020-04-17 |
| ATTAC-Co: Pro-thrombotic Status in Patients With SARS-Cov-2 Infection |
Coronavirus disease 19 infection, Respiratory failure, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azienda Ospedaliero-Universitaria di Ferrara |
|
Italy |
2020-04-08 |
2021-06-30 |
250320, ATTAC-Co, NCT04343053 |
Phase Not Applicable |
Recruiting |
1 |
14 Months |
60 |
Gianluca Campo, MD, Marco Contoli, MD, Savino Spadaro, MD, Veronica Lodolini |
2020-04-17 |
| Early Extubation for Patients With Acute Hypoxemic Respiratory Failure |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
air flow meter alone, arterial blood gas sampling alone, endotracheal intubation alone, helmet alone, non-invasive ventilation alone, oxygen therapy alone, positive-end expiratory pressure valve alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-15 |
2021-06-01 |
20-0594, NCT04349332 |
Phase Not Applicable |
Not yet recruiting |
0 |
13 Months |
108 |
Anne Pohlman, MSN, Bhakti Patel, MD |
2020-04-17 |
| Battle Against COVID-19 Using Mesenchymal Stromal Cells |
Coronavirus disease 19 infection, Respiratory distress syndrome |
allogeneic and expanded adipose tissue-derived mesenchymal stromal cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz |
Clinica Universidad de Navarra, Fundacion De La Comunitat Valenciana Para La Gestión De Instituto De Investigación Sanitaria Y Biomédica De Alicante (Fundación Para La Gestión De Isabial), Hospital General Universitario De Alicante, Hospital General Universitario Gregorio Marañon, Hospital Universitario Virgen de la Arrixa, University Hospital of Salamanca |
|
2020-04-06 |
2020-09-30 |
BALMYS-19, NCT04348461 |
Phase 2 Clinical |
Not yet recruiting |
0 |
5 Months |
100 |
Barbara Juan, MD, Mireia Arcas |
2020-04-17 |
| Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 |
Coronavirus disease 19 infection, Rhinopharyngitis |
Johnson's baby shampoo nasal irrigation therapy alone, saline nasal irrigation therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-05-31 |
2022-06-30 |
NCT04347538, PENDING IRB |
Phase Not Applicable |
Not yet recruiting |
0 |
25 Months |
90 |
Justin H. Turner, MD, PhD, Kate Von Wahlde, MJ, CCRP, Kyle Kimura, MD |
2020-04-17 |
| LACCTT: Lagos COVID-19 Chloroquine Treatment Trial |
Coronavirus disease 19 infection |
Chloroquine phosphate alone, Hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lagos State University |
Nigerian Institute of Medical Research |
Nigeria |
2020-04-17 |
2020-10-16 |
LACCTT, PACTR202004801273802 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
600 |
Akin Abayomi, Hussein AbdurRazzaq, Samuel Anya |
2020-04-17 |
| Q-PROTECT: Qatar Prospective, RCT Of Therapy Eliminating Covid Transmission |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamad Medical Corp |
|
Qatar |
2020-04-14 |
2020-05-30 |
MRC-05-001, NCT04349592, Q-PROTECT |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
456 |
Tim Richard Edmund Harris |
2020-04-17 |
| Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P18A/ 2020, NCT04348214 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
3000 |
Fatma Soliman Elsayed Ebeid |
2020-04-17 |
| COVID-19 Antibody Self-testing Using Virtual Point-of-care |
Coronavirus disease 19 infection |
COVID-19 IgM/IgG rapid testing alone, telemedicine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Neuroganics LLC |
|
US |
2020-04-30 |
2021-04-30 |
2020/03/18, NCT04348864 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
100 |
Donald Cooper, Ph.D., Joe Ramos, MD/JD |
2020-04-17 |
| save: Prevention of severe respiratory failure in Covid-19 |
Coronavirus disease 19 infection, Respiratory failure |
Bactrimel plus anakinra |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hellenic Institute for the Study of Sepsis |
|
Greece |
2020-04-15 |
|
2020-001466-11, SAVE, save |
Phase 2 Clinical |
Recruiting |
1 |
|
100 |
President of the Board |
2020-04-17 |
| FAV-001: Efficacy and Safety of Favipiravir in Management of COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FAV-001, FMASU P14 / 2020, NCT04349241 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Hany Dabbous |
2020-04-17 |
| Effect of Methylprednisolone on Treatment of COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
methylprednisolone alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-28 |
|
IR.TUMS.VCR.REC.1399.054, IRCT20200404046947N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
40 |
Abdorahman Rostamian, Ahmadreza Jamshidi, Mahdi Mahmoudi, Maryam Akhtari, Maryam Edalatifard, Zohre Naderi, mohammad ali sahraian |
2020-04-17 |
| COVID STEROID: Hydrocortisone for COVID-19 and Severe Hypoxia |
Coronavirus disease 19 infection, Hypoxia |
hydrocortisone alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Scandinavian Critical Care Trials Group |
Aarhus University Hospital, Copenhagen Trial Unit, Koebenhavns Universitet, Rigshospitalet, Denmark |
Denmark |
2020-04-15 |
2021-12-30 |
2020-001395-15, COVID STEROID, NCT04348305, RH-ITA-008 |
Phase 3 Clinical |
Not yet recruiting |
3 |
20 Months |
1000 |
Anders Perner, MD, PhD, Maj-brit N Kjær, RN, MSc, Marie Warrer Petersen, MD, PhD, Professor |
2020-04-17 |
| Emocovid: Emotional Burden of Healthcare Professionals and Covid Infection 19 |
Anxiety disorder, Coronavirus disease 19 infection |
|
|
|
University Hospital, Limoges |
|
France |
2020-04-15 |
2021-06-15 |
87RI20-0015/EMOCOVID, Emocovid, NCT04350099 |
Phase Not Applicable |
Not yet recruiting |
2 |
14 Months |
200 |
Anne Laure Fauchais, MD, Anne-Laure FAUCHAIS, MD, Philippe NUBUKPO, MD, Stéphanie DUMONTEIL |
2020-04-17 |
| Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease |
Coronavirus disease 19 infection |
clazakizumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cedars-Sinai Medical Center |
|
US |
2020-04-21 |
2021-03-31 |
00000644, NCT04348500 |
Phase 2 Clinical |
Not yet recruiting |
0 |
11 Months |
60 |
Noriko Ammerman, PharmD, Stanley Jorda |
2020-04-17 |
| SR-NOCS: Observational, clinical trial for the evaluation of an automated nasal and pharyngeal swab exam to test COVID-19 patients |
Coronavirus disease 19 infection |
robotic autonomous naso-oropharyngeal swab collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Klinikum rechts der Isar der Technischen Universitaet Muenchen |
Technical University of Munich |
Germany |
2020-04-01 |
|
152/20 S-KH, DRKS00021420, SR-NOCS |
Phase 1 Clinical |
Recruiting |
1 |
|
30 |
Dirk Wilhelm |
2020-04-17 |
| COVID19-BMT: Role of Immune and Inflammatory Response in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 |
Coronavirus disease 19 infection |
blood sampling alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Great Ormond Street Hospital for Children NHS Foundation Trust |
|
UK |
2020-04-15 |
2021-01-15 |
20BO08, COVID19-BMT, NCT04349540 |
Phase Not Applicable |
No longer recruiting |
1 |
9 Months |
40 |
|
2020-04-17 |
| COVVA: Occupational health and safety among health care personnel in a COVID-19 pandemic |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad de Valladolid |
|
Spain |
2020-04-01 |
2020-04-22 |
COVVA, ISRCTN18348009, V_01_2020_REF.03.V_02 |
Phase Not Applicable |
No longer recruiting |
2 |
|
80 |
Prof Martín-Rodríguez |
2020-04-17 |
| BREATHE: An adaptive,pivotal, randomized, placebo-controlled, double-blind, multicenter clinical study to assess the impact of intravenous gimsilumab on mortality in COVID-19 patients with lung injury or ARDS |
Acute lung injury, Adult respiratory distress syndrome, Coronavirus disease 19 infection |
gimsilumab alone |
GM-CSF ligand inhibitor |
|
Roivant Sciences Ltd |
|
US |
|
|
BREATHE |
Phase Not Applicable |
Recruiting |
0 |
|
270 |
Dr. Gerard Criner |
2020-04-17 |
| A randomized, double-blind, placebo, parallel-controlled, phase I/II clinical trial to assess safety and efficacy of COVID-19 vaccine (inactivated, Vero cells) in Chinese healthy subjects for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
COVID-19 vaccine (inactivated, Vero cells/intramuscular), Wuhan Institute of Biological Products/Wuhan Institute of Virology, CAS alone |
|
Healthy volunteers accepted, Asian Ancestry |
Wuhan Institute of Biological Products Co Ltd |
|
China |
|
|
|
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
336 |
Xia Shengli |
2020-04-17 |
| Effect of a Brief Problem Management Intervention on COVID 19-Related Anxiety and Depression |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
Problem Management Plus alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UNSW Sydney |
National Health and Medical Research Council |
Australia |
2020-04-20 |
|
ACTRN12620000468921p |
Phase Not Applicable |
Not yet recruiting |
1 |
|
140 |
Prof Richard Bryant |
2020-04-17 |
| Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus |
Coronavirus disease 19 infection |
Nasodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Firebrick Pharma Pty Ltd |
|
Australia |
2020-04-20 |
|
ACTRN12620000470998p, FBP-004 |
Phase 0 Clinical |
Not yet recruiting |
1 |
|
20 |
Prof Peter Friedland |
2020-04-17 |
| A clinical study of stem cells to treate hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection |
stem cells, Calidi Biotherapeutics Inc alone |
|
|
Personalized Stem Cells Inc |
Calidi Biotherapeutics Inc |
US |
2020-05-31 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-16 |
| PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) |
Coronavirus disease 19 infection |
povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-05-31 |
2020-08-31 |
IRB-56134, NCT04347954 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
45 |
Neelaysh Vukkadala, MD, Peter H Hwang, MD |
2020-04-17 |
| UPMC-REMAP-COVID19: A novel clinical trial to evaluate the effect of hydroxychloroquine in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
hydroxycloroquine alone, immunomodulators alone, standard of care alone, steroids alone |
|
|
University of Pittsburgh School of Medicine |
|
US |
|
|
UPMC-REMAP-COVID19 |
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
Derek Angus |
2020-04-16 |
| Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
anti-coronavirus antibody (immunoglobulin) therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale Papa Giovanni XXIII |
Aferetica Srl |
Italy |
2020-04-30 |
2020-07-31 |
DFPP COVID 19, NCT04346589 |
Phase Not Applicable |
Not yet recruiting |
5 |
3 Months |
10 |
Anna Falanga, MD, Annalisa Perna, Stat., Annapaola Callegaro, MD, Claudio Farina, MD, Diego Curto, MD, Diego Curtò, MD, Ferdinando Luca Lorini, MD, Giuseppe Remuzzi, MD, Lorenzo Grazioli, MD, Luca Barcella, MD, Marina Marchetti, Biol. Sci.D., Marina Noris, Ch., Miriam Galbusera, Biol.Sci. D., Piero Luigi Ruggenenti, Piero Luigi Ruggenenti, MD, Stefano Rota, MD |
2020-04-17 |
| Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
online mindfulness session alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
|
Hong Kong |
2020-05-01 |
2021-04-30 |
NCT04346082, ONLINE-MIND |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
30 |
Kam Pui Lee, MSc, kam pui Lee, Msc |
2020-04-16 |
| A study to investigate the therapeutic benefit and safety of convalescent plasma in patients with Covid-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Feinstein Institute for Medical Research, Mayo Clinic Foundation, Northwell Health Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Craig Devoe, MD |
2020-04-16 |
| Compassionate Use Open-Label, Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Respiratory disease |
IC-14 alone |
Monocyte differentiation antigen CD14 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Implicit Bioscience Ltd |
|
Italy |
|
|
COV02, NCT04346277 |
Phase Not Applicable |
Recruiting |
1 |
|
|
Lorenzo Dagna, MD |
2020-04-17 |
| ProCov: Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: A Pilot Study |
Coronavirus disease 19 infection |
prone positioning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Aix-Pertuis |
|
France |
2020-04-01 |
2020-05-01 |
20202703-2, NCT04344106, ProCov |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
25 |
Camille begne, MD, Laurence Maulin, MD, Laurent Lefebvre, MD, Marie Bernardi, MD, Stephanie Martinez, MD, Thibaut Helbert, MD, Xavier ELHARRAR, Xavier ELHARRAR, MD, Youssef Trigui, MD |
2020-04-17 |
| Explore: Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19 |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
Explore, FMASU P17A/ 2020, NCT04346056 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
500 |
Sara Hassan Agwa |
2020-04-17 |
| Strain Study: To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database |
Coronavirus disease 19 infection |
Ion AmpliSeq alone, next-generation sequencing (NGS) alone, phylogenetic analysis alone, polymerase chain reaction (PCR) alone, reverse transcription polymerase chain reaction (rRT-PCR) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P16A/ 2020, NCT04346043, Strain Study |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
100 |
Hesham Elghazaly,MD |
2020-04-17 |
| A serological testing study as a potential treatment for COVID-19 infection |
Coronavirus disease 19 infection |
EUROIMMUN Anti-SARS-CoV-2 ELISA testing kits alone, EUROLabWorkstations alone |
|
|
Beaumont Health |
|
|
|
|
NCT04349202 |
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-16 |
| COVIDOC: Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital, Montpellier |
|
France |
2020-04-10 |
2021-04-06 |
COVIDOC, NCT04345861, RECHMPL20_168 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
11 Months |
150 |
Jacques REYNES, MD PhD, Jacques REYNES, MD,PhD, jacques REYNES, MD, PhD |
2020-04-17 |
| Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus |
Coronavirus disease 19 infection, Insulin dependent diabetes, Non-insulin dependent diabetes |
tele-intervention alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Federal University of Rio Grande do Sul |
|
Brazil |
2020-04-17 |
2020-08-30 |
2020241093, NCT04344210 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
149 |
|
2020-04-17 |
| COVID-19 Plasma Collection |
Coronavirus disease 19 infection |
convalescent plasma collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Thomas Jefferson University |
|
US |
2020-04-13 |
2021-04-12 |
20D.346, NCT04344015 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
2000 |
Julie Karp, MD, Mackenzie Kemp, MPH |
2020-04-17 |
| A randomized, double-blinded, placebo-controlled, phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) |
Coronavirus disease 19 infection |
Recombinant Novel Coronavirus Disease Vaccine (Adenovirus Vector) alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CanSino Biologics Inc, Institute of Biotechnology the Academy of Military Medical Sciences PLA, Jiangsu Province Centers for Disease Control and Prevention |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-12 |
2021-01-31 |
ChiCTR2000031781 |
Phase 2 Clinical |
Not yet recruiting |
3 |
9 Months |
500 |
Hou Lihua, Zhu Fengcai |
2020-04-17 |
| Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen |
Coronavirus disease 19 infection |
vazegepant alone |
CGRP receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Biohaven Pharmaceutical Holding Co Ltd |
|
|
2020-04-30 |
2020-07-31 |
BHV3500-203, NCT04346615 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
120 |
|
2020-04-17 |
| PHYSIO-COVID: Implementation of Physiotherapy on COVID-19 Patients in ICU |
Coronavirus disease 19 infection |
phsyiotherapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
Sociedad Española de Neumología y Cirugía Torácica, Societe française de kinésithérapie en réanimation |
Spain, Italy, Argentina, France, Belgium, Chile |
2017-04-01 |
2022-12-01 |
NCT04347070, PHYSIO-COVID, RECHMPL20_0175 |
Phase Not Applicable |
Recruiting |
6 |
68 Months |
150 |
Gustavo Plotnikow, Gustavo Plotnikow, Physiotherapis, Roberto Martinez-Alejos, Roberto Martinez-Alejos, MD, PhD, roberto Martinez-Alejos, Physiotherapis |
2020-04-17 |
| Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis? |
Coronavirus disease 19 infection |
tuberculin test alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-04-11 |
2020-06-30 |
ASSIUTU12, NCT04347876 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
100 |
Aliae AR Mohamed Hussein, Aliae AR Mohamed-Hussein |
2020-04-17 |
| CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort |
Coronavirus disease 19 infection, Viral pneumonia |
eculizumab alone |
Complement C5 factor inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-30 |
2020-08-31 |
APHP200375-4, CORIMUNO19-ECU, NCT04346797 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
120 |
Régis Peffault de Latour, MD PhD |
2020-04-16 |
| Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit |
Acute stress disorder, Coronavirus disease 19 infection |
|
|
|
Raymond Poincare University Hospital |
Hôpital Cochin |
France |
2020-04-15 |
2020-09-01 |
CSC19APR, NCT04346810 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
100 |
Dominique Fletcher, MD, PhD, HARKOUK Hakim, Hakim Harkouk, M.D. |
2020-04-17 |
| Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
leronlimab alone |
CCR5 chemokine antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
CytoDyn Inc |
|
US |
2020-04-15 |
2021-04-01 |
CD12_COVID-19, NCT04347239 |
Phase 2 Clinical |
Recruiting |
0 |
11 Months |
390 |
Kush Dhody, MBBS, MS, CCRA |
2020-04-17 |
| A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019 |
Coronavirus disease 19 infection |
standard treatment alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jilin University |
|
China |
2020-02-01 |
2020-12-01 |
130004, NCT04346602 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
132 |
Bai ling Yan, Doctor, Dong Yang, Master |
2020-04-17 |
| An Open, Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone, mefloquine (Farmzashita) alone, Variable regimens including azithromycin , hydroxychloroquine , mefloquine (Farmzashita) , tocilizumab |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Burnasyan Federal Medical Biophysical Center |
|
Russian Federation |
2020-04-08 |
2020-08-01 |
FL-01/20, NCT04347031 |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
320 |
Tatiana Astrelina, MD PhD,DSc. |
2020-04-17 |
| A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients |
Coronavirus disease 19 infection |
cadi-05 alone, standard care therapy alone |
Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cadila Pharmaceuticals Ltd |
Council of Scientific and Industrial Research (India) |
India |
2020-04-20 |
2020-07-30 |
CRSC20004, NCT04347174 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
40 |
Sanjay Patel, MBBS |
2020-04-16 |
| CONEC: Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single-Center Over the Course of 12 Months |
Coronavirus disease 19 infection |
blood and urine analysis alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
Austria |
2020-04-11 |
2021-04-11 |
1375/2020, CONEC, NCT04347694 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
400 |
Thomas J Reiter, MD |
2020-04-17 |
| PHYSIO-COVID: Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-09-30 |
2020-A00957-32, 2020_32, NCT04347928, PHYSIO-COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
15 |
Thibault Duburcq, MD |
2020-04-17 |
| TEACHCOVID: Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study |
Coronavirus disease 19 infection, Viral pneumonia |
Hydroxychloroquine alone, standard of care alone, Variable regimens including Hydroxychloroquine , azithromycin , ceftriaxone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
|
2020-05-01 |
2021-08-01 |
7783, NCT04347512, TEACHCOVID |
Phase 3 Clinical |
Not yet recruiting |
0 |
15 Months |
405 |
Loic Kassegne, MD |
2020-04-17 |
| The Randomized, Open, Phase II Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 |
Coronavirus disease 19 infection |
clevudine alone, hydroxychloroquine alone |
DNA polymerase inhibitor, Nucleoside reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bukwang Pharmaceutical Co Ltd |
|
|
2020-04-24 |
2020-12-31 |
BK-CLV-201, NCT04347915 |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
60 |
Bukwang Bukwang |
2020-04-17 |
| A Prospective 'Universal' Observational Database for COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Hackensack Meridian Health |
Cota Inc |
US |
2020-03-27 |
2021-04-30 |
NCT04347993, PRO2020-0342 |
Phase Not Applicable |
Recruiting |
0 |
13 Months |
5000 |
Andrew Ip, MD, Brittany Sinclaire, Urszula Bednarz |
2020-04-17 |
| RAPID-19: Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19 |
Coronavirus disease 19 infection |
Covid-19 Antibody testing alone, Loop mediated isothermal amplification alone |
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Queens University of Belfast |
Belfast Health & Social Care Trust |
UK |
2020-04-13 |
2020-10-13 |
282617, NCT04347408, RAPID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
150 |
Sharon Christie, PhD, Thomas Waterfield, BMBCh |
2020-04-17 |
| Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone, standard of care treatment alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-04-30 |
2021-04-30 |
56032, NCT04346628 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
120 |
Study Team, Yvonne (Bonnie) A Maldonado, MD |
2020-04-16 |
| COVIDHLH: Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH |
Coronavirus disease 19 infection, Hemophagocytic lymphohistiocytosis, Macrophage activation syndrome, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Technical University of Munich |
|
Germany |
2020-03-27 |
2020-08-31 |
161/20 S, COVIDHLH, NCT04347460 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
20 |
Christoph Schmaderer, M.D., Georg Lorenz, M.D., Philipp Moog, M.D. |
2020-04-17 |
| Multicenter, observational study to examine the efficacy of protection during endoscopy examination for Covid-19 infection |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Tokyo |
|
Japan |
2020-04-14 |
|
UMIN000040162 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Ryota Niikura |
2020-04-17 |
| IMPACT: Impact of Antimalarials on Covid Infections in RAPPORT |
Coronavirus disease 19 infection, Rheumatoid arthritis |
B-cell depletor therapy alone, IL-17 blocker therapy alone, JAK kinase inhibitor therapy alone, T-cell c-stimulation inhibitor therapy alone, anti-IL-6 blocker therapy alone, anti-TNF inhibitor therapy alone, chloroquine alone, disease modifying anti-rheumatic drug therapy alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alberta |
|
Canada |
2020-04-15 |
2021-04-30 |
IMPACT, NCT04347798, PRO00100000 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
500 |
Stephanie O Keeling, MD, Walter P Maksymowych, MD |
2020-04-17 |
| PRoVENT-COVID: Paactice of Ventilation in COVID-19 Patients |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Academic Medical Center, University of Amsterdam |
|
Netherlands |
2020-03-06 |
2020-08-31 |
NCT04346342, PROVENT-COVID, PRoVENT-COVID |
Phase Not Applicable |
Recruiting |
19 |
5 Months |
1000 |
Anissa Tsonas, MD, Anna Geke Algera, MD, Ary Serpa Neto, MD, PhD, Frederique Paulus, PhD, Marcus Schultz, MD, PhD, Michela Botta, Michela Botta, MD |
2020-04-17 |
| A phase III study of Actemra for the treatment of hospitalized patients with severe COVID-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
Chugai Pharmaceutical Co Ltd |
|
Japan |
|
|
|
Phase 3 Clinical |
Planned |
1 |
|
|
|
2020-04-16 |
| Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
bone marrow-derived mesenchymal stem cells alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Guangzhou Institute Of Respiratory Disease |
Guangzhou 8th People's Hospital, Tongji Hospital, Huazhong University of Science and Technology |
China |
2020-04-30 |
2020-12-31 |
NCT04346368, SC-2020-01 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
20 |
Ming Liu, MD, ShiYue Li, Shiyue Li, MD |
2020-04-17 |
| Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome |
Coronavirus disease 19 infection, Systemic inflammatory response syndrome |
anti-IL-6-R antibody therapy alone, ventilation support alone |
|
|
Brugmann University Hospital |
|
Belgium |
2020-03-20 |
2020-12-31 |
CHUB-IL6-COVID-19, NCT04346017 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
200 |
Carole Nagant, MD, Carole Nagant, PhD, Francis Corazza, Francis Corazza, MD, Patrick Stordeur, PhD |
2020-04-17 |
| DHYSCO: Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome |
standardized ventilatory management alone, dexamethasone plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Association Marie Lannelongue |
|
France |
2020-04-30 |
2020-08-31 |
2037815010, DHYSCO, NCT04347980 |
Phase 3 Clinical |
Not yet recruiting |
1 |
4 Months |
122 |
Francois STEPHAN, MD, PhD, Lilia Lamrani |
2020-04-16 |
| RegCOVID19: Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Instituto de Investigacion Marques de Valdecilla, IDIVAL |
|
|
2020-04-15 |
2021-01-01 |
IDI-REM-2020-1, NCT04347278, RegCOVID19 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
100 |
LUCIA LAVIN ALCONERO, Phd, MARIA DEL MAR GARCIA SAIZ, MDPhD |
2020-04-17 |
| Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent plasma alone, supportive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-14 |
2020-06-30 |
ILBS-COVID-02, NCT04346446 |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
20 |
Dr Meenu Bajpai, MD, Dr Shiv Kumar Sarin, DM |
2020-04-17 |
| COVID-HEP: Preventing COVID-19 Complications With Low and High-dose Anticoagulation |
Blood clotting disorder, Coronavirus disease 19 infection, Thrombosis |
enoxaparin sodium alone, unfractionated heparin alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires De Geneve |
|
Switzerland |
2020-04-14 |
2020-11-30 |
2020-00794, COVID-HEP, NCT04345848 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
200 |
Marc Blondon |
2020-04-16 |
| A phase I clinical study of 7HP-349 in healthy subjects for the potential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
7HP-349 alone |
CD11a agonist, CD49d agonist, ICAM-1 stimulator, Integrin agonist, Vascular cell adhesion protein 1 agonist |
Healthy volunteers accepted |
7 Hills Pharma Llc |
|
US |
|
|
|
Phase 1 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-17 |
| Effect of SARS-CoV-2 infection upon male reproductive system |
Coronavirus disease 19 infection |
|
|
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shandong Provincial Hospital |
|
China |
2020-04-09 |
2021-04-01 |
ChiCTR2000031779 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
50 |
Liqiang Guo, Shengtian Zhao |
2020-04-17 |
| PEACE: Post-exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With Choloroquine Compounds |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Specialized Healthcare and Medical Education Department |
Forman Christian College, Harvard TH Chan School of Public Health, Mayo Hospital, Pakistan Kidney and Liver Institute, SERVICES INSTITUTE OF MEDICAL SCIENCES |
US |
2020-04-14 |
2021-05-28 |
NBC-COVID19-02, NCT04346667, PEACE |
Phase 4 Clinical |
Not yet recruiting |
0 |
13 Months |
400 |
Ammar Sarwar, Ammar Sarwar, MD |
2020-04-17 |
| A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease |
Coronavirus disease 19 infection |
RT-PCR test alone, artificial intelligence technology deep learning method alone, computed tomography imaging alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xinqiao Hospital of Chongqing |
|
China |
2020-01-17 |
2020-05-31 |
NCT04347369, XQONC-015 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
1000 |
Jianguo Sun, Sun JG |
2020-04-16 |
| Predict Adverse Events by Covid-19 Nephritis |
Coronavirus disease 19 infection, Nephritis |
urine analysis alone |
|
Healthy volunteers accepted |
University Hospital Goettingen |
Transplantationszentrum Köln-Merheim, University Hospital, Aachen, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-04-13 |
2021-12-31 |
NCT04347824, UMG_CO19-NEPHRITIS |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
100 |
Oliver Gross, MD, Prof. Dr. O. Gross |
2020-04-17 |
| Chloroquine UN: Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Colombia |
Fundacion Salud de los Andes |
Colombia |
2020-04-20 |
2020-10-01 |
Chloroquine UN, NCT04346329, UNAL-COVID-CP |
Phase 3 Clinical |
Not yet recruiting |
2 |
5 Months |
86 |
Calos A Parra-Lopez, MD PhD, Carlos A Parra-López, MD, PhD, Carlos A parra-Lopez, MD PhD, Carlos Alberto Parra Lopez, David A Bernal-Estevez, MD PhD, David A Bernal-Estévez, MD, PhDc |
2020-04-17 |
| Safety and Efficacy of Ruxolitinib for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado, Denver, US |
|
US |
2020-04-30 |
2020-10-31 |
20-0869, NCT04348071 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
6 Months |
80 |
Angela Rachubinski, PhD, Joaquin Espinosa, PhD, Joaquin M Espinosa, PhD |
2020-04-17 |
| Prophylactic Hydroxychloroquine versus Vitamin C in Healthcare Workers: RCT |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stony Brook University Hospital |
|
US |
2020-04-20 |
2020-12-30 |
IRB2020-00222, NCT04347889 |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
1212 |
Adam Singer |
2020-04-16 |
| COVIDotheque: A Cohort of Patients With Possible or Confirmed SARS-CoV-2(COVID-19) |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted |
University Hospital, Montpellier |
|
France |
2020-02-01 |
2022-12-30 |
COVIDotheque, NCT04347850, RECHMPL20_0185 |
Phase Not Applicable |
Recruiting |
1 |
34 Months |
500 |
Edouard TUAILLON, MD, PhD |
2020-04-17 |
| Phase II, randomized, placebo-controlled, double-blind, single-center study evaluating the safety and efficacy of adipose-derived mesenchymal stem cells (HB-adMSCs) in COVID-19 patients |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
|
Hope Biosciences Inc |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
100 |
|
2020-04-17 |
| A clinical trial of ADX-629 for the treatment of patients with COVID-19-associated respiratory disease |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ADX-629 alone |
Acetaldehyde dehydrogenase inhibitor |
|
Aldeyra Therapeutics Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-16 |
| Spironolactone in Covid-19 Induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
spironolactone alone |
Aldosterone antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-04-21 |
2020-10-21 |
10042020, NCT04345887 |
Phase 4 Clinical |
Not yet recruiting |
1 |
6 Months |
60 |
Olcay Dilken, Yalim Dikmen |
2020-04-17 |
| CoVid-19 - Infection and Antibody Formation in the Viennese Population |
Coronavirus disease 19 infection |
serum blood and antibody measurement alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ludwig Boltzmann Institute for Lung Vascular Research |
|
Austria |
2020-04-27 |
2020-09-30 |
LEAD COVID-19, NCT04346264 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
5500 |
Otto C Burghuber, Prof.MD |
2020-04-17 |
| Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19 |
Coronavirus disease 19 infection, Hypoxia |
double-trunk mask alone, standard nasal cannula alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Clinique Universitaires Saint-Luc, Universite Catholique de Louvain |
|
Belgium |
2020-04-09 |
2020-06-30 |
DTM-001, NCT04346420 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
15 |
Poncin, William Poncin, William Poncin, PT, PhD |
2020-04-17 |
| WUHAN: Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT |
Coronavirus disease 19 infection |
standard medical care alone, black cumin plus honey |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Federal Postgraduate Medical Institute |
Mayo Hospital |
Pakistan |
2020-04-15 |
2020-05-30 |
1.6/M.EDU/141/2020, NCT04347382, WUHAN |
Phase 3 Clinical |
Recruiting |
1 |
1 Month |
30 |
Ahmad Imran, MBBS, Ayesha Hamayun, PhD, Muhammad Ahmad Imran, MBBS, Muhammad Ashraf, PhD, Shoaib Ashraf, PhD, Sohaib Ashraf, MBBS |
2020-04-17 |
| CALAVI: Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus) |
Coronavirus disease 19 infection |
Best Supportive Care alone, acalabrutinib alone |
Btk tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AstraZeneca plc |
Acerta Pharma BV |
US, Europe |
2020-12-18 |
2022-01-28 |
ACE-ID-201, CALAVI, D822FC00001, NCT04346199 |
Phase 2 Clinical |
Not yet recruiting |
0 |
13 Months |
428 |
AstraZeneca Cancer Study Locator, AstraZeneca Clinical Study Information Center, Louis M. Staudt, Wyndham H. Wilson |
2020-04-17 |
| A Study to Assess the Virus, RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease |
Conjunctivitis, Coronavirus disease 19 infection, Inflammatory disease |
Schirmer Test I alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universita Degli Studi G D`Annunzio Chieti |
|
Italy |
2020-04-14 |
2020-04-30 |
NCT04346160, UCHIETI03 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
25 |
Leonardo Mastropasqua, Leonardo Mastropasqua, Professor, Manuela Lanzini, Doctor |
2020-04-17 |
| COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff |
Coronavirus disease 19 infection |
Elisa-test for IgM and IgG alone, IgM and IgG diagnostic kits test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Herlev Hospital Region Hovedstaden |
HS Hvidovre Hospital, Mental Health Services in the Capital Region of Denmark, Nordsjaellands Hospital, Rigshospitalet, Denmark, University Hospital Bispebjerg and Frederiksberg |
Denmark |
2020-04-15 |
2021-08-01 |
NCT04346186, REGHCOVIDSCREENING |
Phase 4 Clinical |
Not yet recruiting |
14 |
15 Months |
30000 |
Curt Sten, Fredrik Folke, Associate prof., Henning Bundgaard, Prof., Henrik Ullum, Prof., Ida Hageman, Jørgen Rungby, Jørgen Rungby, Prof., Kasper Iversen, Kasper Iversen, Prof., Ove Andersen, Prof., Rasmus Hasselbalch, Rasmus Hasselbalch, MD, Susanne Dam Poulsen, Prof., Thea Kølsen Fischer, Thomas Benfield, Prof. |
2020-04-17 |
| SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with moderate COVID-19 |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
|
2020-04-14 |
|
SIMPLE |
Phase 3 Clinical |
Recruiting |
0 |
|
|
|
2020-04-16 |
| SIMPLE: A global phase III trial to evaluate safety and efficacy of intravenous remdesivir in patients with severe COVID-19 |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
|
Gilead Sciences Inc |
|
|
2020-04-14 |
|
SIMPLE |
Phase 3 Clinical |
Recruiting |
0 |
|
|
|
2020-04-16 |
| MACOVIA: A phase II/III, double-blinded, randomized, placebo-controlled, multicenter, pivotal study to assess the safety and efficacy of MultiStem therapy in subjects with moderate to severe acute respiratory distress syndrome (ARDS) induced by the novel coronavirus disease (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
multipotent adult progenitor cell therapy (ischemia/ARDS/ocular diseases), Athersys/ Healios alone |
|
|
Athersys Inc |
|
US |
2020-06-30 |
|
MACOVIA |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
|
400 |
|
2020-04-17 |
| A randomized-controlled, double-blind study to evaluate the effectiveness of the Kerecis Omega3 Viruxide system in COVID-19 patients |
Coronavirus disease 19 infection |
Kerecis Omega3 Viruxide system alone |
|
|
Kerecis Ehf |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-16 |
| Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19 |
Advanced solid tumor, Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
BMS-986253 alone |
IL-8 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
Bristol-Myers Squibb Co |
US |
2020-04-30 |
2022-09-30 |
AAAS9881, NCT04347226 |
Phase 2 Clinical |
Not yet recruiting |
0 |
29 Months |
138 |
Lisa Olmos, RN, Matthew Dallos, MD |
2020-04-17 |
| ProCoV: Prospective molecular biological and serological examination for the detection of SARS-CoV-2 (COVID-19) in employees of a hospital of regular care in Germany |
Coronavirus disease 19 infection |
serological examination alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Krankenhaus Reinbek St. Adolf-Stift |
|
Germany |
2020-04-14 |
|
038/20 I, DRKS00021270, ProCoV |
Phase Not Applicable |
Not yet recruiting |
1 |
|
800 |
Jonas Herzberg, Tim Strate |
2020-04-17 |
| A randomized, placebo-controlled, phase II study to assess the effect of fenretinide in patients with Covid-19 |
Coronavirus disease 19 infection, Lung inflammation |
fenretinide (pulmonary Pseudomonas aeruginosa infections in cystic fibrosis), McGill University/Laurent Pharmaceuticals alone |
Nuclear factor kappa B gene modulator |
|
Laurent Pharmaceuticals |
|
US, Canada |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
200 |
|
2020-04-17 |
| A clinical trial of baricitinib for the potential treatment of hospitalized patients diagnosed with COVID-19 |
Coronavirus disease 19 infection |
baricitinib alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Eli Lilly & Co |
National Institute of Allergy and Infectious Diseases |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-17 |
| A Study to Assess the Effect of SoftWaves in Patients with Covid-19 |
Coronavirus disease 19 infection |
SoftWaves alone |
|
|
Tissue Regeneration Technologies Llc |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-16 |
| A clinical trial to evaluate the effectiveness of different combinations of the anti-malarial drugs chloroquine and hydroxychloroquine and azithromycin in treating ill patients infected with the novel coronavirus |
Coronavirus disease 19 infection |
chloroquine alone, hydroxychloroquine alone, Variable regimens including azithromycin , chloroquine , hydroxychloroquine |
|
|
Washington University in St Louis |
Barnes-Jewish Hospital Foundation, National Center For Advancing Translational Sciences |
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
500 |
Jane O’Halloran, Rachel M. Presti |
2020-04-16 |
| A phase I clinical trial of S-protein COVID antigen vaccine for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
protein subunit vaccine (COVID-19), Sanofi Pasteur alone |
|
|
GlaxoSmithKline plc, Sanofi Pasteur, Sanofi SA |
|
|
2020-12-31 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-16 |
| An questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19) infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
hydroxychloroquine alone |
|
|
The Second XiangYa Hospital of Central South University |
Hunan Provincial Department of Finance |
China |
2020-04-10 |
2020-06-30 |
ChiCTR2000031782 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
1200 |
Hui Jin, Qianjin Lu |
2020-04-17 |
| Investigation for Prevention Awareness against COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Male, Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Universitad Major de S. Andres,, Wuhan University |
|
Bolivia |
2020-03-17 |
|
ChiCTR2000031783 |
Phase Not Applicable |
No longer recruiting |
1 |
|
883 |
DIANA MARIA CESPEDES ARCANI |
2020-04-17 |
| A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Central Hospital of Huanggang |
|
China |
2020-04-08 |
2020-05-08 |
ChiCTR2000031794 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
130 |
Liping Jia, Quanshui Hao |
2020-04-17 |
| Evaluation of Hydroxychloroquine for prevention of hospitalization and respiratory complications in patients with confirmed diagnosis or suspected infection by (COVID-19) |
Coronavirus disease 19 infection, Respiratory disease |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
EMS SA, Hospital Alemao Oswaldo Cruz |
|
Brazil |
2020-04-10 |
2020-07-10 |
A27736297878, RBR-3cbs3w |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
1300 |
Dayane Correa Vila Nova, Priscila Kazue Kunitake, Álvaro Avezum |
2020-04-17 |
| Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes |
Coronavirus disease 19 infection, Lung disease |
Non-specific Toning Exercise Program alone, Respiratory Exercise Program alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Sevilla |
|
Spain |
2020-04-01 |
2020-04-15 |
ET-SEF-21/20, RBR-6m69fc |
Phase Not Applicable |
Recruiting |
1 |
|
99 |
Carlos Bernal Utrera |
2020-04-17 |
| A clinical study of GV-1001 to treat COVID-19 patients |
Coronavirus disease 19 infection |
tertomotide alone |
Telomerase modulator |
|
GemVax & Kael Co Ltd |
|
South Korea |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
2 |
|
2020-04-15 |
| A clinical study of Cellgram-AKI, a stem cell therapy, for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
Cellgram-AKI alone |
|
|
FCB-Pharmicell Co Ltd |
|
South Korea |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
24 |
|
2020-04-15 |
| CoVitTrial: Covid-19 and Vitamin D Supplementation: a Multicenter, Randomized, Controlled Trial of High-Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
Zymad alone |
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
Mylan Laboratories Ltd |
France |
2020-04-30 |
2020-07-31 |
2020-001602-34, CoVitTrial, NCT04344041 |
Phase 3 Clinical |
Not yet recruiting |
9 |
3 Months |
260 |
Achille TCHALLA, Bertrand FOUGERE, Claire ROUBAUD BAUDRON, Cédric ANNWEILER, DCRI Angers, Frédéric SHOLASTIQUE, Guillaume CHAPELET, Jean Baptiste BEUSCART, Marjorie HOUVET, Olivier GUERIN, Thomas CELARIER |
2020-04-16 |
| Angiotensin Converting Enzyme Inhibitors in Treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including captopril , chloroquine , enalapril |
ACE inhibitor |
|
Tanta University |
|
Egypt |
2020-04-15 |
2029-12-01 |
ACEIS COVID 19, NCT04345406 |
Phase 3 Clinical |
Not yet recruiting |
1 |
115 Months |
60 |
Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. |
2020-04-16 |
| Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
Assiut University |
|
Egypt |
2020-05-31 |
2020-10-31 |
COVID-19 MENTAL HEALTH, NCT04344834 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
300 |
Haidi Karam |
2020-04-16 |
| CovidRegOUH: Prospective Quality Register of Patients With Confirmed COVID-19 at Oslo University Hospital |
Coronavirus disease 19 infection |
|
|
|
Oslo University Hospital |
|
Norway |
2020-03-15 |
2021-05-01 |
COVIDREGOUH, CovidRegOUH, NCT04345536 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
400 |
Aleksander Holten, MD, Aleksander Holten, PhD, Aleksander Rygh Holten, Kristian Tonby, MD |
2020-04-16 |
| CYTOCOV-19: Effect of CytoSorb Adsorber on Hemodynamical and Immunological Parameters in Critical Ill Patients With COVID-19 |
Coronavirus disease 19 infection |
CytoSorb adsorber alone, hemoadsorption alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitätsklinikum Hamburg-Eppendorf |
|
Germany |
2020-04-01 |
2021-02-28 |
CYTOCOV-19, CYTOCOV-19, DRKS00021199, NCT04344080, U1111-1250-2078 |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
24 |
Axel Nierhaus, MD, Dominik Jarczak, MD, Kevin Roedl, MD, Stefan Kluge, MD |
2020-04-17 |
| ChilblainCOVID: Assessment of Chilbains Occuring During Covid-19 Infection |
Coronavirus disease 19 infection, Dermatological disease |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-09 |
2020-06-30 |
20DERMATOCOVID.02, ChilblainCOVID, NCT04344119 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
30 |
Cynthia CAILLON, Sylvie MALERBA, Thierry PASSERON |
2020-04-17 |
| PISCO: Pyridostigmine in Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
Mestinon alone, medical care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Ciencias Medicas y Nutricion |
|
Mexico |
2020-04-04 |
2021-04-30 |
INF-3323, NCT04343963, PISCO |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
12 Months |
436 |
José C Crispín, MD, PhD, Juan Sierra-Madero, MD, Sergio I Valdés-Ferrer, MD, PhD |
2020-04-16 |
| Covid-19, Case-Cluster Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
University of Bonn |
Ministerium für Arbeit, Gesundheit und Soziales NRW |
Germany |
2020-03-31 |
|
DRKS00021306, Lfd. Nr. 085/20 |
Phase Not Applicable |
Recruiting |
1 |
|
1400 |
Hendrik Streeck |
2020-04-15 |
| EVICT-CORONA-ALI: Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury |
Acute lung injury, Coronavirus disease 19 infection, Hypoxia |
vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Virginia Commonwealth University |
|
US |
2020-04-22 |
2021-05-31 |
EVICT-CORONA-ALI, HM20018977, NCT04344184 |
Phase 2 Clinical |
Not yet recruiting |
0 |
13 Months |
200 |
Alpha (Berry) A Fowler, III, MD, Brian Davis, MD, Markos G Kashiouris, MD MPH |
2020-04-15 |
| Gargling and Nasal Rinses to Reduce Oro and Nasopharyngeal Viral Load in Patients With COVID-19 |
Coronavirus disease 19 infection |
chlorhexidine gluconate alone, povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
NYU Langone Health |
|
US |
2020-04-09 |
2020-05-09 |
NCT04344236, S20-00444 |
Phase 2 Clinical |
Recruiting |
0 |
1 Month |
48 |
Lindsey Moses, MD, Scott Rickert, Scott Rickert, MD |
2020-04-15 |
| OHB10cov: Management by Hyperbaric Oxygen Therapy of Patients With Hypoxemic Pneumonia With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hyperbaric chamber alone, hyperbaric oxygen plus normobaric oxygen |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Direction Centrale du Service de Sante des Armees |
|
France |
2020-04-30 |
2021-05-31 |
2020PPRC03, NCT04344431, OHB10cov |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
13 Months |
100 |
Jean-Eric BLATTEAU, MD, PhD |
2020-04-16 |
| APCOLIS STUDY: The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver |
Coronavirus disease 19 infection, Hepatitis, Liver cirrhosis, Liver disease |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-14 |
2020-06-30 |
APCOLIS STUDY, ILBS-COVID-01, NCT04345640 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
100 |
Dr Ashok Choudhary, DM, Dr Shiv Kumar Sarin, DM |
2020-04-16 |
| CORIMMUNO-COAG: Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
Coronavirus disease 19 infection, Lung disease |
heparin sodium Choay alone, nadroparin calcium alone, tinzaparin sodium alone |
Antithrombin III, Factor Xa antagonist, Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-20 |
2020-09-30 |
APHP200389-6, CORIMMUNO-COAG, NCT04344756 |
Phase 2 Clinical |
Not yet recruiting |
3 |
5 Months |
808 |
Damien Roux, MD PhD, Frédéric Penne, MD PhD, Jean-Luc Diehl, Tristan Mirault |
2020-04-16 |
| Effect of Trifluoperazine in treatment of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , ribavirin , trifluoperazine |
HIV protease inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Birjand University |
|
Iran |
2020-04-16 |
|
IR.BUMS.REC.1399.004, IRCT20200408046992N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
70 |
Dr Masood Ziaee, Kazem Dastjerdi, Masood Ziaee, Motahareh Mahi-Birjand |
2020-04-17 |
| RCT: Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone, azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
LCMC Health |
|
US |
2020-04-10 |
2021-12-10 |
COVID 2020-001, NCT04344444, RCT |
Phase 3 Clinical |
Recruiting |
0 |
20 Months |
600 |
Jeannine Ascani, Jeannine Ascani, MS, Meredith Clement, MD |
2020-04-16 |
| CovidDB: The Covid-19 Inpatient Database |
Coronavirus disease 19 infection |
|
|
|
ClarData |
|
Romania, Germany |
2020-03-30 |
2023-06-30 |
COVIDDB, CovidDB, NCT04344171 |
Phase Not Applicable |
Recruiting |
4 |
39 Months |
5000 |
Julia Ferencz, MD, Marius Ghidau, Dr., Ovidiu Bedreag, Prof., Sebastian Dieng, Thomas Seufferlein, Prof. |
2020-04-16 |
| Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
danoprevir plus ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, Hepatitis C virus NS3 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Huoshenshan Hospital |
Ascletis Pharmaceutical Co Ltd |
China |
2020-03-18 |
2020-05-31 |
ASC-CTP-HS-01, ChiCTR2000031734, NCT04345276 |
Phase 4 Clinical |
Recruiting |
1 |
2 Months |
40 |
Bo Wei, MD, Junxue Wang, MD, Yahong Chen, MD |
2020-04-17 |
| Phase I/II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia |
Coronavirus disease 19 infection |
natural killer cell alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National University of Colombia |
Fundacion Salud de los Andes |
Colombia |
2020-04-13 |
2020-11-10 |
NCT04344548, UNAL FSA COVID |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
2 |
6 Months |
10 |
Carlos A Parra-Lopez, MD PhS, Carlos Alberto Parra Lopez, David A Bernal E., MD PhD, David A Bernal-Estévez, MD PhD, Doris Mejía |
2020-04-16 |
| NIAID: COVID-19 Plasma Collection |
Coronavirus disease 19 infection |
plasma collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
National Institutes of Health Clinical Center |
|
US |
2020-04-15 |
2025-04-01 |
200081, NCT04344977, NIAID |
Phase Not Applicable |
Not yet recruiting |
0 |
59 Months |
2800 |
|
2020-04-16 |
| CORIMUNO-19-BEVA: Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zirabev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
Coronavirus disease 19 infection |
bevacizumab alone, bevacizumab biosimilar, Pfizer alone |
VEGF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-15 |
2020-11-30 |
APHP200389-7, CORIMUNO-19-BEVA, NCT04344782 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
130 |
Jacques Cadranel, MD PhD |
2020-04-17 |
| A Study to Assess the Effect of Allocetra in Patients with COVID-19 |
Coronavirus disease 19 infection |
Allocetra alone |
|
|
Enlivex Therapeutics Ltd |
Israeli Government |
Israel |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-15 |
| COVIDICUS: Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Airvo-2, Fisher and Paykel Healthcare alone, continuous positive airway pressure (CPAP) alone, conventional oxygen therapy alone, dexamethasone alone, high-flow-nasal cannula alone, mechanical ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-10 |
2020-12-31 |
2020-001457-43, APHP200388, COVIDICUS, NCT04344730 |
Phase 2 Clinical |
Recruiting |
1 |
8 Months |
550 |
Jean François TIMSIT, Pr, Jean-François TIMSIT, Pr, LILA BOUADMA, Pr, Lila Bouadma, Pr |
2020-04-16 |
| A Study of CM-4620 Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
CM-4620 alone |
Ca2+ release activated Ca2+ channel 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CalciMedica Inc |
|
US |
2020-04-08 |
2020-09-30 |
CM4620-204, NCT04345614 |
Phase 2 Clinical |
Recruiting |
0 |
5 Months |
60 |
Charles Bruen, MD, Joseph Miller, MD, Kathleen Wilson, RN, Ken Stauderman, PhD, Marissa K. Peterson, Sudarshan Hebbar, MD |
2020-04-16 |
| Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hackensack Meridian Health |
|
US |
2020-04-14 |
2022-04-08 |
NCT04345653, PRO2020-0356 |
Phase 2 Clinical |
Recruiting |
0 |
23 Months |
45 |
Jawad Kirmani, MD |
2020-04-17 |
| Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients |
Coronavirus disease 19 infection, Viral pneumonia |
bacterial species isolation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
France |
2020-04-30 |
2020-12-31 |
NCT04344509, PAVM COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
10000 |
Christophe BURUCOA |
2020-04-16 |
| A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Dyspnea, Viral pneumonia |
exercise rehabilitation under remote monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jiangsu Provincial People’s Hospital |
CF PharmTech Inc |
China |
2020-04-20 |
2020-10-20 |
ChiCTR2000031834 |
Phase Not Applicable |
Not yet recruiting |
2 |
6 Months |
120 |
Li Jianan, Wang Wenxia |
2020-04-16 |
| Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universite Libre de Bruxelles |
|
Belgium |
2020-04-15 |
2020-07-15 |
NCT04344145, PSY-ENCOVID19 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
200 |
Andrée Marcoen, Julien Tiete, PhD |
2020-04-16 |
| A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
|
The First People's Hospital of Jingzhou |
National Natural Science Foundation of China |
China |
2020-02-01 |
2020-12-31 |
ChiCTR2000031836 |
Phase Not Applicable |
No longer recruiting |
1 |
11 Months |
45 |
Jinzhi Lu |
2020-04-16 |
| A Real-life Experience on Treatment of Patients With COVID 19 |
Coronavirus disease 19 infection |
Alexoquine alone, Yomesan alone, favipiravir alone, ivermectin alone, nitazoxanide alone, Alexoquine plus azithromycin |
Chloride channel modulator, RNA polymerase inhibitor |
|
Tanta University |
|
Egypt |
2020-04-15 |
2029-12-31 |
COVID 19 TREATMENT, NCT04345419 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
116 Months |
100 |
Eslam Saber, ass. lect, Mai Khalaf, ass. lect., Sherief Abd-Elsalam, Sherief Abd-Elsalam, ass. prof. |
2020-04-16 |
| Covid-19 Pandemic. Emerging Legal and Ethical Disputes Over Patient Confidentiality |
Coronavirus disease 19 infection |
questionnaire alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Assiut University |
|
Egypt |
2020-04-30 |
2020-07-31 |
2020A10, NCT04344938 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
874 |
Noha Esmael Ebrahem, |
2020-04-16 |
| Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
rehabilitation exercise alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beijing Sport Uninversity |
|
China |
2020-04-27 |
2020-09-16 |
ChiCTR2000031860 |
Phase 0 Clinical |
Not yet recruiting |
1 |
4 Months |
150 |
Jinghua Qian, Zicheng Gao |
2020-04-16 |
| COVI-GAPP: Can the Ava fertility tracker device detect early signs of COVID-19? |
Coronavirus disease 19 infection |
AVA bracelet alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Lab Medical Center Dr. Risch AG |
Government of the Principality of Liechtenstein, HANELA-Stiftung, House of Liechtenstein |
Liechtenstein |
2020-03-20 |
2021-12-31 |
1.2, COVI-GAPP, ISRCTN51255782 |
Phase Not Applicable |
Recruiting |
1 |
21 Months |
7170 |
Dr Martin Risch, Dr Stefanie Aeschbacher, Mrs Kirsten Grossmann, Prof David Conen, Prof Risch |
2020-04-17 |
| Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
natural killer (NK) cells from umbilical cord blood alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huzhou Central Hospital |
Huzhou Science and Technology Bureau |
China |
2020-03-01 |
2021-02-28 |
ChiCTR2000031735 |
Phase 0 Clinical |
Not yet recruiting |
1 |
12 Months |
20 |
Enhai Cui, Feng Hua |
2020-04-16 |
| Anti COVID-19 Convalescent Plasma Therapy |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 convalescent plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
OrthoSera Korlátolt Felelősségű Társaság |
Hungarian National Blood Service, Semmelweis University, University Of Pécs |
Hungary |
2020-04-14 |
2021-04-01 |
ANTICOVID19ORT, NCT04345679 |
Phase 0 Clinical |
Not yet recruiting |
1 |
11 Months |
20 |
Eszter Fodor, medical doctor, Veronika Müller, MD, PhD, Zsombor Lacza, MD, PhD |
2020-04-16 |
| Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Puai Hospital |
|
China |
2020-04-01 |
2022-04-01 |
ChiCTR2000031751 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
90 |
zhu pengfei |
2020-04-16 |
| Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
mesenchymal stromal cells alone, Tylenol plus cetirizine |
Histamine H1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baylor College of Medicine |
Center for Cell and Gene Therapy, Houston Methodist |
US |
2020-05-31 |
2022-02-28 |
H-47561 MSC FOR COVID-19, NCT04345601 |
Phase 0 Clinical |
Not yet recruiting |
0 |
21 Months |
30 |
LaQuisa Hill, MD |
2020-04-16 |
| HEROs: Does taking hydroxychloroquine before and during exposure to patients protect frontline healthcare workers from coronavirus? |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University Health Network |
Canadian Institutes of Health Research, National Research Council of Canada |
Canada |
2020-03-29 |
2022-01-30 |
HEROS PROTOCOL 1.1, HEROs, ISRCTN14326006 |
Phase 2 Clinical |
Recruiting |
6 |
22 Months |
988 |
Dr Julie Wright, Dr Kevin Kain, Dr Megan Landes |
2020-04-16 |
| COVER: The impact of the COVID-19 pandemic on the provision, practice, and outcomes of vascular surgery (COVER study) |
Coronavirus disease 19 infection, Vascular disease |
|
|
|
University Hospitals Coventry & Warwickshire NHS Trust |
National Institute for Health Research (NIHR) |
Serbia, Seychelles, El Salvador, Guyana, Guinea-Bissau, British Indian Ocean Territory, Kyrgyzstan, Lithuania, Mozambique, Brazil, Greenland, Nauru, French Polynesia, Portugal, Timor-Leste, Turkmenistan, Sierra Leone, Taiwan, Virgin Islands, India, Liberia, Austria, Brunei, Botswana, Djibouti, Algeria, Saint Barthelemy, Russian Federation, Solomon Islands, Bahrain, Benin, Bolivia, Ivory Coast, Christmas Island, Cyprus, Pakistan, Romania, Turks and Caicos Islands, Tunisia, Tonga, Tuvalu, Honduras, Cambodia, Anguilla, Congo, Colombia, Dominican Republic, Egypt, Saint Pierre and Miquelon, Saudi Arabia, Venezuela, Wallis and Futuna, Zambia, Jersey, Montserrat, Namibia, Albania, Azerbaijan, Cook Islands, Cuba, Belize, Western Sahara, Guinea, Poland, Pitcairn, Haiti, Lebanon, Madagascar, Macedonia, The Former Yugoslav Republic of, Malawi, Bangladesh, Chile, Germany, Denmark, Eritrea, Faroe Islands, Niue, Palau, Saint Helena, Tanzania, Mayotte, Greece, Israel, Sri Lanka, Maldives, Armenia, Australia, Burkina Faso, Bouvet Island, Estonia, Finland, Falkland Islands, Gabon, Norfolk Island, Panama, Palestine, Somalia, Saint Vincent and the Grenadines, Vietnam, Iceland, Cayman Islands, American Samoa, Bulgaria, Malta, Netherlands Antilles, Angola, Antarctica, Belgium, Canada, Nepal, Papua New Guinea, Philippines, Paraguay, Rwanda, Tajikistan, Tokelau, Ukraine, US, Guam, Ireland, Moldova, Republic of, Hong Kong, Saint Kitts and Nevis, Latvia, Mali, Mongolia, Mauritania, Barbados, Dominica, Nigeria, Qatar, Suriname, Sao Tome and Principe, Uzbekistan, France, Ghana, Sudan, Togo, Turkey, Vanuatu, Bhutan, China, Ecuador, Fiji, Georgia, Svalbard and Jan Mayen, Swaziland, French Southern Territories, Uganda, Zimbabwe, Croatia, Isle of Man, Japan, Kiribati, Libya, Morocco, Northern Mariana Islands, Antigua and Barbuda, Bahamas, Iraq, Italy, Liechtenstein, Monaco, Burma, Mexico, Niger, United Arab Emirates, Guernsey, Gambia, Netherlands, Nicaragua, Puerto Rico, Slovenia, Chad, Jamaica, Kazakhstan, Kuwait, Montenegro, Marshall Islands, Malaysia, New Caledonia, Andorra, Switzerland, Samoa, Indonesia, Jordan, Comoros, South Korea, Lesotho, Luxembourg, Central African Republic, Gibraltar, Norway, Oman, Sweden, San Marino, United States Minor Outlying Islands, Iran, Saint Lucia, Aruba, Bermuda, Belarus, Costa Rica, Afghanistan, Bosnia and Herzegovina, Burundi, Cape Verde, Cocos (Keeling) Islands, Ethiopia, UK, French Guiana, Guadeloupe, Equatorial Guinea, Syria, Thailand, Yemen, South Africa, Hungary, Czech Republic, Spain, Grenada, New Zealand, Peru, Singapore, Slovakia, Senegal, Trinidad and Tobago, Uruguay, Guatemala, Heard Island and McDonald Islands, Kenya, Laos, Martinique, Mauritius, Argentina, Cameroon |
2020-03-23 |
2022-04-01 |
COVER, COVER_01, IRAS 282224, ISRCTN80453162 |
Phase Not Applicable |
Recruiting |
234 |
24 Months |
|
Athanasios Saratzis, Prof Christopher Imray, Ruth Benson, Sandip Nandhra |
2020-04-16 |
| ConPlas-19: Convalescent Plasma Therapy Versus SOC for the Treatment of COVID-19 in Hospitalized Patients |
Coronavirus disease 19 infection |
Variable regimens including chloroquine , convalescent plasma , darunavir + cobicistat , hydroxychloroquine , lopinavir + ritonavir , tocilizumab |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Puerta de Hierro Majadahonda |
|
Spain |
2020-04-03 |
2020-07-31 |
CONPLAS-19, ConPlas-19, NCT04345523 |
Phase 2 Clinical |
Recruiting |
9 |
3 Months |
278 |
Antonio Ramos, MD, PhD, Cristina Avendaño Solá, Cristina Avendaño Solá, MD, PhD, Cristina Hernández Guitiérrez, MD, Cristina Hernández Gutiérrez, MD, Elena Flores Ballester, MD, Elena Muñez, MD, PhD, Gemma Moreno, MD, Ignacio de Santos Gil, MD, Inmaculada Casas Flecha, PharmD, PhD, Isabel Vicuña Andrés, MD, Jaime Lora Tamayo, MD, Javier Anguita Velasco, MD, Javier Martínez Sanz, MD, José Antonio Moreno Chulilla, MD, PhD, José Luis Bueno, MD, José Ramón Paño Pardo, MD, PhD, Margarita Barberana, MD, Marina Machado, MD, María Isabel Saez Serrano, MD, María Liz Paciello, MD, Miguel Cervero Jiménez, MD, Rafael Duarte Palomino, MD, PhD, Vicente Estrada Pérez, MD |
2020-04-16 |
| COVCALL: Prevalence of COVID-19 Symptoms History in Patients With Autoimmune Diseases |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondation Ophtalmologique Adolf De Rothschild |
|
France |
2020-04-30 |
2020-10-31 |
COVCALL, GDE_2020_11, NCT04345159 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
1500 |
Amélie YAVCHITZ, MD, Damien GATINEL, MD, Guillaume DEBELLEMANIERE, MD |
2020-04-16 |
| CCU-COVID19: Impact of COVID19 Outbreak in Cardiac Acute Care |
Cardiac failure, Coronavirus disease 19 infection |
CT scan alone, RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
Action, France |
France |
2020-03-20 |
2020-08-31 |
CCU-COVID19, INDS 0522070420, NCT04344912 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
500 |
Gilles MONTALESCOT, MD PhD, Johanne SILVAIN, MD PhD |
2020-04-16 |
| PROTECT: Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
peginterferon lambda-1a, Eiger BioPharmaceuticals alone |
Interferon receptor modulator, Interleukin-29 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
Eiger BioPharmaceuticals Inc |
US |
2020-04-30 |
2021-06-30 |
IRB00248163, NCT04344600, PROTECT |
Phase 2b Clinical |
Not yet recruiting |
0 |
14 Months |
164 |
Mark Sulkowski, MD, Stephanie Katz, BSN |
2020-04-16 |
| Effect of Intravenous vitamin c in Patients with COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including atazanavir + ritonavir , hydroxychloroquine , vitamin C |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.TUMS.VCR.REC.1399.078, IRCT20200411047025N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
110 |
Besharat Zarezade, Fereshteh Ghiasvand |
2020-04-16 |
| Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalized COVID-19 Patients With High Risk of Progression |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Malaya |
|
Malaysia |
2020-04-15 |
2020-10-31 |
NCT04345445, TVCS-COVID19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
310 |
Adeeba Kamarulzaman, MBBS, Chee Loon Leong, MBBS, Reena Rajasuriar, PhD, Sharifah Faridah Syed Omar, MBBS, Suresh Kumar Chidambaram, MBBS, Tiang Koi Ng, MBBS |
2020-04-16 |
| GRAVID: Lung Cancer Patients COVID-19 Disease |
Coronavirus disease 19 infection, Lung tumor |
|
|
|
Spanish Lung Cancer Group |
|
Spain |
2020-05-15 |
2022-05-15 |
GECP 20/02_GRAVID, GRAVID, NCT04344002 |
Phase Not Applicable |
Not yet recruiting |
2 |
24 Months |
200 |
Cristina MD Avendaño Solá, MD, Eva Pereira, Mariano MD Provencio, MD, María MD González-Cao, MD |
2020-04-16 |
| COVID-19: Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , indomethacin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Perseverance Research Center, LLC |
|
Canada, US |
2020-04-16 |
2020-09-30 |
COVID-19, HIZ-PRC-COVID-19, NCT04344457 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
80 |
Brandon McCravey, Laura Chrisitans, Nicole C Hank, PhD,MCR,MHSM, Nicole C. Hank, PhD, MCR, MHSM, Teresa Gaither, NP |
2020-04-16 |
| A comprehensive trial to assess the accuracy of saliva test collected using DNA 1000 Saliva Collection Kit compared to swab test in the diagnosis of COVID-19 infection |
Coronavirus disease 19 infection |
DNA 1000 Saliva Collection Kit alone, Saliva test alone |
|
|
Accurate Diagnostic Labs, RUCDR Infinite Biologics |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-15 |
| Convalescent Plasma versus Standard Plasma for COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stony Brook University Hospital |
Chembio Diagnostic Systems Inc |
US |
2020-04-08 |
2021-08-31 |
NCT04344535, SBU-COVID19-CONVALESCENTPLASMA |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
16 Months |
500 |
Elliott Bennett-Guerrero, MD |
2020-04-16 |
| A Randomized, Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
clazakizumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-03-31 |
2020-07-01 |
NCT04343989, S20-00392 |
Phase 2 Clinical |
Recruiting |
0 |
3 Months |
30 |
Bonnie Lonze, MD, Elaina Weldon, ACNP-BC |
2020-04-16 |
| CORTI-Covid: Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
prednisone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
France |
2020-04-30 |
2020-11-30 |
2020-001553-48, 69HCL20_0321, CORTI-Covid, NCT04344288 |
Phase 2 Clinical |
Not yet recruiting |
2 |
7 Months |
304 |
Marie GROUSSAUD, Marielle BUISSON, Vincent COTTIN, Vincent COTTIN, Pr |
2020-04-16 |
| CCAP-RCT: Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Plaquenil alone, baricitinib alone, convalescent anti-SARS-CoV-2 plasma alone, sarilumab alone, standard care alone |
IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HS Hvidovre Hospital |
|
Denmark |
2020-04-20 |
2021-06-15 |
2020-001367-88, 25032020, CCAP-RCT, NCT04345289 |
Phase 3 Clinical |
Recruiting |
12 |
13 Months |
1500 |
Birgitte Lindegaard Madsen, MD, PhD, Clara Clausen, MD, Isik Johansen, MD, DMSc, Jan Gerstoft, MD, DMSc, Janne Jensen, MD, PhD, Karen Brorup Heje Pedersen, MD, Kasper Iversen, MD, DMSc, Lars Østergaard, MD, DMSc, Lothar Wiese, MD, PhD, Louise Thorlacius-Ussing, MD, Michaela Tinggaard, MD, Nichlas Hovmand, MD, Ole Hilberg, MD, DMSc, Rajesh Mohey, MD, PhD, Sandra Hansen, MD, Simone Bastrup Israelsen, MD, Stine Johnsen, MD, PhD, Thomas Benfield, Thomas Benfield, MD, DMSc |
2020-04-17 |
| The effect of IL-6 inhibitor (Tocilizumab) on the prognosis of covid-19 patients with acute respiratory failure hospitalized in Imam Reza Hospital in Tabriz |
Coronavirus disease 19 infection, Respiratory failure |
Routine treatment alone, Tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-21 |
|
IR.TBZMED.REC.1399.010, IRCT20200406046968N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
10 |
Adibkiya khosro, Mikaili, Haleh, Mikaili, haleh |
2020-04-16 |
| PREP-COVID: Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-14 |
2020-08-31 |
2020-001273-73, APHP200386, NCT04344379, PREP-COVID |
Phase 3 Clinical |
Not yet recruiting |
6 |
4 Months |
900 |
Guillaume Masson, MsC, Jean Marc Treluyer, MD PhD, Joe Elie Salem, MD, Lamiae Grimaldi, MD PhD, Michaela Semeraro, MD PhD, Olivier HANON, MD PhD, Olivier Sanchez, MD PhD, Tabassome Simon, MD PhD |
2020-04-16 |
| Study on SARS-CoV-2-Serology (COVID-19) in Bremen's public sector |
Coronavirus disease 19 infection |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Performa Nord Zentrum für Gesunde Arbeit Arbeitsmedizinischer Dienst |
|
Germany |
2020-03-31 |
|
713, DRKS00021289 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Mr Dr Jan Neumann |
2020-04-16 |
| Effect of Bromhexine Hydrochloride on patients with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Bromhexine Hydrochloride alone, standard regimen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.TBZMED.REC.1399.013, IRCT20200317046797N4 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
60 |
Dr Khalil Ansarin, Mohammadreza Ardalan, Sepideh Zununi Vahed |
2020-04-16 |
| CCF: COVID-19 in Cardiology Unit in France: Risk Factors for Mortality |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Société Française de Cardiologie |
INSERM |
France |
2020-04-10 |
2020-07-09 |
2020-02, CCF, NCT04344327 |
Phase Not Applicable |
Recruiting |
10 |
3 Months |
500 |
Alexandre GAUTIER, MD, Antonin TRIMAILLE, MD, Arthur DARMON, MD, Clémence DOCQ, Clément KARSENTY, MD, Corentin CHAUMONT, MD, Guillaume BONNET, MD, Joffrey CELLIER, MD, Orianne WEIZMAN, MD, Sophie RIBEYROLLES, MD, Tessa BERGOT, Vassili PANAGIDES, MD |
2020-04-16 |
| A clinical study to evaluate the safety and efficacy of Virazole in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
ribavirin (inhalation solution, respiratory syncytial virus infection), Bausch Health alone |
Inosine monophosphate dehydrogenase inhibitor |
|
Bausch Health Companies Inc |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-15 |
| A clinical study to diagnose COVID-19 using Fiberflex Rayon (a 3D printed nasopharyngeal [NP] swab) |
Coronavirus disease 19 infection |
Fiberflex Rayon alone |
|
|
Markforged |
Neurophotometrics, Rady Children's Hospital, San Diego, Scripps Research Institute, University of California San Diego |
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
50 |
|
2020-04-15 |
| An open-label, interventional study to evaluate the safety and efficacy of Virazole in hospitalized adult patients with respiratory distress who tested positive for COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ribavirin (inhalation solution, respiratory syncytial virus infection), Bausch Health alone, standard of care therapy alone |
Inosine monophosphate dehydrogenase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bausch Health Companies Inc |
|
Canada |
|
|
238007, BHC-RIB 5401-HC |
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-15 |
| A Global, Randomized Clinical Trial of Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19 |
Coronavirus disease 19 infection |
selinexor alone |
Exportin 1 inhibitor |
|
Karyopharm Therapeutics Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-15 |
| CORSA: Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent |
Coronavirus disease 19 infection |
next generation Sequencing (NGS) analysis alone, rapid molecular test alone, serological test alone, serum chemistry analysis alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL |
Azienda Unita Sanitaria Locale Della Romagna |
Italy |
2020-03-27 |
2022-03-31 |
CORSA, IRSTB113, NCT04345315 |
Phase Not Applicable |
Recruiting |
2 |
24 Months |
500 |
Giovanni Martinelli, Prof, Giovanni Martinelli, Prof., Oriana Nanni, Dr |
2020-04-16 |
| Non-Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
BiPAP system alone, aerosol-reducing mask alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lawson Health Research Institute |
|
Canada |
2020-04-30 |
2020-08-31 |
137654, NCT04344925 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
50 |
Chelsea Darling, Tarek Loubani, Tarek Loubani, MD |
2020-04-16 |
| Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey |
Coronavirus disease 19 infection |
surgery questionnaire alone |
|
Healthy volunteers accepted |
University of Rome Tor Vergata |
|
Italy |
2020-04-02 |
2020-04-15 |
NCT04344197, S-COVID SURVEY |
Phase Not Applicable |
Recruiting |
1 |
|
1200 |
Vittoria Bellato |
2020-04-16 |
| OAHU-COVID19: A Randomized, Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Queens Medical Centre |
|
US |
2020-03-26 |
2021-12-31 |
NCT04345692, OAHU-COVID19, RA-2020-018 |
Phase 3 Clinical |
Recruiting |
0 |
21 Months |
350 |
May Vawer, RN, Todd Seto, MD |
2020-04-16 |
| Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic |
Coronavirus disease 19 infection, Inflammatory bowel disease |
infliximab alone, vedolizumab alone |
Integrin alpha-4/beta-7 antagonist, MAdCAM inhibitor, TNF alpha ligand inhibitor, TNF binding agent |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-04-15 |
2021-09-01 |
NCT04344249, RC20_0150 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
850 |
Arnaud Bourreille, Pr |
2020-04-16 |
| Testing for COVID-19 Infection in Asymptomatic Persons |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Deutsches Krebsforschungszentrum |
|
Germany |
2020-04-20 |
2020-12-31 |
COVID-19-1.0-DKFZ, NCT04345510 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
500 |
|
2020-04-16 |
| Pegylated Interferon Lambda Treatment for COVID-19 |
Coronavirus disease 19 infection |
peginterferon lambda-1a, Eiger BioPharmaceuticals alone |
Interferon receptor modulator, Interleukin-29 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Eiger BioPharmaceuticals Inc |
US |
2020-05-01 |
2021-12-31 |
2020P00XXXX, NCT04343976 |
Phase 2 Clinical |
Not yet recruiting |
0 |
20 Months |
40 |
Arthur Kim, MD, Jenna Gustafson, MSc, Raymond Chung, MD |
2020-04-16 |
| Treatment of COVID-19 with allogeneic mesenchymal cells (MSV) |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
allogeneic mesenchymal stem cells MSV-allo alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Citospin Sociedad Limitada |
|
Spain |
|
|
2020-001682-36, MSV_COVID |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
24 |
CRO, Effice spi S.L. |
2020-04-16 |
| Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
sevoflurane alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Incliva |
|
Spain |
2020-04-14 |
|
2020-001379-34, SEVO-COVID19 |
Phase 4 Clinical |
Recruiting |
1 |
|
50 |
Subdirectora Científica |
2020-04-16 |
| Preventing SARS-CoV-2 virus infection and severity of COVID-19 diseases during pregnancy with hydroxychloroquine |
Coronavirus disease 19 infection |
Dolquine (Products and technology SL) alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Barcelona Institute for Global Health |
|
Spain |
2020-04-08 |
|
02/04/2020-001, 2020-001587-29 |
Phase 4 Clinical |
Recruiting |
1 |
|
714 |
Clara Menéndez |
2020-04-16 |
| COVID-19 HUF: Clinical Trial to Evaluate Efficacy of Three Types of Treatment in Patients With Pneumonia by COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Dolquine (Products and Technology SL) , baricitinib , imatinib , lopinavir + ritonavir |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario de Fuenlabrada |
Centro Nacional de Investigaciones Oncologicas |
Spain |
2020-04-13 |
2020-09-30 |
2020-001321-31, 24032020, COVID-19 HUF, NCT04346147 |
Phase 2 Clinical |
No longer recruiting |
2 |
5 Months |
165 |
Comisión de Investigación, David Bernal, Ph MD |
2020-04-17 |
| Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
US Department of Defense |
|
US |
2020-04-30 |
2020-08-31 |
NCT04343677, PENTAGON 20-1 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
1450 |
Angela Phillips, PhD, David S Robinson, MD, John S Baxter, MD, JD, Scott A Wallace, MD |
2020-04-16 |
| Study to Evaluate the Efficacy and Safety of Leronlimab for Mild-to-Moderate COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
leronlimab alone |
CCR5 chemokine antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CytoDyn Inc |
|
US |
2020-04-01 |
2021-04-04 |
CD10_COVID-19, NCT04343651 |
Phase 2 Clinical |
Recruiting |
0 |
12 Months |
75 |
Kush Dhody, MBBS, MS, CCRA |
2020-04-16 |
| COVIDAtoZ: Coronavirus 2019 - Using Ascorbic Acid and Zinc Supplementation |
Coronavirus disease 19 infection |
ascorbic acid alone, zinc gluconate alone, ascorbic acid plus zinc gluconate |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cleveland Clinic Foundation |
|
US |
2020-04-08 |
2021-04-30 |
COVIDAtoZ, IRB 20-361, NCT04342728 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
520 |
Milind Desai, M. D. |
2020-04-17 |
| CloroCOVID19II: Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection |
Coronavirus disease 19 infection |
chloroquine diphosphate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Foundation of Tropical Medicine Doctor Heitor Vieira Dourado |
|
Brazil |
2020-04-08 |
2020-09-30 |
CAAE: 30504220.5.0000.0005, CloroCOVID19II, NCT04342650 |
Phase 2b Clinical |
Recruiting |
1 |
5 Months |
210 |
Fernando Val, PhD, Marcus Lacerda, MD, Mayla Borba, MD |
2020-04-15 |
| Convalescent Plasma in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Saint Francis Care |
|
US |
2020-04-10 |
2021-04-01 |
NCT04343261, SFH-20-23 |
Phase 2 Clinical |
Not yet recruiting |
0 |
11 Months |
15 |
Latha Dulipsingh, MD |
2020-04-15 |
| The Role of Resistant Potato Starch in COVID-19 Infection |
Coronavirus disease 19 infection |
Bob's red mill resistant potato starch alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yale University |
University of Michigan, University of Minnesota |
US |
2020-05-01 |
2021-05-01 |
2000027887, NCT04342689 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
1300 |
Mary M Riwes, DO, Sherry Mansour, MD, MS |
2020-04-17 |
| Clinical trial to assess the efficacy and safety of cyclosporine A treatment associated with standard treatment versus standard treatment only in hospitalized patients with confirmed coronavirus infection |
Coronavirus disease 19 infection |
Variable regimens including chloroquine , ciclosporin, Novartis , darunavir , interferon beta-1b , lopinavir , ritonavir , spironolactone , tocilizumab |
Aldosterone antagonist, Calcineurin inhibitor, Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Instituto de Investigación Sanitaria de la Fundacion Jimenez Diaz |
Jimenez Diaz Foundation |
Spain |
2020-04-09 |
|
2020-001262-11, FJD-COVID19-20-01 |
Phase 4 Clinical |
Recruiting |
1 |
|
120 |
CLINICAL RESEARCH UNIT |
2020-04-15 |
| Clinical trial to avoid infection by SARS-CoV-2 in high-risk population. COVID-19 |
Coronavirus disease 19 infection |
melatonin (controlled release, insomnia), Neurim alone |
Melatonin receptor agonist |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz |
|
Spain |
2020-04-09 |
|
2020-001530-35, MeCOVID |
Phase 4 Clinical |
Recruiting |
1 |
|
450 |
Alberto Borobia |
2020-04-14 |
| DIC: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Clinical Trial |
Coronavirus disease 19 infection |
Variable regimens including Interferon beta-1A , Interferon beta-1B , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-10 |
2020-04-24 |
DIC, DIFFERENT INTERFERONS IN COVID, NCT04343768 |
Phase 4 Clinical |
Recruiting |
2 |
|
60 |
Ilad Alavi Darazam, MD, Minoosh Shabani, MD, Mohammadreza Haji Esmaelie, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA, Shervin Shokouhi, MD |
2020-04-17 |
| COVID-19 Endo: COVID-19 Endoscopy Survey |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Al-Azhar University |
|
Iran, Egypt, US |
2020-04-10 |
2020-12-10 |
COVID-19 Endo, NCT04342637, WES-2 |
Phase Not Applicable |
Not yet recruiting |
3 |
8 Months |
40 |
Mohamed Alboraie, Mohamed Alboraie, MD, MRCP(UK) |
2020-04-14 |
| SARICOVID: Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild to moderate pneumonia and COVID19 infection versus standard of care |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including azithromycin , hydroxychloroquine , sarilumab |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital del Mar |
Instituto de Salud Carlos III |
Spain |
2020-04-11 |
|
2020-001290-74, SARICOVID, SARICOVID |
Phase 3 Clinical |
Recruiting |
1 |
|
216 |
Ana Aldea |
2020-04-15 |
| Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
Patient Centered Outcome Research Institute |
US |
2020-04-10 |
2099-12-31 |
NCT04342806, PRO00105284 |
Phase Not Applicable |
Recruiting |
0 |
956 Months |
100000 |
Emily O'Brien, PhD, Laura Webb, Nina Y Hines |
2020-04-16 |
| Clinical trial of Dalargin hexapeptide for the treatment of coronavirus pneumonias complicated by difficulty breathing |
Coronavirus disease 19 infection, Viral pneumonia |
dalargin hexapeptide alone |
|
|
Federal Medical Biological Agency |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-14 |
| MetCOVID: Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 |
Coronavirus disease 19 infection |
methylprednisolone sodium succinate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Foundation of Tropical Medicine Doctor Heitor Vieira Dourado |
|
Brazil |
2020-04-30 |
2020-09-30 |
CAEE: 30615920.2.0000.0005, MetCOVID, NCT04343729 |
Phase 2b Clinical |
Not yet recruiting |
1 |
5 Months |
420 |
Fernando Val, Marcus Lacerda |
2020-04-17 |
| Early tracheostomy in COVID-19 |
Coronavirus disease 19 infection |
Airway management alone, COVID-19 medications alone, Mechanical ventilation alone, Tracheotomy tube alone |
|
|
Baqiyatallah University of Medical Sciences |
|
Iran |
2020-04-06 |
2020-04-13 |
IR.BMSU.REC.1399.055, IRCT20180129038542N1 |
Phase Not Applicable |
Completed |
1 |
|
30 |
Hossein Pirmohammadi, Shahriar Najafizadeh |
2020-04-15 |
| Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
mesenchymal stem cell therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Iranian Academic Center For Education Culture & Research, National Institute for Medical Research Developement |
|
Iran |
2020-03-15 |
2020-04-25 |
IR.NIMAD.REC.1398.412, IRCT20200217046526N1 |
Phase 1/Phase 2 Clinical |
No longer recruiting |
2 |
1 Month |
6 |
Abdol Hossein Shahverdi, Hossein Baharvand, Masoume Nouri, Mohammad Reza Hashemian, Morteza Zarrabi, Rasoul Alian Nejad |
2020-04-17 |
| Investigation of the effect of Zufa syrup on clinical symptoms with suspected Corona (COVID-19) |
Coronavirus disease 19 infection |
Zufa syrup (Booali Daroo Pharmaceutical Company) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Deputy of Research and Technology, Qom University of Medical Sciences |
BooaliDaroo pharmaceutical company |
Iran |
2020-03-10 |
|
IR.MUQ.REC.1398.165, IRCT20200404046934N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
130 |
Ehsan Sharifi pour, Majid Asghari, Razieh Borujerdi |
2020-04-15 |
| Effect of crocetin on COVID-19 |
Coronavirus disease 19 infection |
crocetin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.052, IRCT20081019001369N3 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi |
2020-04-15 |
| Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including hydroxychloroquine , intravenous immunoglobulin (IVIG) (Behring company) , lopinavir + ritonavir , ribavirin |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-20 |
2020-07-22 |
IR.TBZMED.REC.1399.003, IRCT20200317046797N3 |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
100 |
Dr Khalil Ansarin, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed |
2020-04-17 |
| BCG-CORONA-ELDERLY: Reducing hospital admission of elderly in Coronavirus pandemic by boosting the immune system through vaccination with bacillus Calmette-Guerin (BCG) |
Coronavirus disease 19 infection |
BCG vaccine alone |
|
Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Radboudumc |
|
Netherlands |
2020-04-09 |
|
2020-001591-15, BCG-CORONA-ELDERLY, NL73430.091.20 |
Phase 4 Clinical |
Recruiting |
1 |
|
1600 |
Jaap ten Oever |
2020-04-15 |
| Comparative effectiveness of Chloroquine and Vitamin C prophylaxis in household contacts of confirmed COVID-19 patients |
Coronavirus disease 19 infection |
chloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Health System Research Institute (HSRI), Siriraj Hospital |
|
Thailand |
2020-04-27 |
|
TCTR20200404004 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
400 |
Suvimol Niyomnaitham |
2020-04-15 |
| Use of Covid-19 Rapid Test for Hospital Care: GI Procedure |
Coronavirus disease 19 infection |
Covid-19 rapid test alone, endoscopy alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chulalongkorn University |
|
Thailand |
2020-03-19 |
|
TCTR20200405001 |
Phase Not Applicable |
Recruiting |
1 |
|
20 |
Sombat Treeprasertsuk, Tongluk Teerasarntipan |
2020-04-15 |
| COVID19PUGG2: National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19 |
Coronavirus disease 19 infection |
|
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-03-22 |
2020-04-05 |
AR20-0031V1, COVID19PUGG2, NCT04343781 |
Phase Not Applicable |
Completed |
1 |
|
353 |
Cédric Annweiler, M.D., Ph.D. |
2020-04-15 |
| Pragmatic clinical trial of hydroxychloroquine in the treatment of oncohematological patients and health professionals with COVID-19 infection without radiological alteration |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Catalan de Oncologia |
|
Spain |
2020-04-01 |
|
2020-001765-37, PROTOCOLO/ICO/COVID20 |
Phase 2 Clinical |
Recruiting |
1 |
|
103 |
Margarita García Martín |
2020-04-15 |
| Randomized, open, pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection |
Coronavirus disease 19 infection |
sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario de La Princesa |
Sanofi SA |
Spain |
2020-04-09 |
|
2020-001634-36, SARCOVID |
Phase 2 Clinical |
Recruiting |
1 |
|
30 |
Rosario García de Vicuña |
2020-04-15 |
| A Study of LY-3127804 in Participants With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
LY-3127804 alone, Standard of care treatment alone |
Angiopoietin ligand-2 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Eli Lilly & Co |
National Institute of Allergy and Infectious Diseases |
US |
2020-04-18 |
2020-07-10 |
17824, I7W-MC-UDAA, NCT04342897 |
Phase 2 Clinical |
Not yet recruiting |
0 |
2 Months |
200 |
|
2020-04-16 |
| Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
chlorine dioxide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Genesis Foundation, United States |
|
Colombia |
2020-04-01 |
2020-06-01 |
GENESIS AKCOVID- FG-1, NCT04343742 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
20 |
BLANCA BOLANO, researcherer, EDUARDO INSIGNARES-CARRIONE, Research Direc., Eduardo Insignares Carrione, YOHANNY ANDRADE, INVESTIGATOR, oswaldo leyva, researcher, yohanny andrade, researcher |
2020-04-15 |
| A Study on the Prospective, Cohort Library of COVID-19 in Southern |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
|
The Second Hospital and Yuying Children's Hospital of Wenzhou Medical University |
Cangnan People's Hospital, Lishui People's Hospital, People's Hospital of Pingyang, Ruian People's Hospital, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, Wenzhou Medical University, Wenzhou Yueqing People's Hospital, Yongjia People's Hospital |
China |
2020-03-16 |
2021-03-31 |
NCT04342702, SAHOWMU-CR2020-NCP-202 |
Phase Not Applicable |
No longer recruiting |
2 |
12 Months |
504 |
Xiaokun Li |
2020-04-15 |
| Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
mesenchymal stem cells alone, extracellular vessicles plus mesenchymal stem cells |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Iranian Academic Center For Education Culture & Research, National Institute for Medical Research Developement |
|
Iran |
2020-04-05 |
|
IR.NIMAD.REC.1398.412, IRCT20200217046526N2 |
Phase 2/Phase 3 Clinical |
Recruiting |
2 |
|
60 |
Abdol Hossein Shahverdi, Hossein Baharvand, Masoume Nouri, Mohammad Reza Hashemian, Morteza Zarrabi, Rasoul Alian Nejad, Reza Mlekzadeh |
2020-04-15 |
| CRASH-19: Coronavirus Response - Active Support for Hospitalized Covid-19 Patients |
Coronavirus disease 19 infection |
aspirin alone, losartan alone, simvastatin alone, Variable regimens including aspirin , losartan , simvastatin |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist, HMG CoA reductase inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
London School of Hygiene and Tropical Medicine |
|
Pakistan, Nigeria |
2020-04-30 |
2021-08-31 |
2020-KEP-420, CRASH-19, NCT04343001 |
Phase 3 Clinical |
Not yet recruiting |
2 |
16 Months |
10000 |
Aasia Kayani, Haleema Shakur-Still, Ian Roberts, Kiran Javaid, Nike Bello, Oladapo Olayemi, Rizwana Chaudhri, Temitayo Shokunbi |
2020-04-15 |
| Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) |
Coronavirus disease 19 infection, Viral respiratory tract infection |
nitazoxanide (controlled-release, viral infections), Romark alone |
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Romark Laboratories LC |
|
|
2020-04-30 |
2020-08-31 |
NCT04343248, RM08-3006 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
600 |
Matthew Bardin, PharmD, BCPS |
2020-04-17 |
| STOP-COVID: Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Brigham & Women's Hospital |
|
US |
2020-04-01 |
2022-06-01 |
2007P000003, NCT04343898, STOP-COVID |
Phase Not Applicable |
Recruiting |
0 |
26 Months |
2000 |
David E Leaf, MD, MMSc, Shruti Gupta, MD, MPH |
2020-04-17 |
| EPILOGUE: Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment |
Coronavirus disease 19 infection, Drug dependence |
psychoactive substances consumption alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
|
France |
2020-04-08 |
2020-09-30 |
EPILOGUE, NCT04343339, RECHMPL20_0195 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
100 |
Hélène Donnadieu-Rigole, MD PhD, hélène Donnadieu-Rigole, doctor |
2020-04-16 |
| COVID-19 Community Research Partnership |
Coronavirus disease 19 infection |
IgM/IgG test alone |
|
Healthy volunteers accepted |
Wake Forest University Health Sciences, US |
|
US |
2020-04-30 |
2021-12-31 |
IRB00064912, NCT04342884 |
Phase Not Applicable |
Not yet recruiting |
0 |
20 Months |
150000 |
John W Sanders, MD, MPH&TM, Wake Forest Baptist Medical Center |
2020-04-16 |
| STOP COVID: A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection |
Coronavirus disease 19 infection |
fluvoxamine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University in St Louis |
|
US |
2020-04-10 |
2020-07-01 |
202004023, NCT04342663, STOP COVID |
Phase 2 Clinical |
Recruiting |
0 |
2 Months |
152 |
Angela Stevens, Eric J Lenze, MD, Marissa Rhea, MA |
2020-04-16 |
| A clinical study to assess leronlimab in the treatment of patients with severe COVID-19 |
Coronavirus disease 19 infection |
leronlimab alone |
CCR5 chemokine antagonist |
|
CytoDyn Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-14 |
| FASTER: Facilitating A SARS CoV-2 Test for Rapid triage |
Coronavirus disease 19 infection, SARS coronavirus infection, Streptococcus pneumoniae infection |
|
|
|
Liverpool School of Tropical Medicine, Pfizer Inc |
|
|
|
|
FASTER |
Phase Not Applicable |
Recruiting |
0 |
|
400 |
|
2020-04-14 |
| Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hackensack Meridian Health |
|
US |
2020-04-30 |
2021-04-30 |
NCT04343755, PRO2020-0375 |
Phase 2a Clinical |
Recruiting |
0 |
12 Months |
55 |
Mariefel Vendivil, Marlo Kemp, Michele L Donato, MD |
2020-04-17 |
| SAFER: SARS-CoV-2 Acquisition in Frontline Health Care Workers – Evaluation to Inform Response |
Coronavirus disease 19 infection, SARS coronavirus infection, Streptococcus pneumoniae infection |
|
|
|
Liverpool School of Tropical Medicine, Pfizer Inc |
|
|
|
|
SAFER |
Phase Not Applicable |
Recruiting |
0 |
|
100 |
|
2020-04-14 |
| New: Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia |
Coronavirus disease 19 infection |
|
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dr Cipto Mangunkusumo General Hospital |
|
Indonesia |
2020-04-12 |
2020-12-31 |
MH-COVID19, NCT04343664, New |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
10000 |
Belinda J Murtani, dr., Tjhin Wiguna, PhD |
2020-04-15 |
| Ruxo-Sim-20: Study of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19 |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis plus simvastatin |
HMG CoA reductase inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HM Research Foundation Hospitals |
Apices Soluciones, S.L. |
Spain |
2020-04-12 |
2020-05-13 |
2020-001405-23, NCT04348695, Ruxo-Sim-20, Ruxo-Sim-20 |
Phase 2 Clinical |
Recruiting |
2 |
1 Month |
94 |
FUNDACION DE INVESTIGACION HM HOSPI, Jesús García Donas, MD, Paula Villares Fernández, MD |
2020-04-17 |
| Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
HA330 hemoperfusion alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King Chulalongkorn Memorial Hospital |
ASTROMED CO., LTD |
Thailand |
2020-05-01 |
|
TCTR20200409006 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
206 |
Nattachai Srisawat |
2020-04-15 |
| Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19 |
Coronavirus disease 19 infection |
Biovitals alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-01 |
2022-01-31 |
COVID19_BIOVITALS_PROTOCOL_1, NCT04343794 |
Phase Not Applicable |
Recruiting |
2 |
22 Months |
200 |
David Siu, MD, David Siu, MD FRCP, Ivan FN Hung MD, Ivan Hung, MD, Ivan Hung, MD FRCPath |
2020-04-16 |
| ECMO-COVID-19: Place of Venovenous ECMO in the Management of Refractory ARDS Associated with SARS-COV-2 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-01 |
2020-04-15 |
7772, ECMO-COVID-19, NCT04343404 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Anne OLLAND, MD, PhD, Ferhat MEZIANI, MD, PhD, Francis SCHNEIDER, MD, PhD, Jean-Philipe MAZZUCOTELLI, MD, PhD, Julien POTTECHER, MD, PhD, Michel MERTES, MD, PhD, Pierre-Emmanuel FALCOZ, MD, PhD, Saïd CHAYER, PhD, HDR |
2020-04-15 |
| Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Heart injury, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jiangsu Provincial People’s Hospital |
|
China |
2020-01-01 |
2020-04-15 |
ChiCTR2000031752 |
Phase Not Applicable |
No longer recruiting |
2 |
3 Months |
75 |
Gang Yang, Yun Liu |
2020-04-15 |
| CORIMUNO-NIVO: Trial Evaluating Efficacy and Safety of Nivolumab (Optivo) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort |
Coronavirus disease 19 infection |
nivolumab alone |
Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-15 |
2020-09-30 |
APHP200389-5, CORIMUNO-NIVO, NCT04343144 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
92 |
Jacques Cadranel, MD PhD |
2020-04-15 |
| Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 Infection |
Coronavirus disease 19 infection |
hyperbaric oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ochsner Health System |
|
US |
2020-04-30 |
2020-06-30 |
NCT04343183, STUDY00001051 |
Phase 2 Clinical |
Not yet recruiting |
0 |
2 Months |
48 |
Jeffery S Kuo, MD, John Engle, John F Engle, MD, Michael D Lindley, MD |
2020-04-15 |
| Urgent Public Health Research Study: A phase IIa clinical trial of ORBCEL for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ORBCEL-C alone |
|
|
Orbsen Therapeutics Ltd |
Wellcome Trust |
UK |
|
|
Urgent Public Health Research Study |
Phase 2a Clinical |
Recruiting |
1 |
|
|
Belfast Health and Social Care Trust, Queen's University Belfast |
2020-04-14 |
| Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai |
Coronavirus disease 19 infection, Viral pneumonia |
Nursing care alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Sixth People’s Hospital |
Shanghai Jiao Tong University |
China |
2020-01-22 |
2020-02-29 |
2020RK44, ChiCTR2000031770 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
119 |
Sanlian Hu, Yuli Hu |
2020-04-15 |
| A Phase IIa/IIb study of FW-1022 for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
FW-1022 alone |
|
|
First Wave Bio, Inc |
|
EU, US |
2020-06-30 |
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-15 |
| Evaluating the effect of Phyllanthus emblica on COVID 19 patients |
Coronavirus disease 19 infection |
Phyllanthus emblica drink intake alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ahvaz University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.AJUMS.REC.1399.011, IRCT20200404046937N2 |
Phase 3 Clinical |
Recruiting |
3 |
|
60 |
Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani |
2020-04-15 |
| A clinical study to assess LUNAR-COV19 in healthy subjects for the treatment of COVID-19 infectiion |
Coronavirus disease 19 infection |
LUNAR-COV19 alone |
|
Healthy volunteers accepted |
Arcturus Therapeutics Inc |
|
Singapore |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
76 |
|
2020-04-14 |
| Ivermectin Adjuvant to Hydroxychloroquine in COVID19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine plus ivermectin |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Baghdad |
|
Iraq |
2020-04-08 |
2020-08-01 |
NCT04343092, PRO20040001 |
Phase 1 Clinical |
Not yet recruiting |
1 |
3 Months |
50 |
|
2020-04-15 |
| A phase II, double-blind, randomized, placebo-controlled study to evaluate safety and efficacy of intranasal vazegepant for the treatment of COVID-19 infection associated pulmonary complications |
Coronavirus disease 19 infection, Lung disease |
vazegepant alone |
CGRP receptor antagonist |
|
Biohaven Pharmaceutical Holding Co Ltd |
Thomas Jefferson University |
US |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
|
Jesse Roman, Michael Baram, Steven Schnittman |
2020-04-14 |
| A first-in-human clinical trial of peptide-based vaccine for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
peptide-based vaccine (COVID-19), Axon Neuroscience alone |
Coronavirus spike glycoprotein inhibitor |
|
Axon Neuroscience SE |
|
|
2020-09-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-15 |
| Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs |
Coronavirus disease 19 infection, Viral pneumonia |
ciclosporin, Novartis plus tocilizumab (intravenous), Roche/Chugai |
Calcineurin inhibitor, IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Vall D'Hebron |
|
Spain |
2020-04-09 |
|
2020-001437-12, COVID-19_ASS |
Phase 4 Clinical |
Recruiting |
1 |
|
290 |
Salvador Augustin |
2020-04-15 |
| A nested phase II, two-part study to evaluate TD-0903 in hospitalized patients with COVID-19 |
Coronavirus disease 19 infection |
TD-0903 alone |
JAK tyrosine kinase inhibitor |
|
Theravance Biopharma Inc |
|
Europe, US, UK |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
|
|
2020-04-15 |
| A first in human, phase I study to evaluate safety of single- and multiple-ascending doses of TD-0903 in healthy subjects |
Acute lung injury, Coronavirus disease 19 infection |
TD-0903 alone |
JAK tyrosine kinase inhibitor |
Healthy volunteers accepted |
Theravance Biopharma Inc |
|
UK |
2020-04-30 |
|
|
Phase 1 Clinical |
Planned |
1 |
|
|
|
2020-04-15 |
| A clinical study of hydroxychloroquine and/or other lupus therapies in preventing or reducing the symptoms of COVID-19 in Lupus patients |
Coronavirus disease 19 infection |
Lupus therapy alone, hydroxychloroquine alone |
|
|
Lupus Therapeutics |
|
US, Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
20000 |
|
2020-04-16 |
| SOS-COVID19: Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome |
Coronavirus disease 19 infection, Respiratory failure |
Auricular neuromodulation alone, SEDATELEC alone, chlorhexidine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondation Ophtalmologique Adolf De Rothschild |
|
France |
2020-04-30 |
2020-06-30 |
CRN_2020_8, NCT04341415, SOS-COVID19 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
60 |
Amélie YAVCHITZ, Claire-Marie RANGON |
2020-04-16 |
| ECMO-VID: Early Versus Late ECMO Therapy in COVID-19 Induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Extracorporal Membrane Oxygenation (ECMO) Implantation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
Klinikum der Albert-Ludwigs Universitaet Freiburg, Rheinisch-Westfaelische Technische Hochschule Aachen, University Hospital Muenster |
Germany |
2020-06-01 |
2025-12-01 |
ECMO-VID, ECMO-VID, NCT04341285 |
Phase Not Applicable |
Not yet recruiting |
1 |
66 Months |
200 |
Peter Rosenberger, Prof. |
2020-04-17 |
| Predicting Factors for Progression to Severe Illness of COVID-19 Infection |
Coronavirus disease 19 infection |
|
|
|
Hospital Raja Permaisuri Bainun |
|
Malaysia |
2020-04-20 |
2020-08-31 |
54622, NMRR-20-704-54622 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
|
Dr Ker Hong Bee, Dr LEONG E LI |
2020-04-15 |
| MentalStatCOVID: Mental Health Status of Stable Hospitalized COVID-19 Patients in Hospital Kuala Lumpur, Hospital Sungai Buloh and Hospital Permai Johor Bahru |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-15 |
2020-05-31 |
54541, MentalStatCOVID, NMRR-20-711-54541 |
Phase Not Applicable |
Recruiting |
3 |
1 Month |
|
Dr Mohd Shaiful Azlan Bin Kassim, Dr Muhammad Najib bin Abdullah, Dr Norazam Bin Harun, Dr Umi Adzlin binti Silim |
2020-04-15 |
| QT interval with HCQ in COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Taiping Hospital |
|
Malaysia |
2020-04-13 |
2020-04-30 |
54651, NMRR-20-712-54651 |
Phase Not Applicable |
Status not specified |
1 |
|
|
Dr Cheah Wee Kooi, Dr Narwani Hussin |
2020-04-15 |
| COVID in Malaysia |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-11 |
2020-12-31 |
54598, NMRR-20-720-54598 |
Phase Not Applicable |
Recruiting |
3 |
8 Months |
|
Dr Chong Zhuo Lin |
2020-04-16 |
| CXR IN COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
chest radigraph alone |
|
|
Hospital Sungai Buloh |
|
Malaysia |
2020-04-05 |
2020-12-31 |
54589, NMRR-20-726-54589 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
|
DR AIDA BINTI ABDUL AZIZ, Dr Mohan Dass Pathmanathan |
2020-04-15 |
| Evaluation of IL-6 cytokine levels during progression of severe COVID-19 disease in relation to assessing the efficacy of intravenous tocilizumab treatment |
Coronavirus disease 19 infection |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
Universiti Malaysia Sabah |
|
Malaysia |
2020-04-14 |
2021-02-27 |
54610, NMRR-20-729-54610 |
Phase Not Applicable |
Status not specified |
2 |
10 Months |
|
Dr Fong Siew Moy, Dr Lee Heng Gee, Dr Shahleni A/P Paramasivam, Nadirah binti Sulaiman |
2020-04-15 |
| Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sociedad Española de Farmacia Hospitalaria |
Instituto de Salud Carlos III |
Spain |
2020-04-06 |
|
2020-001421-31, QUINAVID-19 |
Phase 4 Clinical |
Recruiting |
1 |
|
1530 |
Emilio Garcia Cabrera |
2020-04-15 |
| Interferon beta 1b in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , interferon beta 1 b , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-03-25 |
|
IR.MAZUMS.REC.1399.005, IRCT20190804044429N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
|
70 |
Majid Saeedi, Monireh Ghazaeian |
2020-04-14 |
| Evaluation the effect of licorice for treatment of coronavirus |
Coronavirus disease 19 infection |
licorice extract alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.047, IRCT20200404046933N1 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Dr. Dehghan Nayeri, Gholamreza Karimi, Mohsen Tafaghodi |
2020-04-15 |
| PROSCLOROCOV 19: Post-exposure hydroxycloroquine prophylaxis for Covid 19 |
Coronavirus disease 19 infection |
hydroxycloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.TBZMED.REC.1399.012, IRCT20130306012728N8, PROSCLOROCOV 19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
500 |
Behrouz Naghili, Sakineh Hajebrahimi |
2020-04-15 |
| Evaluation and comparison of the effectiveness of standard treatment with standard treatment plus Vitamin A in treatment in covid19 patients |
Coronavirus disease 19 infection |
standard national treatment alone, vitamin A alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Saveh University of Medical Sciences |
|
Iran |
2020-04-07 |
|
IR.SAVEHUMS.REC.1399.003, IRCT20180520039738N2 |
Phase 3 Clinical |
No longer recruiting |
2 |
|
140 |
Dr, Mohammad Ghorbanli, Dr., Hamidreza Koohestani, Hasan Mozaffar, Mahmood Karimy, Mohamadreza Rohani, Mohammadreza Rouhani |
2020-04-14 |
| A clinical study of SAB-185 for the treatment in COVID-19 patients |
Coronavirus disease 19 infection |
SAB-185 alone |
|
|
CSL Behring (UK) |
|
North America |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-14 |
| Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease |
Coronavirus disease 19 infection |
Convalescent Plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Semnan University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.SEMUMS.REC.1399.004, IRCT20151228025732N53 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
12 |
Maral Hemati, Parviz Kokhaei |
2020-04-14 |
| CRR: COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fiona Stanley Hospital, South Metropolitan Area Health Service |
|
Australia |
2020-04-07 |
|
ACTRN12620000444987, ANZCTR12620000444987, CRR |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100000 |
Ms Giuliana Daulerio, Prof Toby Richards |
2020-04-14 |
| A Phase II Study to Assess The Effect of Ifenprodil in Patients with COVID-19 |
Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals, Nash Pharmaceuticals Inc |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-13 |
| A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 |
Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals, Nash Pharmaceuticals Inc |
|
Australia |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-13 |
| A Study to Assess The Effect of Ifenprodil in Patients with COVID-19 |
Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals, Nash Pharmaceuticals Inc |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-13 |
| Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care |
Coronavirus disease 19 infection |
exercises alone, telerehabilitation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Flinders Medical Centre |
Flinders University of South Australia |
Australia |
2020-05-01 |
|
ACTRN12620000443998p, ANZCTR12620000443998 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
58 |
A/Prof Kate Laver, Prof Maria Crotty |
2020-04-14 |
| A Phase II Study to Assess The Effect of Ifenprodil in Patients with Severe COVID-19 Infection |
Coronavirus disease 19 infection |
repurposed ifenprodil (oral, IPF/UC/IBD/crohn's disease/cough), Nash Pharmaceuticals alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals, Nash Pharmaceuticals Inc |
|
Canada |
|
|
|
Phase 2 Clinical |
Planned |
1 |
|
|
|
2020-04-13 |
| GARGLES: A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients |
Coronavirus disease 19 infection, Viral infection |
hydrogen peroxide alone, povidone-iodine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Aga khan University |
University Of Karachi |
Pakistan |
2020-07-01 |
2021-03-31 |
2020-SUR-ERC-20, GARGLES, NCT04341688 |
Phase 2 Clinical |
Not yet recruiting |
1 |
9 Months |
40 |
Farhan R Khan, MS, FCPS, Farhan Raza Khan, Syed MR Kazmi, FCPS |
2020-04-17 |
| MEFLOCOVID-19: Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19) |
Coronavirus disease 19 infection |
mefloquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Miguel Hernandez de Elche |
Foundation for Health Research and Biomedical Valencia |
Spain |
2020-03-30 |
|
2020-001194-69, MEFLOCOVID-19, MEFLOCOVID-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
200 |
Unidad de Enfermedades Infecciosas |
2020-04-14 |
| Clinical trials with low-dose rapamycin to protect elderly from COVID-19 |
Coronavirus disease 19 infection |
sirolimus alone |
mTOR inhibitor |
|
The Biogerontology Research Foundation |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-14 |
| COV-HCQ: Hydroxychloroquine for COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine Sulfate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
Bernhard-Nocht-Institute for Tropical Medicine, Robert Bosch Medical Center, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-03-29 |
2022-02-28 |
2020-001224-33, COV-HCQ, COV-HCQ, NCT04342221 |
Phase 3 Clinical |
Recruiting |
1 |
23 Months |
220 |
Benjamin Mordmüller, Prof., Diane Egger-Adam, Dr., Thirulamaisamy Velavan, Prof., Thirumalaisamy Velavan, Prof. |
2020-04-13 |
| PanCOVID19: Efficacy of different treatments in patients infected with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Dolquine (Products and Technology SL) alone, azithromycin cinfa (Laboratorios Cinfa, SA) alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz |
Servicio de Farmacología Clínica, Unidad de Ensayos Clínicos (UCICEC) |
Spain |
2020-03-27 |
|
2020-001156-18, PanCOVID19, PanCOVID19 |
Phase 3 Clinical |
Recruiting |
1 |
|
1000 |
Alberto Borobia |
2020-04-14 |
| Acquiring Convalescent Specimens for COVID-19 Antibodies |
Coronavirus disease 19 infection |
Blood draw alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Columbia University |
|
US |
2020-03-25 |
2021-03-31 |
AAAS9517, NCT04342195 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
12 |
Brett Gray, David Ho, M.D,, Yang Luo, PhD |
2020-04-14 |
| Hydroxychloroquine, Hydroxychloroquine, Azithromycin in the Treatment of SARS CoV-2 Infection |
Coronavirus disease 19 infection |
chloroquine sulfate alone, hydroxychloroquine alone, Variable regimens including azithromycin , chloroquine sulfate , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
Cigna Corp |
US |
2020-04-04 |
2021-08-01 |
202003188, NCT04341727, WU352 |
Phase 3 Clinical |
Recruiting |
0 |
15 Months |
500 |
Adriana Rauseo Acevedo, MD, Carlos Mejia Chew, RN, Jane O'Halloran, MD PhD, Jane O'Hallorhan, MB BA PhD, Klebert Michael, RN PhD, Michael Klebert, RN PhD, Philip Spinella, MD, Rachel M. Presti, Rachel Presti, MD PhD, Spec Andrej, MD |
2020-04-16 |
| Tocilizumab in COVID-19 |
Coronavirus disease 19 infection |
tocilizumab (AryoGen Pharmed Co.) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AryoGen Pharmed Co |
|
Iran |
2020-03-15 |
|
IR.NIMAD.REC.1398.414, IRCT20150303021315N17 |
Phase 3 Clinical |
Recruiting |
9 |
|
500 |
Dr. Ali Javad Mousavi, Dr. Behzad Mohsenpour, Dr. Davood Attaran, Dr. Ehsan Sharifipour, Dr. Mohammad Reza Salehi, Dr. Nafiseh Abdollahi, Dr. Payam Tabarsi, Farzin Khorvash, Nassim Anjidani, Payam Tabarsi, Roya Ghasemian, Rozita Khodashahi |
2020-04-15 |
| A phase I safety clinical study of CORAVAX for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
CORAVAX alone |
Coronavirus spike glycoprotein inhibitor |
|
Thomas Jefferson University |
|
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-15 |
| SCOPE: Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
sirolimus alone |
mTOR inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Cincinnati |
|
US |
2020-04-30 |
2020-09-30 |
2020-0337, NCT04341675, SCOPE |
Phase 2 Clinical |
Not yet recruiting |
0 |
5 Months |
30 |
Nishant Gupta, MD |
2020-04-13 |
| Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus Kaletra in hospitalized patients with COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine (Iran daroo Co, Iran) plus favipiravir (Nafas farmed Co, Iran) |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ardabil University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.ARUMS.REC.1399.012, IRCT20150808023559N20 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Somaieh Matin |
2020-04-14 |
| The effectiveness of Sovodak (sofosbuvir+daclatasvir) in Covid-19 patients |
Coronavirus disease 19 infection |
Standard of care alone, Sovodak plus ribavirin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-03-05 |
|
IR.MAZUMS.REC.1399.019, IRCT20200328046886N1 |
Phase 3 Clinical |
No longer recruiting |
1 |
|
48 |
Hamideh Abbaspour Kasgari |
2020-04-14 |
| A short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome, serious complications associated with severe COVID-19 disease |
Coronavirus disease 19 infection |
anakinra plus emapalumab |
Interferon gamma ligand inhibitor, Type I IL-1 receptor antagonist |
|
Swedish Orphan Biovitrum AB |
|
Italy |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-14 |
| ASC COVID-19: ASC Therapy for Patients With Severe Respiratory COVID-19 |
Coronavirus disease 19 infection, Lung disease, Respiratory distress syndrome, Viral pneumonia |
allogeneic adipose-derived mesenchymal stromal cell alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rigshospitalet, Denmark |
|
Denmark |
2020-04-20 |
2021-04-30 |
2020-001330-36, ASC COVID-19, NCT04341610 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
12 Months |
40 |
Abbas Ali Qayuum, MD PhD, JKastrup, Jens Kastrup, Professor MD |
2020-04-14 |
| CONCOVID: Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease |
Coronavirus disease 19 infection, SARS coronavirus infection |
Convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Erasmus University Rotterdam |
Maasstad Hospital |
Netherlands |
2020-04-01 |
2020-07-01 |
CONCOVID, NCT04342182, NL73489.078.20 |
Phase 2/Phase 3 Clinical |
Recruiting |
2 |
3 Months |
426 |
Arvind Gharbharan, MD, Bart Rijnders, MD, PhD, Casper Rokx, MD, PhD, Jan Den Hollander, MD, PhD |
2020-04-15 |
| NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure |
Coronavirus disease 19 infection, Respiratory failure |
aggravation monitoring alone, continuous positive airway pressure (CPAP) alone, non-invasive ventilation (NIV) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Morales Meseguer (Murcia, Spain) |
|
Spain |
2020-04-01 |
2020-07-01 |
08-04-2020, NCT04342104 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
100 |
Antonio Esquinas, Miguel Filipe Martins de Matos Navarro Guia, Miguel Guia |
2020-04-14 |
| A clinical study of silmitasertib in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
silmitasertib alone |
Casein kinase II inhibitor |
|
Senhwa Biosciences Inc |
National Institute of Allergy and Infectious Diseases |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-13 |
| Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
|
University Hospital of Cologne |
Center for Molecular Medicine Cologne |
Germany |
2020-04-30 |
2020-10-31 |
KICC19, NCT04341168 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
160 |
Centina Kuiper-Makris, Christoph Hünseler, PD Dr., Esther Mahabir-Brenner, Prof. Dr., Florian Klein, PD Dr., Jan Rybniker, PD Dr. Dr., Julia Fischer, Dr., Katja Höpker, PD Dr., Lutz Weber, Prof. Dr., Miguel A Alejandre Alcazar, Prof. Dr. Dr., Robert W Koerner, Dr., Robert W Körner, Dr., Rolf Kaiser, Dr., Saleta Sierra - Aragón, PD Dr., Tom Schildberg, Dr. |
2020-04-15 |
| The Impact of Family-Based Empowerment Model on Stress, Anxiety and Satisfaction |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection |
empowerment training sessions alone |
|
|
Torbate-Heidaria University of Medical Sciences |
|
Iran |
2020-03-20 |
|
IR.THUMS.REC.1398.060, IRCT20180429039463N2 |
Phase Not Applicable |
Recruiting |
1 |
|
30 |
mohammad namazi nia, محمد نمازی نیا |
2020-04-14 |
| WHIP COVID-19: Will Hydroxychloroquine Impede or Prevent COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Henry Ford Health System |
|
US |
2020-04-07 |
2021-04-30 |
1410401, NCT04341441, WHIP COVID-19 |
Phase 3 Clinical |
Recruiting |
0 |
12 Months |
3000 |
Dee Dee Wang, MD, John McKinnon, MD, Laurie Nightengale, MD, William W O'Neill, MD |
2020-04-16 |
| BURDENCOV: Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers |
Coronavirus disease 19 infection, Influenza virus infection, Post traumatic stress disorder, Viral pneumonia |
burnout alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-09 |
2021-12-31 |
APHP200389, BURDENCOV, NCT04341519 |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
1464 |
Elie AZOULAY, MD PhD, Matthieu RESCHE-RIGON, MD PhD, Nancy KENTISH-BARNES, MD PHD, Nancy KENTISH-BARNES, PhD, matthieu resche-rigon, MD-PhD |
2020-04-15 |
| Evaluation the effects of Favipiravir in COVID-19 patients |
Coronavirus disease 19 infection |
favipiravir (Toliddaru-Sobhan Oncology company, Iran) alone, standard and supportive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-05 |
|
IR.SBMU.RETECH.REC.1399.011, IRCT20151227025726N14 |
Phase 3 Clinical |
Recruiting |
1 |
|
84 |
Afshin Zarghi, Ali Saffaei, Farzaneh Dastan, Hossein Vahidi, Payam Tabarsi |
2020-04-14 |
| CTII-nCoV: A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) |
Coronavirus disease 19 infection |
Ad5-nCoV alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Institute of Biotechnology the Academy of Military Medical Sciences PLA |
CanSino Biologics Inc, Hubei Provincial Center for Disease Control and Prevention, Jiangsu Province Centers for Disease Control and Prevention, Zhangnan Hospital |
China |
2020-04-12 |
2021-01-31 |
CTII-nCoV, JSVCT089, NCT04341389 |
Phase 2 Clinical |
Recruiting |
2 |
9 Months |
500 |
Fengcai Zhu, MD, Wenjuan Wang, MD, Zhao Wang, MD |
2020-04-16 |
| COVID19-COVIDornase: Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2/COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
dornase alfa alone |
Deoxyribonuclease I stimulator, Deoxyribonuclease stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Foundation Adolphe De Rothschild |
|
France |
2020-04-10 |
|
2020-001492-33, CGE_2020_9, COVID19-COVIDornase |
Phase 3 Clinical |
No longer recruiting |
1 |
|
100 |
Clinical Research Director |
2020-04-15 |
| Evaluation the efficacy of hot foot-bath on COVID-19 |
Coronavirus disease 19 infection |
hot foot bath alone |
|
|
Shaheed Beheshti Medical University |
|
Iran |
2020-04-15 |
|
IR.SBMU.RETECH.REC.1399.029, IRCT20180923041093N5 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Afshin Zarghi, Fatemeh sadat Hasheminasab, Roshanak Mokaberinejad |
2020-04-15 |
| BIOCOVU: Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-08-31 |
2020-A00906-33, 2020_33, BIOCOVU, NCT04341792 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
1000 |
Delphine Garrigue, MD |
2020-04-14 |
| A clinical study of elsulfavirine in combination with favipiravir for the treatment of severe COVID-19 infection |
Coronavirus disease 19 infection |
elsulfavirine plus favipiravir |
HIV-1 reverse transcriptase inhibitor, Non-nucleoside reverse transcriptase inhibitor, RNA polymerase inhibitor |
|
Viriom Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-14 |
| Study of TJ-003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
TJM-2 alone |
GM-CSF ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
I-Mab Biopharma |
|
US |
2020-04-11 |
2020-09-30 |
NCT04341116, TJ003234COV201 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
5 Months |
144 |
Chadi A. Hage, MD, Claire Xu, MD, PhD, Joseph Kim, MD, Julia Garcia-Diaz, MD, Robert Jeanfreau, MD, US Site Head |
2020-04-17 |
| A first in human trial to evaluate spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
spike protein receptor-binding domain specific mAbs (SARS-CoV-2), Tsinghua/3rd People’s Hospital of Shenzhen/Brii Biosciences alone |
Coronavirus spike glycoprotein inhibitor |
|
Brii Biosciences, The Third People’s Hospital of Shenzhen, Tsinghua University |
|
|
2020-09-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-13 |
| Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic |
Coronavirus disease 19 infection |
telephone consultation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universite Pierre et Marie Curie |
|
France |
2020-03-16 |
2020-06-15 |
GREEN GRC01, NCT04341714 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
400 |
Camille Chesnel, MD, Gérard Amarenco, PhD |
2020-04-13 |
| CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
anakinra alone |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-12-31 |
APHP200375-5, CORIMUNO-ANA, NCT04341584 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
240 |
Matthieu Resche-Rigon, MD, PhD, Xavier Mariette, MD, PhD |
2020-04-15 |
| NoCovid: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 |
Coronavirus disease 19 infection |
nitric oxide (NO) alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Nu-Med Plus, Xijing Hospital |
US |
2020-03-21 |
2022-04-01 |
COVID19 NOGAS MILD, NCT04290858, NCT04305457, NOGAS MILDCOVID-19, NoCovid |
Phase 2 Clinical |
Recruiting |
0 |
24 Months |
240 |
Lei Chong, Lorenzo Berra, Lorenzo Berra, MD |
2020-04-14 |
| University of Utah COVID-19 Hydrochloroquine Trial |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Utah |
|
US |
2020-04-14 |
2023-04-30 |
IRB_00131893, NCT04342169 |
Phase 2 Clinical |
Recruiting |
0 |
36 Months |
400 |
Adam Spivak, MD, Christina Pacchia, PhD |
2020-04-17 |
| COVID-SER: Assessment of Serological Techniques for Screening Patients Regarding COVID-19 |
Coronavirus disease 19 infection |
serological tests alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
|
2020-04-09 |
2020-09-09 |
69HCL20-0329, COVID-SER, NCT04341142 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
400 |
Jean-Baptiste Mr FASSIER, Dr |
2020-04-14 |
| Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-04-10 |
2020-07-01 |
GPA1347, NCT04342208 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
500 |
Ayşe Zengin Alpözgen, Gamze Polen Aksimsek |
2020-04-13 |
| Hydroxychloroquine Versus Nitazoxanide in Patients With COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine plus nitazoxanide |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Materno-Perinatal Hospital of the State of Mexico |
|
Mexico |
2020-04-06 |
2020-12-30 |
2020-03-681, NCT04341493 |
Phase 4 Clinical |
Recruiting |
1 |
8 Months |
86 |
Acela Marle Santamaria Benhumea, PhD., Hugo Mendieta Zeron, Hugo Mendieta Zeron, PhD, Hugo Mendieta Zeron, PhD., José Meneses Calderon, MD |
2020-04-14 |
| COVIDeHPAD: Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease |
Coronavirus disease 19 infection |
telehealth applications alone |
|
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Limoges |
|
|
2020-04-30 |
2020-09-30 |
87RI20_0013, COVIDeHPAD, NCT04337788 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
200 |
Achille TCHALLA, MD |
2020-04-14 |
| Effects of DPP4 Inhibition on COVID-19 |
Coronavirus disease 19 infection, Non-insulin dependent diabetes |
insulin plus linagliptin |
Dipeptidyl peptidase IV inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Miami |
|
US |
2020-04-30 |
2020-09-30 |
20200384, NCT04341935 |
Phase 4 Clinical |
Not yet recruiting |
0 |
5 Months |
20 |
Gianluca Iacobellis, MD PhD |
2020-04-15 |
| Video-Based Exercises and Well-Being During Social Isolation |
Coronavirus disease 19 infection, Influenza virus infection |
Video based aerobic exercise alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs) |
Biruni Üniversitesi |
Istanbul University-Cerrahpasa |
Turkey |
2020-04-06 |
2020-06-30 |
NCT04335851, PHYSICAL ACTIVITY PROJECT |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
30 |
Ayse Zengin Alpozgen, Assistant Professor, PhD, Ayşe Zengin Alpözgen, Assistant Professor, PhD, Begum Kara Kaya, MSc, Esma Nur Kolbaşı, MSc, Eylül Pınar Kısa, MSc, Gamze Polen Şimşek, MSc, Pelin Tiryaki, MSc |
2020-04-13 |
| SHARP COVID-19: Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-risk Population (SHARP): a Cluster-randomized, Controlled Trial |
Coronavirus disease 19 infection |
hydroxychloroquine sulfate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tan Tock Seng Hospital |
Duke-NUS Graduate Medical School, Dutch Ministry of Health, Welfare and Sport, National Center for Infectious Diseases, Saw Swee Hock School of Public Health, Singapore Clinical Research Institute, Singapore Eye Research Institute |
Singapore |
2020-04-30 |
2020-10-31 |
2020/00402, NCT04342156, SHARP COVID-19 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
3000 |
Rupesh Agrawal, MD |
2020-04-14 |
| Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19 |
Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
Ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Creteil |
|
France |
2020-03-31 |
2020-09-30 |
COVID-ECHO, NCT04341766 |
Phase Not Applicable |
Recruiting |
7 |
6 Months |
200 |
Antoine Luchez, MD, Ayman KHEIR, MD, Gilles MANGIAPAN, MD, Gilles Mangiapan, MD, Marie Coudurier, MD, Sophie Laroumagne, MD, Thomas Flament, MD, Yannick Simonneau, MD |
2020-04-14 |
| CORIMUNO-VIRO: Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO |
Coronavirus disease 19 infection, Lung disease, Viral pneumonia |
standard of care alone, Variable regimens including azithromycin , hydroxychloroquine , sarilumab |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-11 |
2020-07-31 |
APHP200375-3, CORIMUNO-VIRO, NCT04341870 |
Phase 2/Phase 3 Clinical |
Recruiting |
4 |
3 Months |
60 |
David Saadoun, MD PhD, Matthieu Resche-Rigon, MD PhD |
2020-04-15 |
| A clinical trial to assess MN-166 in the treatment of acute respiratory distress syndrome (ARDS) in COVID-19 patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ibudilast (oral, neuropathic pain/opiate dependence/neurodegeneration/TBI/drug dependence), MediciNova alone |
IL-6 receptor antagonist, Interleukin-1 beta ligand inhibitor, Macrophage migration inhibitory factor inhibitor, PDE 10 inhibitor, PDE 4 inhibitor, TLR-4 antagonist, TNF alpha ligand inhibitor |
|
Yale School of Medicine |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Geoffrey Chupp, Dr. Insoo Kang, r. Maor Sauler |
2020-04-13 |
| Evaluation of the efficacy of oral 25-hydroxyvitamin D3 on COVID-19 |
Coronavirus disease 19 infection |
25-hydroxyvitamin D3 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N2 |
Phase 3 Clinical |
Recruiting |
2 |
|
540 |
Arash Shirvani, Mohammadali Sahraian, Zhila Maghbooli |
2020-04-15 |
| Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
plasma alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.MUMS.REC.1399.055, IRCT20200409047007N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
32 |
Dr Abolghasem Allahyari, Dr Mohsen Seddigh Shamsi |
2020-04-14 |
| Effect of minocycline on COVID-19 |
Coronavirus disease 19 infection |
minocycline alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.053, IRCT20081019001369N4 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri |
2020-04-14 |
| MultiCov: Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Combined use of a respiratory broad panel multiplex PCR and procalcitonin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
bioMerieux SA |
France |
2020-04-30 |
2020-08-31 |
2020-001324-33, APHP200392, MultiCov, NCT04334850 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
194 |
Guillaume VOIRIOT, MD, Muriel FARTOUKH, PU-PH MD PHD |
2020-04-14 |
| Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19) |
Coronavirus disease 19 infection |
telerehabilitation exercise alone |
|
Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-04-20 |
2020-07-31 |
002, NCT04334434 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
30 |
Ayse Zengin Alpözgen, Ass.Prof.PhD, Ayse zengin alpozgen, Ece Acikbas, MSc, Eren Avcil, MSc, Fulya Demirhan, MSc, Kubra Koce, MSc, Kubra Koce, MSc PT, Kubra Sagir, MSc |
2020-04-17 |
| Al-COVE: AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience |
Coronavirus disease 19 infection, Sepsis, Transplant rejection |
AlloSure dd-cf DNA test alone |
|
|
CareDx Inc |
|
|
2020-04-01 |
2021-03-01 |
AL-COVE, Al-COVE, NCT04341103 |
Phase Not Applicable |
Not yet recruiting |
0 |
11 Months |
500 |
Alana Burns |
2020-04-14 |
| COVA: A phase II/III study to assess the efficacy and the safety of Sarconeos (BIO-101) in the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
20‐hydroxyecdysone (oral, sarcopenia/sarcopenic obesity/Duchenne muscular dystrophy), BIOPHYTIS alone |
Proto-oncogene Mas agonist |
|
BIOPHYTIS |
|
US, France, Belgium |
|
|
COVA |
Phase 2/Phase 3 Clinical |
Planned |
2 |
|
|
|
2020-04-13 |
| The effect of elderberry syrup against COVID-19 symptoms |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Lymphocytopenia, Myalgia |
elderberry extract syrup alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.045, IRCT20200406046965N1 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Mohammad Javad Dehghan Nayyeri, Seyed Ahmad Emami |
2020-04-14 |
| Non-contact ECG Sensor System for COVID-19 |
Coronavirus disease 19 infection |
non-contact ECG alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Northwestern Medicine |
|
US |
2020-04-15 |
2020-09-15 |
20-0407, NCT04341506 |
Phase Not Applicable |
Not yet recruiting |
0 |
5 Months |
100 |
Andrew Gostine, Andrew Gostine, MD |
2020-04-14 |
| Remdesivir in treatment of COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
Variable regimens including atazanavir , chloroquine phosphate , hydroxychloroquine sulfate , lopinavir + ritonavir , remdesivir , ribavirin |
HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-03-20 |
|
IR.TUMS.VCR.REC.1398.1076, IRCT20171122037571N2 |
Phase 2/Phase 3 Clinical |
Recruiting |
12 |
|
120 |
Aydin PoorKazemi, Azar Haddadi, Farhang BabaMahmoudi, Farzin Khorvash, Hamed Hosseini, Ilad Alavi Darazam, Mansooreh Momen-Heravi, Mehrdad Hasibi, Mohammad Reza Salehi, Mostafa Ghanei, Payam Tabarsi, Rozita Khodashahi, Saeed Kalantari |
2020-04-14 |
| The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19 |
Cancer, Coronavirus disease 19 infection |
chemotherapy alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital |
|
China |
2020-04-10 |
2020-07-10 |
2020-TJ-COVID-19, NCT04341480 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
207 |
Qinglei Gao, Qinglei Gao, Dr. |
2020-04-14 |
| The effect of SOVODAK in the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
training alone, Variable regimens including Sovodak (sofosbuvir + daclatasvir) , azithromycin , hydroxychloroquine , naproxen , pantoprazole |
H+ K+ ATPase inhibitor |
|
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-08 |
|
IR.MAZUMS.REC.1399.017, IRCT20200403046926N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Fatemeh Roozbeh |
2020-04-14 |
| SIC: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
methylprednisolone (Pfizer) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Ramón y Cajal |
|
Spain |
2020-04-01 |
|
2020-001307-16, SIC, SIC |
Phase 3 Clinical |
Recruiting |
1 |
|
104 |
Anabel Sánchez |
2020-04-14 |
| DEFACOVID: Defibrotide as prevention and treatment of respiratory distress and cytokine release syndrome of COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
defibrotide (iv, veno-occlusive disease), Gentium alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fundación Para La Formación E Investigación Sanitarias De La Región De Murcia (Ffis) |
Instituto de Salud Carlos III |
Spain |
2020-04-08 |
2020-08-08 |
2020-001409-21, DEFACOVID, IMIB-DFC-2020-02, NCT04348383 |
Phase 2b Clinical |
Recruiting |
2 |
4 Months |
120 |
José M. Moraleda, MD, LOLA SERNA GUIRAO |
2020-04-17 |
| Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Asociación Instituto de Investigación Sanitaria BioCruces |
|
Spain |
2020-04-07 |
|
2020-001606-33, HIACO-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
132 |
Epidemiologist |
2020-04-14 |
| TACROVID: Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury |
Coronavirus disease 19 infection, Lung injury |
methylprednisolone plus tacrolimus (oral sustained-release), Astellas |
Calcineurin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitari de Bellvitge |
Institut Investigació Biomèdica Bellvitge |
Spain |
2020-04-01 |
2020-07-01 |
2020-001445-39, NCT04341038, TACRO-BELL-COVID, TACROVID |
Phase 3 Clinical |
Recruiting |
1 |
3 Months |
84 |
Arnau Antolí, MD, Xavier Corbella, MD, PhD, Xavier Solanich, MD |
2020-04-16 |
| Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases |
Coronavirus disease 19 infection, Liver cirrhosis |
Breath Analysis Test alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mayo Clinic FLORIDA |
|
US |
2019-09-10 |
2021-12-31 |
19-001971, NCT04341012 |
Phase Not Applicable |
Recruiting |
0 |
27 Months |
120 |
Joanna Roopkumar, Robert Brannock, Tushar Patel, Tushar Patel, MBChB |
2020-04-14 |
| The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury |
Coronavirus disease 19 infection, Heart injury, Hemophagocytic lymphohistiocytosis, Respiratory distress syndrome |
immunophenotyping alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barts and The London NHS Trust |
Queen Mary University of London |
UK |
2020-04-10 |
2020-06-10 |
282289, NCT04340921 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
140 |
Daniel E Harding, BM BCh, Federica Marelli-Berg, PhD, Sam (Saidi) Mohiddin, MD |
2020-04-14 |
| HOME-CoV: Hospitalization or Outpatient Management of Patients With a SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
HOME-CoV rule implementation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France, Belgium, Monaco |
2020-04-09 |
2020-06-01 |
2020-A00831-38, HOME-CoV, NCT04338841 |
Phase Not Applicable |
Recruiting |
28 |
1 Month |
4000 |
Andréa PENALOZA, Anthony CHAUVIN, Christian BRICE, MD, Delphine DOUILLET, Francis COUTURAUD, GHUYSEN Alexandre |
2020-04-14 |
| REPLACECOVID: Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 |
Cardiovascular disease, Coronavirus disease 19 infection, Hypertension, Renal injury, Respiratory disease |
Angiotensin Converting Enzyme Inhibitors alone, Angiotensin Receptor Blockers alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Pennsylvania |
|
|
2020-03-31 |
2020-12-31 |
842810, NCT04338009, REPLACECOVID |
Phase Not Applicable |
Not yet recruiting |
0 |
9 Months |
152 |
James Brian Byrd, MD, Jordana B. Cohen, MD, MSCE, Julio A Chirinos, Roberto Viau Colindres, Thomas C. Hanff, MD, MPH, Vicente Corrales-Medina, MD, PhD |
2020-04-14 |
| AspiFlu: Aspergillosis in patients with severe influenza or coronavirus |
Coronavirus disease 19 infection, Influenza virus infection, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St George's University Hospitals NHS Foundation Trust |
Gilead Sciences Inc |
UK |
2019-07-06 |
2021-08-05 |
AspiFlu, CPMS 43440, IRAS 271269, ISRCTN51287266 |
Phase Not Applicable |
Recruiting |
4 |
25 Months |
|
Dr Tihana Bicanic, Dr Youngs |
2020-04-13 |
| Multicenter, randomized, controlled, parallel study to study the effectiveness and safety of hydroxychloroquine (ZAO Biocom, Russia) in patients with a new coronavirus infection COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine, Biocom alone |
|
|
JSC Biocom |
|
Russian Federation |
2020-04-09 |
2021-03-30 |
ST-23032020-HQBIO |
Phase 3 Clinical |
Status not specified |
1 |
11 Months |
120 |
|
2020-04-13 |
| Utilizing lung ultrasound in COVID-19 patients in ICU – comparison of management strategies on survival and time on ventilation |
Coronavirus disease 19 infection |
lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Griffith University, Royal Brisbane & Women's Hospital |
|
Australia |
2020-04-20 |
|
ACTRN12620000438954 |
Phase Not Applicable |
Not yet recruiting |
4 |
|
60 |
A/Prof Jennifer Paratz |
2020-04-14 |
| C4: Chloroquine Chemorophylaxis Countermeasure against COVID-19 |
Coronavirus disease 19 infection, SARS coronavirus infection |
chloroquine phosphate alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Australian Defence Force Malaria and Infectious Disease Institute |
Defence Materiel Technology Centre (DMTC) |
Australia |
2020-03-30 |
2020-05-11 |
ACTRN12620000417987, C4 |
Phase 4 Clinical |
Not yet recruiting |
1 |
1 Month |
680 |
Dr Scott Hahn, Prof Dennis Shanks |
2020-04-14 |
| VOICE: Online-Survey on distress and mental resources of medical health care workers during Covid-19-pandemic |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitätsklinikum Erlangen Psychosomatische und Psychotherapeutische Abteilung |
Universitatsklinikum Erlangen, Universitätsklinikum Bonn Klinik für Psychosomatische Medizin und Psychotherapie, Universitätsklinikum Ulm Psychosomatik |
Germany |
2020-04-20 |
|
133_20 B, DRKS00021268, VOICE |
Phase Not Applicable |
Not yet recruiting |
5 |
|
2000 |
Andrea Borho, Eva Morawa |
2020-04-13 |
| Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The National Institute of Mental Health |
National Institutes of Health Clinical Center |
US |
2020-04-20 |
2022-04-01 |
20-M-N085, 999920085, NCT04339790 |
Phase Not Applicable |
Recruiting |
0 |
23 Months |
5000 |
Alison Gibbons, Joyce Y Chung, M.D. |
2020-04-16 |
| HCQINRLGII: Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals |
Coronavirus disease 19 infection |
Bisolvon plus Plaquenil |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Rehabilitacion |
|
Mexico |
2020-04-10 |
2020-07-10 |
20/20, HCQINRLGII, NCT04340349 |
Phase 0 Clinical |
Not yet recruiting |
1 |
3 Months |
100 |
Julio Granados Montiel |
2020-04-13 |
| NODS-Cov2: Nosocomial Dissemination Risk of SARS-Cov2 |
Coronavirus disease 19 infection |
|
|
|
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-13 |
2020-06-15 |
APHP200417, NCT04339881, NODS-Cov2 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
100 |
Bich-Tram Huynh, Didier Guillemot, Didier Guillemot, Pr |
2020-04-13 |
| COVID-19 Risk Stratification |
Coronavirus disease 19 infection |
risk score validation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Brigham & Women's Hospital |
|
US |
2020-03-01 |
2020-04-15 |
2020P000944, NCT04339387 |
Phase Not Applicable |
Recruiting |
0 |
1 Month |
1500 |
David Levine, David Levine, MD, David M Levine, MD MPH MA |
2020-04-13 |
| FRENCH CORONA: French, Multicenter, Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-03 |
2021-04-30 |
2020-A00797-32, FRENCH CORONA, NCT04340466 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
220 |
Anissa MEGZARI, CLAIRE ROGER, CLAIRE ROGER, MD, PhD, Claire Roger, MD, PhD |
2020-04-15 |
| Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection |
Coronavirus disease 19 infection |
atovaquone plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HonorHealth Research Institute |
|
US |
2020-04-30 |
2021-04-30 |
HRI-COVID-19-ANTI-MALARIAL-001, NCT04339426 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
25 |
Heather Lane, Karen Lewandowski, RN, Michael Gordon, MD |
2020-04-16 |
| Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt (COVID-19) |
Coronavirus disease 19 infection |
|
|
|
Assiut University |
|
Egypt |
2020-05-01 |
2020-07-30 |
COVID-19 IN EGYPT, NCT04339322 |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
200 |
Haidi Karam |
2020-04-13 |
| Multicentric, Retrospective, Observational Study of Thoracic Scanner Performance in COVID Screening |
Coronavirus disease 19 infection, Lung injury |
thoracic CT scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation |
|
|
2020-04-30 |
2020-11-30 |
NCT04339686, POWER-COVID_CT |
Phase Not Applicable |
Not yet recruiting |
0 |
7 Months |
56000 |
Guillaume HERPE |
2020-04-14 |
| Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection |
Acute lung injury, Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
losartan alone, standard of care alone |
Angiotensin II AT-1 receptor antagonist, Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sharp HealthCare |
|
US |
2020-03-27 |
2020-12-31 |
2003902, COVID-ARB, NCT04340557 |
Phase 4 Clinical |
Recruiting |
0 |
9 Months |
200 |
Adriana Valdez-Hernandez, RN, Cary Murphy, RN, George Sakoulas, MD, Katie Miller, Matthew Geriak, Matthew Geriak, PharmD |
2020-04-13 |
| Evaluation of the efficacy of Oral 25-hydroxyvitamin D3 on COVID-19 |
Coronavirus disease 19 infection |
25-hydroxyvitamin D3, Dishmen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-15 |
|
IR.TUMS.VCR.REC.1399.061, IRCT20200401046909N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
260 |
Arash Shirvani, Mohammadali Sahraian, Mohammadali Sahraian, Research Deputy, Zhila Maghbooli |
2020-04-15 |
| COVID-19 Convalescent Plasma |
Coronavirus disease 19 infection |
COVID-19 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-10 |
2021-12-31 |
IRB20-0523, NCT04340050 |
Phase 0 Clinical |
Recruiting |
0 |
20 Months |
10 |
Maria Lucia Madariaga, Maria Lucia Madariaga, MD |
2020-04-16 |
| Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
CVVH machine alone, Low flow ECMO driving alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Peking Union Medical College Hospital |
|
China |
2020-03-03 |
2020-10-15 |
LOW FLOW-ECMO BY CVVH IN NCP, NCT04340414 |
Phase Not Applicable |
Recruiting |
2 |
7 Months |
10 |
Huaiwu He, MD, Wei Cheng, MD, Xiang Zhou, MD, Yun Long, Yun Long, MD |
2020-04-13 |
| Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy |
Coronavirus disease 19 infection |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabula Rasa HealthCare Inc |
|
US |
2020-04-07 |
2021-04-06 |
COVID-PACE-2020-001, NCT04339634 |
Phase Not Applicable |
No longer recruiting |
0 |
12 Months |
12123 |
Veronique Michaud, PhD |
2020-04-15 |
| Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) |
Coronavirus disease 19 infection |
point-of-care ultrasonography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Minnesota |
|
US |
2020-04-15 |
2020-10-31 |
NCT04339998, STUDY00009429 |
Phase Not Applicable |
Not yet recruiting |
0 |
6 Months |
500 |
Jon Kirsch, MD, Matthew Yocum, MD |
2020-04-13 |
| Eating Habits of Adults During the Quarantine |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Eastern Mediterranean University |
Cyprus Science University |
Cyprus, Turkey |
2020-04-10 |
2020-05-31 |
NCT04339842, NUTR2020 |
Phase Not Applicable |
Recruiting |
2 |
1 Month |
400 |
Eliz Arter, Eliz Arter, MSc, Zalihe Yarkiner, PhD |
2020-04-16 |
| Max COVID19 Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-02 |
2020-06-30 |
COVID-19/MHC/2020, NCT04339608 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
10000 |
Samreen Siddiqui, PhD, Sandeep Budhiraja, MRCP (U.K), MD, Sujeet Jha, MRCP (U.K) |
2020-04-13 |
| ONCOVID: Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic |
Anxiety disorder, Cancer, Coronavirus disease 19 infection, Mood disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Ziekenhuis Gent |
|
Belgium |
2020-03-30 |
2020-09-30 |
BC-07505-LGE, NCT04340219, ONCOVID |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
180 |
Emiel De Jaeghere, MD, Hannelore Denys, Hannelore Denys, MD, PhD, Heini Kanervo, RN |
2020-04-13 |
| AZIQUINE-ICU: Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomized, Controlled Trial |
Coronavirus disease 19 infection, Respiratory failure |
azithromycin plus hydrochloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Charles University |
Faculty Hospital Olomouc, General University Hospital, Prague, Masaryk Hospital Usti nad Labem, St. Anne's University Hospital Brno, Czech Republic, The Faculty Hospital Na Bulovce, University Hospital Motol, University Hospital Pilsen |
Czech Republic |
2020-04-20 |
2022-06-30 |
2020-001456-18, AZIQUINE-ICU, AZIQUINE-ICU-25032020, NCT04339816 |
Phase 3 Clinical |
Not yet recruiting |
1 |
26 Months |
240 |
Frantisek Duska |
2020-04-14 |
| Evaluation of Serum Zinc Levels Response to Treatment of Covid-19 Positive Patients |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-03-20 |
2020-05-03 |
NCT04339556, ZINCCOVID19 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
25 |
Pınar Yalcin bahat |
2020-04-13 |
| A Study on Melatonin and Vitamin C and Zinc Efficacy in Patients With COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including ascorbic acid , melatonin , zinc sulfate |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Semnan University of Medical Sciences |
|
Iran |
2020-04-07 |
|
IR.SEMUMS.REC.1399.005, IRCT20151228025732N52 |
Phase 3 Clinical |
Recruiting |
1 |
|
20 |
Fatemeh Ehsani, Mahboubeh Darban |
2020-04-14 |
| The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation |
Coronavirus disease 19 infection, Injury |
FAST+ examination alone, computed tomography alone, lung ultrasound alone |
|
Healthy volunteers accepted |
University of Colorado, Denver, US |
|
US |
2020-05-01 |
2021-05-01 |
20-0751, NCT04340479 |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
20 |
Jose L Diaz-Miron, MD |
2020-04-13 |
| Evaluating the effect of marshmallow and licorice on COVID 19 patients |
Coronavirus disease 19 infection |
marshmallow and licorice mixed herbal drink intake alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ahvaz University of Medical Sciences |
|
Iran |
2020-04-09 |
|
IR.AJUMS.REC.1399.012, IRCT20200404046937N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
60 |
Mehran Varnaseri Ghandali, Mohammad Badavi, Niloofar Mohammad Rezaee Esferjani |
2020-04-13 |
| Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
conventional treatment alone, human umbilical cord-derived MSCs alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan Puren Hospital |
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, Shanghai University |
China |
2020-02-01 |
2020-06-30 |
NCT04339660, PR20200402 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
5 Months |
30 |
Yan Liu, MD, Yue Zhu |
2020-04-17 |
| Physical Activity During Social Isolation |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul University |
|
Turkey |
2020-04-30 |
2020-06-30 |
30042020-1, NCT04339491 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
500 |
Ayse Zengin Alpozgen, PhD, Saliha Gurdal Karakelle, Saliha Gurdal Karakelle, MSc |
2020-04-10 |
| COMIHY: Hydroxychloroquine for the Treatment of Mild COVID-19 Disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
Bernhard-Nocht-Institute for Tropical Medicine, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-04-10 |
2022-09-30 |
COMIHY, COMIHY, NCT04340544 |
Phase 3 Clinical |
Not yet recruiting |
1 |
29 Months |
2700 |
Diane Egger-Adam, Dr., Peter Kremsner, Prof. |
2020-04-13 |
| Safety and Efficacy of Baricitinib for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
baricitinib alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado, Denver, US |
|
US |
2020-04-30 |
2020-10-31 |
20-0738, NCT04340232 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
6 Months |
80 |
Angela Rachubinski, PhD, Joaquin Espinosa, PhD |
2020-04-13 |
| Effects of Viroherb capsule and Fenugreek syrup derived from traditional Persian medicine on clinical and paraclinical outcomes and survival of patients with mild to moderate COVID-19 hospitalized in medical centers of Tehran University of Medical Sciences |
Coronavirus disease 19 infection |
medications alone, Fenugreek syrup plus Viroherb capsule |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-05 |
|
IR.TUMS.VCR.REC.1399.099, IRCT20200402046923N1 |
Phase 3 Clinical |
Recruiting |
3 |
|
110 |
Ali Asadollahi-Amin, Dr. Mohammad Ali Sahraeian, Hadise Hosami Roodsari, Roja Rahimi, Saeed Reza Jamali Moghaddam |
2020-04-13 |
| TCOutpatient: TXA and Coronavirus 2019 (COVID-19) in Outpatients |
Coronavirus disease 19 infection |
enoxaparin sodium plus tranexamic acid |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-04-15 |
2020-10-30 |
NCT04338074, TCOutpatient, TXACOVID1 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
100 |
Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD |
2020-04-13 |
| A first-in-human, phase I study of CORVax12 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
APOLLO electroporation device alone, DNA vaccine targeting SARS-CoV-2 spike protein + tavokinogene telseplasmid (APOLLO electroporation, COVID-19), OncoSec Medical alone |
IL12 gene stimulator |
Healthy volunteers accepted |
Providence Cancer Institute at Providence Hospital |
OncoSec Medical Inc |
US |
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
Rom Leidner, MD |
2020-04-09 |
| CLOCC: Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19 |
Coronavirus disease 19 infection |
camostat mesylate plus hydroxychloroquine |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Heinrich Heine Universitat Dusseldorf |
Hospital Schwabing Munich, Germany, Klinikum St Georg, Missioklinik, Wuerzburg, Germany, University Hospital Frankfurt, Universitätsklinikum Hamburg-Eppendorf |
Germany |
2020-06-01 |
2021-12-31 |
CLOCC, CLOCC-2020, NCT04338906 |
Phase 4 Clinical |
Not yet recruiting |
1 |
19 Months |
334 |
|
2020-04-10 |
| TCInpatient: Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients |
Coronavirus disease 19 infection |
enoxaparin sodium plus tranexamic acid |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-04-15 |
2020-12-15 |
NCT04338126, TCInpatient, TXACOVID2 |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
60 |
Brant Wagener, MD PhD, Sadis Matalon, PhD, Sonya Heath, MD, Timothy J Ness, Timothy J Ness, MD PhD |
2020-04-13 |
| Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection |
Cconventional medication alone, umbilical cord derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Huangshi Hospital of Traditional Chinese Medicine |
|
China |
2020-02-01 |
2020-12-02 |
ChiCTR2000031494 |
Phase 1 Clinical |
Recruiting |
1 |
10 Months |
36 |
Feng Ganzhu, Leng Nannan |
2020-04-10 |
| Efficacy of Kelofan syrup on COVID-19 |
Coronavirus disease 19 infection |
Kelofan syrup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ardabil University of Medical Sciences |
|
Iran |
2020-04-09 |
|
IR.ARUMS.REC.1399.009, IRCT20200405046960N1 |
Phase 1/Phase 2 Clinical |
Recruiting |
2 |
|
15 |
Dr.Shahab Bohlooli, Ramin Nasimi Doost Azgomi |
2020-04-10 |
| CAP-1002 in Severe COVID-19 Disease |
Coronavirus disease 19 infection |
CAP-1002 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Capricor Inc |
|
US |
|
|
CAP-1002-COVID-19, NCT04338347 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Khaled Alsabaawi, Mitch Gheoghiu, MD, Paula Williams, MS, Raj Makkar, MD, Siegfried Rogy, PhD |
2020-04-10 |
| Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-19 |
Coronavirus disease 19 infection, Pulmonary fibrosis, Viral pneumonia |
nintedanib alone |
CSF-1 antagonist, FGF receptor antagonist, FGF1 receptor antagonist, FGF2 receptor antagonist, FGF3 receptor antagonist, Flt3 tyrosine kinase inhibitor, Lck tyrosine kinase inhibitor, Lyn tyrosine kinase inhibitor, PDGF receptor alpha antagonist, PDGF receptor antagonist, PDGF receptor beta antagonist, Src tyrosine kinase inhibitor, VEGF receptor antagonist, VEGF-1 receptor antagonist, VEGF-2 receptor antagonist, VEGF-3 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tongji Hospital |
|
China |
2020-04-02 |
2020-08-01 |
HUILANZ ZHANG, NCT04338802 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
96 |
Huilan Zhang, Huilan Zhang, PD, Xianglin Yuan, PD |
2020-04-10 |
| ASCOT: To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care |
Coronavirus disease 19 infection |
hydroxychloroquine alone, lopinavir + ritonavir alone, hydroxychloroquine plus lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Melbourne |
Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Royal Brisbane & Womens Hospital Research Foundation, The Pratt Foundation, University of Queensland |
New Zealand, Australia |
2020-04-10 |
|
ACTRN12620000445976, ANZCTR12620000445976, ASCOT |
Phase 3 Clinical |
Not yet recruiting |
65 |
|
2500 |
A/Prof Steven Tong |
2020-04-14 |
| Effect of methylprednisolone in treatment of COVID-19 patients |
Coronavirus disease 19 infection |
methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shiraz University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.SUMS.REC.1399.014, IRCT20200204046369N1 |
Phase 2/Phase 3 Clinical |
Recruiting |
2 |
|
48 |
Dr. Mohsen Moghadami, Mohammad-Javad Fallahi, Mohsen Moghadami |
2020-04-14 |
| Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Royal Brisbane & Women's Hospital |
|
Australia |
2020-03-31 |
|
ACTRN12620000447954, ANZCTR12620000447954 |
Phase 2 Clinical |
Recruiting |
1 |
|
150 |
Prof Kevin B Laupland |
2020-04-10 |
| COVID-19 and Deep Venous Thrombosis |
Coronavirus disease 19 infection, Deep vein thrombosis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jessa Hospital |
|
Belgium |
2020-04-17 |
2020-12-30 |
JESSAH-COVID19-DVT, NCT04338932 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
12 |
Bjorn Stessel, Dr, Ina Callebaut, dr, Stessel Björn, Dr |
2020-04-10 |
| Evaluation of Safety and efficacy of anti-inflammatory regimens in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , naproxen , pantoprazole , prednisolone |
H+ K+ ATPase inhibitor |
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bagheiat-allah University of Medical Sciences, Iran University of Medical Sciences |
|
Iran |
2020-04-10 |
|
IR.BMSU.REC.1399.019, IRCT20200318046812N2 |
Phase 3 Clinical |
Recruiting |
4 |
|
906 |
Ali Qazvini, Dr Abolfazl Mozafari, Dr Mahtab Niroomand, Dr Mariam Qaraati, Dr Seyed Abbas Motevalian, Mostafa Ghanei, Seyed Hassan Saadat, ََAli Qazvini |
2020-04-11 |
| NOCOVID: Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection |
Coronavirus disease 19 infection |
nitric oxide-based antiviral formulation (oral, COVID-19), Sanotize Research and Development alone, standard precautions alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SaNOtize Research and Development Corp |
The Emmes Company, LLC |
Canada |
2020-04-06 |
2020-09-30 |
COVID-CTP-01, NCT04337918, NOCOVID |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
200 |
Chris Miller, Ph.D., Gilly Regev, Ph.D., Jeremy Road, MD |
2020-04-16 |
| Effect of IMFLUNA herbal compound on covid-19 pneumonia symptoms |
Coronavirus disease 19 infection, Viral pneumonia |
IMFLUNA herbal compound, HomaPharmed Pharmaceutical Company alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Medicinal Plants |
|
Iran |
2020-03-30 |
|
IR.BMSU.REC.1399.036, IRCT20080901001157N16 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
60 |
Fallah Huseini Hasan, Mohammadreza Gholibeikian, Morteza Khairabadi, Reza Mohtashami |
2020-04-11 |
| PROTECT: Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: an RCT |
Coronavirus disease 19 infection |
azithromycin alone, oseltamivir alone, Variable regimens including azithromycin , hydroxychloroquine phosphate , hydroxychloroquine sulfate , oseltamivir |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Health Sciences Lahore |
Federal Task Force on Science & Technology |
Pakistan |
2020-04-07 |
2020-11-30 |
12(06)/2016-COORD, NCT04338698, PROTECT |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
500 |
Javed Akram, FRCP, Shehnoor Azhar, Shehnoor Azhar, MPH |
2020-04-11 |
| Effect of Algomed, Menta longifolia, Chamomile, Althaea rosea, Malva sylvestris, Lepidium sativum supplements on the Severity and Consequences of Coronavirus 19 disease (COVID-19) |
Coronavirus disease 19 infection |
Algomed alone, herbal tea intake alone, treatment protocol alone |
|
|
Semnan University of Medical Sciences |
|
Iran |
2020-03-18 |
|
IR.SEMUMS.REC.1398.325, IRCT20151228025732N51 |
Phase Not Applicable |
Recruiting |
1 |
|
60 |
Parviz Kokhaie, Rahimeh Eskandarian |
2020-04-10 |
| Evaluation the Effect of Teicoplanin in Patients With Coronavirus Disease |
Coronavirus disease 19 infection |
Variable regimens including atazanavir + ritonavir , hydroxychloroquine , lopinavir + ritonavir , teicoplanin |
HIV protease inhibitor |
|
Iran University of Medical Sciences |
|
Iran |
2020-03-30 |
|
IR.IUMS.REC.1399.058, IRCT20161204031229N3 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Azadeh Eshraghi, Azadeh Eshraghi، Saeed Kalantari, Dr.Motevalian, Saeed Kalantari |
2020-04-10 |
| NO COV-ED: Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED |
Coronavirus disease 19 infection |
nitric oxide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
|
US |
2020-04-30 |
2022-04-30 |
2019P00XXXX, NCT04338828, NO COV-ED |
Phase 2 Clinical |
Not yet recruiting |
0 |
24 Months |
260 |
N. Stuart Harris MD MFA, N. Stuart Harris, MD, MFA |
2020-04-10 |
| SCOUT: Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study |
Coronavirus disease 19 infection, Viral pneumonia |
lung ultrasound alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universiteit Hasselt |
Ziekenhuis Oost-Limburg |
Belgium |
2020-04-13 |
2020-04-30 |
CTU2020032, NCT04338568, SCOUT |
Phase Not Applicable |
Recruiting |
1 |
|
50 |
David Ruttens, MD, PhD, Inge Thijs, PhD, Marc Daenen, MD, Michiel J Thomeer, MD, PhD, Michiel J Thomeer, MD,PhD, Michiel Thomeer, MD, PhD, Michiel Thomeer, MD,PhD, Prof. dr. Michiel Thomeer |
2020-04-16 |
| Evaluation of the Effects of Ozone Therapy on Covid-19 Positive Patients |
Coronavirus disease 19 infection |
ozone therapy group (covid positive alone, azithromycin plus hydroxychloroquine |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-05-30 |
NCT04337866, OZONECOVID19 |
Phase Not Applicable |
No longer recruiting |
2 |
1 Month |
50 |
Pınar Yalcin bahat |
2020-04-10 |
| TRODVID-19: Dynamic Evaluation of COVID-19 Diagnostic Tests |
Coronavirus disease 19 infection |
antigenic rapid diagnostic orientation test (RODT) alone, polymerase chain reaction (PCR) alone, serological TROD alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de Tourcoing |
|
France |
2020-04-30 |
2020-10-31 |
NCT04337996, RIPH_2020_6, TRODVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
176 |
Barthelemy LAFONDESMURS, MD, Pierre PATOZ, PharmD, Solange TREHOUX, PhD |
2020-04-10 |
| HOPEC: Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis |
Coronavirus disease 19 infection |
hydroxychloroquine (Amin Pharmaceutical company, Isfahan) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shahid Beheshti University of Medical Sciences |
|
Iran |
2020-04-07 |
|
HOPEC, IR.SBMU.RETECH.REC.1399.026, IRCT20130917014693N10 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Afshin Zarghi, Ali Saffaei, Minoosh Shabani, Omidvar Rezaiemirghaed, Zahra Sahraei |
2020-04-13 |
| Sleep COVID-19: Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic |
Coronavirus disease 19 infection, Insomnia |
online self-help leaflet alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Northumbria |
|
UK |
2020-03-25 |
2022-04-06 |
ISRCTN43900695, Sleep COVID-19 |
Phase Not Applicable |
Recruiting |
2 |
24 Months |
75 |
Dr Elder |
2020-04-10 |
| JUPITER: Beat COVID-19 - Observational Trial |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Beat COVID LLC |
|
US |
2020-04-06 |
2021-07-31 |
20200835, JUPITER, NCT04337762 |
Phase Not Applicable |
Recruiting |
0 |
15 Months |
100000 |
Hollis Ledbetter, Rama Jager, M.D. |
2020-04-10 |
| A phase I study of PittCoVacc for the potential prevention of COVID-19 infection |
Coronavirus disease 19 infection |
PittCoVacc alone |
|
|
University of Pittsburgh School of Medicine |
|
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |
| Effect of berberine on COVID-19 |
Coronavirus disease 19 infection |
berberine hydrochloride (Mashhad University School of Pharmacy) alone, standard coronavirus treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.MUMS.REC.1399.030, IRCT20081019001369N2 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri, Mohsen Tafaghdi |
2020-04-10 |
| RuxCoFlam: Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation |
Coronavirus disease 19 infection, Hypoxia, Inflammatory disease, Respiratory disease, Viral pneumonia |
ruxolitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Jena |
|
Germany |
2020-05-01 |
2021-08-31 |
NCT04338958, RUXCOFLAM, RuxCoFlam |
Phase 2 Clinical |
Not yet recruiting |
1 |
16 Months |
200 |
Andreas Hochhaus, Prof. Dr., Christian Fabisch, Dr. |
2020-04-13 |
| The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sheba Medical Center |
|
Israel |
2020-04-05 |
2022-04-01 |
NCT04338672, SMC-20-7078-YZ-CTIL |
Phase Not Applicable |
Not yet recruiting |
1 |
23 Months |
1000000 |
Roi Anteby, MD |
2020-04-09 |
| A clinical trial to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
allogeneic natural killer cells alone |
|
|
Green Cross LabCell |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-09 |
| Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy |
Coronavirus disease 19 infection |
COVID-surgRES questionaire alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
IRCCS AOU San Martino – IST |
|
Italy |
2020-03-15 |
2020-05-01 |
COVID-ItaliansurgRES-SPIGC, COVID-SURGRES-ITALY, NCT04338945 |
Phase Not Applicable |
Recruiting |
7 |
1 Month |
1200 |
Fabio Barra |
2020-04-13 |
| A clinical study to assess allogeneic natural killer cell therapy for the portential treatment of COVID-19 infection |
Coronavirus disease 19 infection |
allogeneic natural killer cells alone |
|
|
Green Cross LabCell |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| POCUSCO: Point Of Care Ultrasonography for Risk-stratification of COVID-19 Patients |
Coronavirus disease 19 infection |
lung ultrasonography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-04-06 |
2021-01-29 |
2020-A00782-37, NCT04338100, POCUSCO |
Phase Not Applicable |
Not yet recruiting |
6 |
9 Months |
300 |
Francis COUTURAUD, Dr, François MORIN, Dr, Karim TAZAROURTE, Pr, Laure BAUDIN, Dr, Louis SOULAT, Pr, Luc-Marie JOLY, Pr, Nicolas MARJANOVIC, Dr, Philippe LE CONTE, Pr, Pierre-Marie ROY, Pr, Thomas DELOMAS, Dr, Thomas FLAMENT, Dr |
2020-04-10 |
| Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 |
Coronavirus disease 19 infection |
COVID-19 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mayo Clinic Foundation |
|
US |
|
|
20-003312, NCT04338360 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Michael Joyner, MD |
2020-04-15 |
| A Phase II efficacy Study of INO-4800 in COVID-19 infection |
Coronavirus disease 19 infection |
INO-4800 alone |
|
|
Inovio Pharmaceuticals Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-15 |
| LEOSS: Lean, European, Open Survey on SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection |
rapid tests alone |
|
|
Deutsches Zentrum für Infektionsforschung |
Willy Robert Pitzer Stiftung |
Ireland, Portugal, Italy, UK, Switzerland, France, Austria, Germany, Belgium, Bosnia and Herzegovina, Spain, Iceland |
2020-03-16 |
|
20-600, DRKS00021145, LEOSS |
Phase Not Applicable |
Recruiting |
51 |
|
20000 |
Jorg Janne Vehreschild |
2020-04-10 |
| PiCCOVID: Hemodynamic Characteristics of Patients With SARS-CoV-2 |
Coronavirus disease 19 infection |
echocardiography alone, transpulmonary thermodilution alone, transpulmonary thermodilution system alone |
|
|
Hopital de Bicetre |
|
France |
2020-04-15 |
2021-04-30 |
2020-A00793-36, NCT04337983, PiCCOVID |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Xavier Monnet, Xavier Monnet, MD.PhD |
2020-04-10 |
| A clinical trial of anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin alone |
|
|
Octapharma AG |
Bio Products Laboratory Ltd, Biotest AG, CSL Ltd, LFB SA, Takeda Pharmaceutical Co Ltd |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| Study of the effect of Chloroquine in addition to standard therapy in COVID-19 patients |
Coronavirus disease 19 infection |
chloroquine phosphate alone, standard therapy alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Command Hospital |
|
India |
2020-04-13 |
|
CTRI/2020/04/024479 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
32 |
SALIL GUPTA |
2020-04-10 |
| A phase I clinical study to assess IPT-001 for the prevention and treatment of COVID-19 infection |
Coronavirus disease 19 infection |
IPT-001 alone |
Coronavirus spike glycoprotein inhibitor, Nucleoprotein inhibitor |
|
INTELLiSTEM Technologies Inc |
|
|
2020-09-30 |
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |
| A clinical trial of ADDomer for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
ADDomer alone |
|
|
Imophoron Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| A clinical trial to assess the efficacy and safety of tPA for the potential treatment of COVID-19-related respiratory failure |
Coronavirus disease 19 infection |
tissue plasma activator alone |
|
|
Beth Israel Deaconess Medical Center |
|
|
2020-04-06 |
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
Christopher D. Barrett, MD, Gyongyi Szabo |
2020-04-09 |
| Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy |
Coronavirus disease 19 infection, SARS coronavirus infection |
questionnaire alone, standard care alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Monash University, University of Melbourne |
|
Australia |
2020-04-10 |
2021-12-31 |
ACTRN12620000449932 |
Phase Not Applicable |
Not yet recruiting |
15 |
20 Months |
200 |
Dr Clare Whitehead, Dr Miranda Davies-Tuck |
2020-04-14 |
| ZINC COVID study: Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection? |
Coronavirus disease 19 infection, SARS coronavirus infection |
Zinc Chloride alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Austin Health, University of Melbourne |
|
Australia |
2020-04-09 |
|
ACTRN12620000454976, DT 62996/2020, ZINC COVID study |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
|
160 |
A/Prof Joseph Ischia A/Prof Joseph Ischia |
2020-04-14 |
| HOPE Study: Hydroxychloroquine for the Community-Based Treatment of COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Medical Research Institute of New Zealand |
Health Research Council of New Zealand |
New Zealand |
2020-04-14 |
|
ACTRN12620000457943p, HOPE Study, MRINZ/20/01 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
70 |
Dr Alex Semprini |
2020-04-14 |
| WriteForIBD: Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
evidenced-based 4-day writing program alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Crohn's & Colitis Australia, Deakin University |
Barwon Health |
Australia |
2020-01-16 |
|
ACTRN12620000448943p, ANZCTR12620000457943, WriteForIBD |
Phase Not Applicable |
Not yet recruiting |
4 |
|
154 |
A/Prof Antonina Mikocka-Walus |
2020-04-10 |
| A largest Chinese study on epidemiologic characteristics of Coronavirus Disease 2019 (COVID-19) Outbreak in China |
Coronavirus disease 19 infection |
|
|
|
The Chinese Centre for Disease Control and Prevention |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
44672 |
|
2020-04-09 |
| Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment |
Coronavirus disease 19 infection, Scoliosis |
MAGEC Spine Rod alone, Titanium blood test alone |
|
|
Royal National Orthopaedic Hospital NHS Trust |
|
UK |
2020-04-30 |
2021-03-31 |
NCT04337151, RNOH MAGEC |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
100 |
Dr Harry Hothi, Harry Hothi, PhD |
2020-04-16 |
| SRA-COV: Renin Angiotesnin System - CoronaVirus |
Coronavirus disease 19 infection, Respiratory distress syndrome |
blood draw alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux De Marseille |
|
France |
2020-04-03 |
2020-07-31 |
2020-16, 2020-A00795-34, NCT04337008, SRA-COV |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
50 |
Emilie Garrido-Pradalie, Francois Silhol, MD, François Silhol, MD |
2020-04-10 |
| Assessment of Distress in Crisis Situations During COVID-19 |
Coronavirus disease 19 infection, Post traumatic stress disorder |
Peritraumatic Distress Inventory alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Wefight |
|
France |
2020-03-31 |
2020-05-31 |
NCT04337047, WEFIGHTDISTRESS20 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
2000 |
benjamin CHAIX |
2020-04-16 |
| CoV-Mortality: CoV-Mortality |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-15 |
2020-10-31 |
54609, CoV-Mortality, NMRR-20-691-54609 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr. Woon Yuan Liang |
2020-04-10 |
| Effects of vitamin C supplementation on patients with COVID-19 |
Coronavirus disease 19 infection |
vitamin C alone |
|
|
Hospital Raja Permaisuri Bainun |
|
Malaysia |
2020-04-14 |
2020-12-31 |
54478, IMVC 001, NMRR-20-684-54478 |
Phase Not Applicable |
Not yet recruiting |
2 |
8 Months |
|
Dr Leong Chee Loon, Dr. G.R. Letchuman Ramanathan, Dr. Sharon Linus Lojikip, LIM XIN JIE |
2020-04-10 |
| COVID-19 ARDS Cyto-MSC |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Cyto-MSC (umbilical cord derived mesenchymal stem cells) alone |
|
|
Cytopeutics Sdn Bhd |
|
Malaysia |
2020-04-13 |
2020-05-31 |
54521, NMRR-20-672-54521, POD0039/CP/R |
Phase 1 Clinical |
Not yet recruiting |
3 |
1 Month |
5 |
Dr Chin Sze Piaw, Dr Toh See Guan, Mohd Shahrizal Bin Mohd Yusoff, Prof S FADILAH ABDUL WAHID |
2020-04-10 |
| A expanded access program of opaganib to treat patients with COVID-19 infection |
Coronavirus disease 19 infection |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection |
Coronavirus disease 19 infection |
hydroxychloroquine plus opaganib |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd |
|
Israel |
|
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-16 |
| A compassionate use program of opaganib to treat patients with confirmed coronavirus (COVID-19) infection with life-threatening clinical conditions |
Coronavirus disease 19 infection, Respiratory distress syndrome, SARS coronavirus infection, Viral pneumonia |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
Cosmo Pharmaceuticals NV, RedHill Biopharma Ltd |
|
Italy |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
160 |
|
2020-04-14 |
| Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine |
Coronavirus disease 19 infection |
social quarantine implementation alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Kultur University |
Istanbul University-Cerrahpasa |
Turkey |
2020-04-12 |
2020-06-10 |
FADP-2, NCT04336787 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
100 |
Ayse Zengin Alpozgen, assistant professor, Ayşe Zengin Alpözgen, Assistant Professor, Basak Polat, PhD Student, Başak Polat, PhD Student, Cicek Duman, PhD Student, Funda Akuzum, PhD Student, Funda Aküzüm, PhD Student, Gamze Ertürk Uzunoglu, PhD Student, Gamze Ertürk Uzunoğlu, PhD Student, Halenur Evrendilek, PhD Student, Tugce Tahmaz, PhD Student, Tuğçe Tahmaz, PhD Student, Çiçek Duman, PhD Student |
2020-04-14 |
| A phase II, single-arm, non-randomized study to evaluate the safety and efficacy of autologous adipose-derived mesenchymal stem cells in patients with high risk COVID-19 infection |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
75 |
|
2020-04-16 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation |
Coronavirus disease 19 infection, Inflammatory disease, Viral pneumonia |
mavrilimumab alone |
C-reactive protein inhibitor, Chemokine CC22 ligand inhibitor, GM-CSF receptor antagonist, Hemoglobin scavenger receptor antagonist, Metalloprotease-1 inhibitor, Metalloprotease-3 inhibitor, Small inducible cytokine A17 ligand inhibitor, VEGF gene inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Virginia Commonwealth University |
|
US |
2020-04-30 |
2020-07-31 |
HM20019145, NCT04337216 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
10 |
Antonio Abbate, MD, PhD |
2020-04-10 |
| Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
allogeneic human dental pulp stem cells (BSH BTC and Utooth BTC) alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Renmin Hospital of Wuhan University |
Beijing Scitop Bio-Tech Shareholding Co.Ltd, Utooth Biological Technology Co., Ltd. Hubei |
China |
2020-04-06 |
2021-03-31 |
2020K-G005, HDPSC-COVID-2019-02-2020, NCT04336254 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
11 Months |
20 |
Chenliang Zhou, PhD, Prof. Qingsong Ye, PhD,DDS, Qingsong Ye, PhD,DDS, Ye Qingsong |
2020-04-09 |
| Demographic and epidemiological characteristics of Covid-19 disease in Helios-Hospital and determinants of clinical course |
Coronavirus disease 19 infection |
|
|
|
HELIOS Kliniken GmbH |
Hygiene Helios Klinik Wuppertal, Klinikum Hildesheim GmbH |
Germany |
2020-02-15 |
|
DRKS00021161, E-01-20200319 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Julius Dengler, Michael Hauptmann |
2020-04-10 |
| An expanded access clinical study of autologous adipose-tissue derived mesenchymal stem cells (AdMSCs) multiple dose infusions for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
autologous mesenchymal stem cell-derived exosomes (Alzheimers disease), Celltex Therapeutics alone |
|
|
Celltex Therapeutics Corp |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
Dr. Derek W. Guillory |
2020-04-08 |
| COVID-ARA2: Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 |
Coronavirus disease 19 infection, Respiratory failure |
angiotensin II type 2 receptor agonists therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Angers |
|
France |
2020-04-03 |
2020-12-06 |
COVID-ARA2, COVID-ARA2, NCT04337190 |
Phase Not Applicable |
Recruiting |
2 |
8 Months |
100 |
Julien Demiselle, M.D., Julien Demiselle, MD, Pierre Asfar, MD, PhD |
2020-04-13 |
| CoCo Study: COVID-19 Contact Study - Immunoreaction after possible SARS-CoV-2 / COVID-19 contact |
Coronavirus disease 19 infection |
immunological analysis alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hannover Medical School |
Deutsche Forschungsgemeinschaft (DFG), Deutsches Zentrum für Infektionsforschung, German Federal Ministry of Education and Research, Novartis Pharma GmbH Germany |
Germany |
2020-04-05 |
|
8973_BO_K_2020, CoCo Study, DRKS00021152 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
1000 |
Georg Behrens |
2020-04-15 |
| Randomized, Comparison of Combination Azithromycin and Hydroxychloroquine versus Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
Plaquenil alone, Plaquenil plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rutgers University |
|
US |
2020-04-01 |
2021-04-30 |
002011, NCT04336332, PRO2020000712 |
Phase 2 Clinical |
Recruiting |
0 |
13 Months |
160 |
Sabiha Hussain, MD, Shobha Swaminathan, MD, Steven K. Libutti, MD, FACS |
2020-04-14 |
| A clinical trial of IVIEW-1201 for the treatment or prevention of COVD-19 infection in the eye |
Coronavirus disease 19 infection |
povidone iodine (long acting/extended-release/gel, adenoviral conjunctivitis), IVIEW therapeutics alone |
|
|
iVIEW Therapeutics Inc |
|
China |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-08 |
| A pan-india non-interventional virtual registry evaluating the prophylactic efficacy of different regimens against SARS-CoV2 infection (COVID-2019) in asymptomatic health care workers |
Coronavirus disease 19 infection, SARS coronavirus infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zifo RnD Solutions |
|
India |
2020-04-17 |
|
CTRI/2020/04/024482 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
10000 |
Arvind Sri Krishna Mani, Viswanathan Niranjan |
2020-04-10 |
| Knowledge, attitude and fear of COVID-19 in Bangladesh |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre for the Rehabilitation of the Paralysed |
|
Bangladesh |
2020-04-09 |
|
CTRI/2020/04/024413 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
K M Amran Hossain, Md Zahid Hossain, Md. Shahoriar Ahmed, Professor Md Obaidul Haque |
2020-04-10 |
| ONCOVID: Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients |
Advanced solid tumor, Coronavirus disease 19 infection, Hematological neoplasm |
Plaquenil plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Institut Gustave Roussy |
|
France |
2020-04-03 |
2022-04-30 |
2020-001250-21, 2020/3078, NCT04341207, ONCOVID |
Phase 2 Clinical |
Recruiting |
2 |
24 Months |
1000 |
Lisa DEROSA, MD, Stefan MICHIELS, MD |
2020-04-13 |
| CovidSurg-Cancer |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Birmingham |
|
Malaysia |
2020-04-08 |
2021-03-31 |
NMRR-20-693-54498 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
100 |
Andee Dzulkarnaen Zakaria |
2020-04-13 |
| Expanded-access study of GENOSYL DS for treating COVID-19 Infection Complicating Pulmonary Hypertension |
Coronavirus disease 19 infection, Pulmonary hypertension |
nitric oxide (GeNOsyl MV-2000, inhaled, ventilator platform), GeNO alone |
|
|
Vero Biotech |
|
|
2020-03-31 |
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-09 |
| EVALUATION: Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure |
Coronavirus disease 19 infection, Respiratory distress syndrome |
PiCCO-monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ludwig-Maximilians University of Munich |
Technical University of Munich |
Germany |
2020-03-11 |
2020-04-30 |
EVALUATION, ISRCTN10077335 |
Phase Not Applicable |
Recruiting |
2 |
1 Month |
25 |
Prof. Wolfgang Huber |
2020-04-09 |
| A phase II clinical study to assess VIR-7832 in the treatent of patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
VIR-7832 alone |
Coronavirus spike glycoprotein inhibitor |
|
GlaxoSmithKline plc |
Vir Biotechnology Inc |
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-08 |
| A phase II clinical study to assess VIR-7831 in the treatent of patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
VIR-7831 alone |
Coronavirus spike glycoprotein inhibitor |
|
GlaxoSmithKline plc |
Vir Biotechnology Inc |
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-08 |
| EasyCoV: Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2 |
Coronavirus disease 19 infection, SARS coronavirus infection |
sample collection alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
Skillcell, Sys2Diag |
France |
2020-04-07 |
2020-04-17 |
EasyCoV, NCT04337424, RECHMPL20_0170 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
180 |
REYNES Jacques, PU PH |
2020-04-08 |
| Imaging Findings In Covid-19 |
Coronavirus disease 19 infection |
|
|
|
Hospital Tawau |
|
Malaysia |
2020-04-13 |
2020-04-30 |
NMRR-20-698-54570 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
70 |
Dr Mohana A/P Letchumanan |
2020-04-08 |
| Evaluation of Blood Results of Covid 19 Positive Pregnants |
Coronavirus disease 19 infection |
|
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-03-21 |
2020-05-22 |
COVID19PREGNANCIES, NCT04337294 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
100 |
Pınar Yalcin bahat |
2020-04-10 |
| Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
favipiravir alone, supportive care alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
ASST Fatebenefratelli Sacco |
|
Italy |
2020-03-25 |
2020-07-31 |
HS216C17-PHASE III, NCT04336904 |
Phase 3 Clinical |
No longer recruiting |
1 |
4 Months |
100 |
Giuliano Rizzardini, Md |
2020-04-09 |
| REMOTE-COVID: Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus) |
Coronavirus disease 19 infection |
SensiumVitals wearable sensor alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Imperial College London |
|
UK |
2020-04-01 |
2021-04-01 |
NCT04337489, REMOTE-COVID, REMOTE-COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Ara Darzi, Prof, Fahad M Iqbal, MBChB (hons), Sadia Khan, Dr |
2020-04-08 |
| Clinical and Radiomic Model of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Universiteit Maastricht |
Wuhan Central Hospital |
China |
2019-12-23 |
2020-03-03 |
NCT04337502, UM_2020_GY_COVID-19 |
Phase Not Applicable |
Completed |
1 |
2 Months |
300 |
|
2020-04-10 |
| UZH COVID-19 Cohort Study: Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center |
Coronavirus disease 19 infection |
Phone calls alone |
|
|
University of Zurich |
|
Switzerland |
2020-03-20 |
2020-12-31 |
ISRCTN77353041, UZH COVID-19 Cohort Study |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
200 |
Dr Dominik Menges, Prof Jan Fehr, Prof Milo A. Puhan |
2020-04-09 |
| Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-06-20 |
COVID19PREGNANCYNEWBORN, NCT04337320 |
Phase Not Applicable |
No longer recruiting |
1 |
2 Months |
70 |
Pınar Yalcin bahat |
2020-04-08 |
| Evaluation of the Effect of High-dose Vitamin C Use in Covid 19 Positive Pregnants |
Coronavirus disease 19 infection |
vitamin C alone |
|
Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-01 |
2020-05-30 |
HIGHDOSEVITCINCOVID19, NCT04337281 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
50 |
Pınar Yalcin bahat |
2020-04-15 |
| Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xiaotan Sanjiefang granule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Beijing University of Chinese Medicine |
Chinese Ministry of Science and Technology |
China |
2020-03-01 |
2020-12-31 |
ChiCTR2000031672, ChiMCTR2000003188 |
Phase 2 Clinical |
Not yet recruiting |
1 |
10 Months |
150 |
Yingshuai Li |
2020-04-14 |
| Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System |
Coronavirus disease 19 infection |
Surgical facial mask alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rigshospitalet, Denmark |
Denmark Technical University, HS Hvidovre Hospital, Nordsjaellands Hospital |
Denmark |
2020-04-02 |
2020-07-01 |
2020-04-02, NCT04337541 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
6000 |
Christian Torp-Pedersen, Prof., DMSc, Henning Bundgaard, Prof., DMSc, Henrik Ullum, Prof., DMSc, Kasper Karmark Iversen, Prof., DMSc, Thomas Benfield, Prof., DMSc |
2020-04-15 |
| Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
interferon treatment alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Wenzhou Central Hospital |
|
China |
2020-02-01 |
2021-01-31 |
ChiCTR2000031699 |
Phase 1 Clinical |
No longer recruiting |
1 |
12 Months |
33 |
Tangshaohua |
2020-04-09 |
| Evaluation of Covid 19 Anxiety in Endometriosis Patients |
Coronavirus disease 19 infection, Endometriosis, Generalized anxiety disorder |
|
|
Healthy volunteers accepted, Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Istanbul Bakirkoy Maternity and Children Diseases Hospital |
|
Turkey |
2020-04-05 |
2020-04-25 |
ENDOCOVID19, NCT04337346 |
Phase Not Applicable |
No longer recruiting |
1 |
|
80 |
Pınar Yalcin bahat |
2020-04-09 |
| COVID-CHD: Impact of Covid-19 in Congenital Heart Disease |
Congenital heart defect, Coronavirus disease 19 infection |
|
|
|
University Hospital, Montpellier |
|
France |
2020-03-01 |
2020-12-30 |
COVID-CHD, NCT04336384, RECHMPL20_0155 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
5000 |
Adeline BASQUIN, MD, Alexis BLANC, MD, BERTRAND LEOBON, MD, Caroline OVAERT, MD, Céline GRUNENWALD GRONIER, MD, Daniela LAUX, MD, Hamouda ABASSI, MD, Jean-Benoît THAMBO, MD, PhD, Karine WARIN-FRESSE, MD, Magalie LADOUCEUR, MD, Nicolas COMBES, MD, Pascal AMEDRO, MD-PHD, Pascal AMEDRO, MD-PhD, Roland HENAINE, PU PH, Sébastien HASCOET, MD, Xavier IRIART, MD |
2020-04-15 |
| Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease |
Coronavirus disease 19 infection |
Ig G test alone, Questionnaire alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-04-30 |
2020-05-31 |
ASSIUTU11, NCT04336657 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
100 |
Aliae AR Mohamed-Hussein, Aliae Mohamed-Hussein |
2020-04-09 |
| HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers |
Coronavirus disease 19 infection, SARS coronavirus infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
|
2020-04-30 |
2020-08-31 |
HCQ PROPHYLAXIS FOR COVID19, NCT04336748 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
440 |
Matthias Vossen |
2020-04-09 |
| CAPTION AI to Minimize Risk of COVID Exposure |
Coronavirus disease 19 infection, Viral pneumonia |
Caption AI alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
Caption Health Inc |
US |
2020-04-30 |
2020-11-09 |
NCT04336774, PRO00105212 |
Phase Not Applicable |
Not yet recruiting |
0 |
6 Months |
500 |
Kristine Arges, BSN, Sreekanth Vemulapallli, MD |
2020-04-09 |
| INCOVPED: Prevalence of Covid-19 in Children Admitted to Pediatric Emergency Departments During the Pandemic Period in France |
Coronavirus disease 19 infection |
nasopharyngeal swab alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00811-38, 2020_21, INCOVPED, NCT04336761 |
Phase Not Applicable |
Not yet recruiting |
5 |
8 Months |
914 |
Camille BREHIN, MD, Christèle LE GUEN, MD,PhD, Flora JOANNES, MD, François DUBOS, MD,PhD, François Dubos, MD,PhD, Hervé HAAS, MD, Marie Chinazzo-Vigouroux, MD |
2020-04-09 |
| A trial to assess brilacidin in the potential treatment of novel coronavirus COVID-19 treatment |
Coronavirus disease 19 infection |
brilacidin alone |
PDE 3 inhibitor, PDE 4 inhibitor |
|
Innovation Pharmaceuticals Inc |
|
Europe |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-08 |
| Rutgers COVID-19 Cohort Study |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rutgers University |
|
US |
2020-04-07 |
2021-10-21 |
2020000679, NCT04336215 |
Phase Not Applicable |
Recruiting |
0 |
18 Months |
750 |
Jeffrey L Carson, MD, Reynold A Panettieri, MD |
2020-04-16 |
| MexCOVID-19: Outcomes of Patients With COVID-19 in the Intensive Care Unit |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Ciencias Medicas y Nutricion |
|
Mexico |
2020-04-01 |
2020-05-30 |
MexCOVID-19, NCT04336345, TEI-3336-20-20-1 |
Phase Not Applicable |
Not yet recruiting |
2 |
1 Month |
150 |
Eduardo Rivero-Sigarroa, MD, Guillermo Dominguez-Cherit, MD, Silvio A. Ñamendys-Silva, MD, MSc |
2020-04-09 |
| Viral Infection and Respiratory illness Universal Study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Society of Critical Care Medicine |
|
Italy, UK, India, US |
2020-04-01 |
|
CTRI/2020/04/024473 |
Phase Not Applicable |
Recruiting |
3 |
|
50000 |
Dr Mradul Kumar Daga, Dr Naresh Kumar |
2020-04-09 |
| A multicenter, phase 2/3, randomized, placebo-controlled study to assess the effect of remestemcel-L in the treatment of COVID-19 patients with acute respiratory distress syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome |
remestemcel-L alone |
|
|
Mesoblast Ltd, National Heart Lung and Blood Institute |
|
US |
|
|
|
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-13 |
| Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/very Severe COVID-19 Illness |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
|
|
|
|
CINC424A2001M, NCT04337359 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Novartis Pharmaceuticals, Novartis Pharmaeuticals |
2020-04-09 |
| PANDOR: Covid-19 Pediatric Observatory |
Coronavirus disease 19 infection |
real-time reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Centre Hospitalier Intercommunal Creteil |
ACTIV, France, GFRUP, GPIP (FR), Societe Francaise de Pediatrie |
France |
2020-04-07 |
2021-06-30 |
NCT04336956, PANDOR, PANDOR |
Phase Not Applicable |
Recruiting |
3 |
14 Months |
250 |
Albert Faye, Camille Jung, Corinne Levy, MD, François Angoulvant, Ralph EPAUD, Xavier DURRMEYER |
2020-04-13 |
| Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent |
Coronavirus disease 19 infection, Viral pneumonia |
novel coronavirus pneumonia (COVID-19) antigen reagent alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese PLA General Hospital, Chongqing Infectious Disease Medical Center, Wuhan Huoshenshan Hospital |
Beijing Savant Biotechnology Co Ltd |
China |
2020-04-07 |
2020-05-31 |
ChiCTR2000031700 |
Phase Not Applicable |
Not yet recruiting |
3 |
1 Month |
600 |
Zhang Chunyan |
2020-04-09 |
| Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment |
Coronavirus disease 19 infection, SARS coronavirus infection, Viral pneumonia |
Surface swab and air sample collection alone, Surface swab from personal protective equipment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chinese University of Hong Kong |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000031712 |
Phase 1 Clinical |
Recruiting |
1 |
12 Months |
60 |
Christopher KC Lai |
2020-04-09 |
| Clinical trial of KTH-222 (alone and/or in combination with anti-viral drugs)for the treatment of cancer patients infected with the COVID-19 virus or in suspected patients with the symptoms |
Coronavirus disease 19 infection |
KTH-222 alone, anti-viral drug therapy alone |
MAP kinase inhibitor |
|
Kalos Therapeutics Inc, Oncology Pharma Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-09 |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers |
Coronavirus disease 19 infection |
CELLECTRA 2000 alone, INO-4800 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Inovio Pharmaceuticals Inc |
Coalition for Epidemic Preparedness Innovations |
US |
2020-04-03 |
2020-11-30 |
COVID19-001, NCT04336410 |
Phase 1 Clinical |
Recruiting |
0 |
7 Months |
40 |
Inovio Call Center, Pablo Tebas, Program Manager Barbara Bradshaw, Program Manager Eileen Donaghy, ShuPing Yang, MD, PhD |
2020-04-13 |
| A phase III in-home, self-dosing clinical trial to assess ENU-200 in the treatment of patients with asymptomatic, mild to moderate coronavirus infections (COVID-19) utilizing their iClickCare secure clinical reporting software service to monitor the in-home trials |
Coronavirus disease 19 infection |
ENU-200 alone, iClickCare alone |
Coronavirus spike glycoprotein inhibitor |
|
Ennaid Therapeutics |
|
US |
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-04-09 |